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Periconceptional folic acid supplementation is a highly prevalent public health 
intervention and is known to reduce the incidence of neural tube defects (NTDs) 
and the risk of small for gestational age (SGA) infants. Increased maternal folate 
status during mid-gestation is associated with increased adiposity and insulin 
resistance in children. In rodents, maternal folic acid supplementation (MFAS) 
reduces plasma triacylglyceride (TAG) and cholesterol in adolescent and adult 
offspring but increases plasma glucose in adult female offspring. Overall, this 
suggests that MFAS, while beneficial perinatally, may affect metabolic regulation 
and susceptibility of offspring to chronic metabolic disease long term; however, the 
potential mechanisms involved remain incompletely understood.  
  
One mechanism by which MFAS may alter long-term metabolic regulation in 
offspring is perturbed DNA methylation. DNA methylation is a heritable form of 
epigenetic modification, which establishes a signature of inactive gene expression 
via the addition of a methyl group to the 5’ position of a cytosine residue; folate, a 
key methyl group donor, may modulate this epigenetic process and state. 
Consistently, MFAS, before and during gestation, increases DNA methylation in 
the regulatory region of IGF2 in blood of the newborn infant. In rodents, MFAS, 
during pregnancy and lactation, decreases hepatic activity of DNA 
methyltransferases (DNMTs), which are key enzymes for maintaining and 
establishing DNA methylation, in adult offspring. Maternal folic acid 
supplementation may act through such pathways to affect epigenetic state and 
phenotype of offspring long term. 
 
Besides affecting protein-coding genes, DNA methylation also regulates the 
expression of small non-coding microRNAs (miRs). These short single-stranded 
RNA molecules can repress post-transcriptional expression of their mRNA targets 
through 3’UTR base-pairing interactions. Many miRs target genes are involved in 
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glucose, lipid and cholesterol metabolism; miRs can act in concert to orchestrate 
co-ordinated post-transcriptional changes by targeting multiple sites and, in turn, 
forming regulatory networks. In addition, miRs can target repressors in DNA 
methylation, enabling for dynamic regulation between these two distinct epigenetic 
processes. This may be a third pathway whereby MFAS influences phenotype of 
offspring.  
 
The present thesis describes studies, in the rodent, of the effects of MFAS, from 
preconception to term, on the expression of key metabolic regulatory genes, 
DNMTs and non-coding miRs in the major glucoregulatory tissues, liver and 
skeletal muscle, of offspring during prenatal and postnatal stages of development. 
 
Maternal folic acid supplementation altered hepatic expression of 13 genes (P < 
0.05) in all adult offspring as well as in a sexually dimorphic manner, as shown by 
microarray analysis. Maternal folic acid supplementation altered the hepatic mRNA 
transcriptome of adult offspring, with 22 genes in males and 36 genes in females 
being differentially expressed (P < 0.05). Gene ontology analysis revealed that the 
differentially expressed genes in liver of offspring following MFAS were closely 
associated with lipid and cholesterol metabolism.  
 
Maternal folic acid supplementation increased hepatic expression of Ppara, an 
upstream regulator of genes closely related to lipid metabolism, in all offspring in 
late gestation (1.22 fold, P = 0.024) but reduced it in adulthood (-0.41 fold, P = 
0.002). Maternal folic acid supplementation also altered hepatic expression of 
lipogenic genes in offspring in a sexually dimorphic and age-dependent manner. In 
male offspring, MFAS decreased hepatic expression of Acaca in late gestation (-
0.32 fold, P = 0.018) but increased it in adulthood (1.56 fold, P = 0.011); in female 
offspring, it was not affected by MFAS in late gestation nor in adulthood. Maternal 
folic acid supplementation decreased hepatic expression of Scd1 in the female 
offspring in late gestation (-0.37 fold, P = 0.017) but increased it in adulthood (1.38 
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fold, P = 0.035); in male offspring, it was not affected by MFAS in late gestation 
nor in adulthood. 
 
Maternal folic acid supplementation altered expression of genes involved in 
cholesterogenesis in female offspring in an age-dependent manner, with hepatic 
expression of Sc4mol being increased in late gestation (1.92 fold, P = 0.003), but it 
was unchanged in adulthood. Maternal folic acid supplementation also decreased 
hepatic expression of a cholesterogenic gene, Idi1 (-0.64 fold, P < 0.0001), in adult 
female offspring. In terms of associations, hepatic expression of Ppara was 
positively correlated with that of Idi1 (r = 0.434, P = 0.036) and Sqle (r = 0.528, P = 
0.012) in the adult female offspring. Hepatic expression of Akr1b10 and Acaca (r = 
0.846, P < 0.0001) were also positively correlated in the adult female offspring. 
Collectively, MFAS induces distinct changes in hepatic expression of genes 
related to lipid and cholesterol metabolism and their regulatory networks in 
offspring during prenatal and postnatal stages of development, particularly, in a 
manner that appears to augment the capacity for hepatic lipid and cholesterol 
homeostasis in later life.  
 
Maternal folic acid supplementation reduced hepatic expression of Dnmt1 (-0.36 
fold, P = 0.039) and Dnmt3b (-0.21 fold, P < 0.0001) in the female foetus in late 
gestation. In addition, MFAS altered hepatic miR expression of 36 miRs (P < 0.05) 
in the female foetus in late gestation, with four miRs being up-regulated (1.18 to 
1.22 fold) and 32 miRs being down-regulated (-0.21 to -1.18 fold). Maternal folic 
acid supplementation did not alter hepatic expression of DNMTs nor that of miRs 
in the male foetus. This suggests that MFAS could partly mediate its effects on 
hepatic gene expression in a sexually dimorphic manner through altering the 
capacity to regulate DNA methylation and miR expression in female foetuses but 
not in males. Effects of MFAS on hepatic expression of miRs and DNMTs in the 




Maternal folic acid supplementation also altered skeletal muscle expression of six 
genes (P < 0.05) in adult offspring, as shown by microarray analysis. Gene 
ontology analysis further revealed these differentially expressed genes in offspring 
following MFAS were closely associated with lipid metabolism, cytoskeletal 
remodelling and potassium ion homeostasis.  
 
Overall, these observations show that MFAS alters hepatic and skeletal muscle 
expression of genes related to lipid and cholesterol metabolism in the offspring 
during prenatal and postnatal development. Maternal folic acid supplementation 
induces sex-specific differences in hepatic expression of DNMTs and non-coding 
miRs in foetal life, with these changes suggested to contribute towards altered 
expression of metabolic regulatory genes and, in effect, an altered capacity for 
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Folate, also known as vitamin B9, is a naturally occurring vitamin essential for 
growth and development. As one of the key moieties in one-carbon metabolism, 
folate facilitates the cellular processes that underpin growth and development, 
including nucleotide synthesis, DNA repair and DNA methylation.260 It is widely 
recognised that inadequate maternal intake of folate during periconception is 
strongly associated with an increased incidence of NTDs; thereby, folate plays a 
cardinal role in neurodevelopmental processes.28, 76, 290 To promote optimal 
neonatal outcomes, women with the intention of conceiving are encouraged to 
consume up to 0.4 mg of folic acid supplements daily from periconception until the 
end of lactation.430 Based upon findings from epidemiological and experimental 
studies, the developmental origins of health and disease (DOHaD) hypothesis 
proposes that maternal nutrition, before and during gestation, can modify 
developmental trajectory, epigenetic regulation and other key processes in 
offspring and through which affect their susceptibility to chronic diseases later in 
life. In light of this, folic acid supplementation, which is common in women of 
reproductive age, may have unforeseen consequences on the long-term metabolic 
health of offspring at the individual and population level, with these consequences 
potentially elicited through changes in DNA methylation and other epigenetic 
regulators. This review summarises what is currently known of the effects of folic 
acid supplementation on maternal and offspring physiology, metabolism and 
epigenetic regulation, including DNA methylation and non-coding miRs. We also 
identify key gaps in the literature, which pertain to the physiological and molecular 
consequences of folic acid supplementation, from preconception to term, with a 
particular focus on metabolic and epigenetic changes in the offspring at prenatal 






1.1.1. FOLATE ABSORPTION AND TRANSPORT 
In humans, folate cannot be endogenously synthesised and must be acquired 
through dietary means.260 Dietary sources abundant in folate include leafy green 
vegetables, citrus fruit, animal liver, kidneys and yeast extracts.260 Natural dietary 
folate exists as a polyglutamate, either in the form of 5-methyltetrahydrofolate (5-
CH3-THF) or formyl tetrahydrofolate (formyl-THF).260 Following ingestion, dietary 
folate, as a polyglutamate, must be deconjugated by glutamate carboxypeptidase 
II in humans or by gamma-glutamyl hydrolase in rats, which allows this anionic 
methyl group donor to be transported across the intestinal lumen as a 
monoglutamate via proton-coupled folate transporters.143  
 
Folic acid, a synthetic analogue of folate, is able to be absorbed by proton-coupled 
folate transporters across the intestinal lumen without deconjugation. The rates at 
which proton-coupled folate transporters transfer folate and its various oxidised 
and reduced forms have been reported to be comparable.450 Upon entry into 
mucosal cells, folic acid undergoes several other metabolic conversions and 
becomes reduced to 5-CH3-THF, the form in which folic acid becomes available 
for systemic distribution.315  
 
In the form of 5-CH3-THF-monoglutamate, folate and folic acid are exported from 
the intestinal mucosal cells into the hepatic portal system, wherein they reach the 
hepatic vein and enter the systemic circulation.450 Transporters responsible for 
mediating the enterocyte export of 5-CH3-THF remain largely unknown, though 
multidrug resistance-associated proteins have been suggested to play a role.219 
Upon reaching the circulation, 5-CH3-THF is subsequently taken up by peripheral 
tissues via several classes of folate transporters embedded in the cellular plasma 
membrane, allowing 5-CH3-THF to participate in one-carbon metabolism and 




As 5-CH3-THF is hydrophilic in nature, it does not diffuse across cell membranes 
passively; hence, its transport must be facilitated by folate specific transporters, of 
which there are three types: reduced folate carrier (RFC); folate receptor (FR); and 
proton-coupled folate transporter (PCFT; Table 1.1).450 Reduced folate carriers are 
saturable anion exchangers that concomitantly import folate into the cell in parallel 
with organic phosphate efflux.450 Expression of this type of folate transporter in 
human tissues is most abundant in placenta and liver, with little in the heart and 
skeletal muscle.426 In the rat, RFCs are present in the kidney, liver, spleen, heart, 
brain, lung, skeletal muscle and small intestine.162, 348 Similarly, in the mouse, 
RFCs are detected in the kidney, brain, heart, liver, choroid plexus, and small and 
large intestine.348, 419  
 
Receptor mediated endocytosis is the principal route by which folate receptors 
transport 5-CH3-THF across the cellular membrane.345 Interestingly, this class of 
folate transporter has three isoforms: FRα; FRβ; and FRγ, with FRα displaying the 
highest affinity for the physiologically available form of folate.435 Folate receptors 
have been detected in various human tissues: FRα in the placenta, kidney, retina, 
lung, ovary, fallopian tube and uterus351; FRβ in the placenta, thymus, spleen, 
mature neutrophils and activated monocytes and macrophages332, 450; and FRγ in 
the spleen, thymus and bone marrow.360 In the rat, FRα has been localised in the 
choroid plexus, kidney, brain and placenta,347 and FRβ has been localised in the 
liver.397 Similarly, in the mouse, FRα has been found to be expressed in retina, 
kidney and liver,371 while expression of FRβ has been found in the liver.119  
 
In addition, there are PCFTs that mediate folate uptake through facilitated diffusion 
by which protons are co-transported with each folate molecule transferred.450 In 
humans, PCFT is highly abundant in the small intestine, spleen, kidney, liver, 
placenta, retina and brain but is not abundant in the large intestine and testicle.326 
In the rat, PCFT is expressed abundantly in the small intestine; moderately in the 
liver, lung, spleen, testicle, choroid plexus and brain; and minimally in the heart, 
stomach and skeletal muscle.175, 429 Correspondingly, PCFT in mouse is 
expressed abundantly in the small intestine, liver and kidney; moderately in the 
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brain, testicle, retina and stomach; and minimally in the heart and lung.327, 399 
Collectively, these observations suggest that folate supplementation is likely to 
impact upon folate stores in glucoregulatory tissues, including liver, skeletal 
muscle and the placenta, thereby affecting its availability to the developing foetus. 
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Table 1.1 Tissue Distribution of Folate Receptors and Transporters in Human, 
Rat and Mouse. 
Folate Specific Transporters   Human Rat Mouse 



















































































1.1.1.1. PLACENTAL TRANSPORTATION OF FOLATE  
As humans and other mammals are unable to synthesise their own folate, they are 
dependent upon exogenous sources for this vitamin; hence, placental transport of 
folate plays a key role in meeting the needs of the developing foetus. Maternal to 
foetal folate transport across the placenta involves the RFC,117 FRα443 and 
PCFT.443 The apical membrane of the placental villi, which is in direct contact with 
the maternal circulation, utilises FRα and RFCs to transport folate via receptor-
mediated endocytosis.200 This system of maternal to foetal folate transport is 
predominantly asymmetrical, with folate travelling more readily from the apical 
membrane to the basal membrane of the placental villi.9, 381  
 
1.1.2. FOLATE IN ONE-CARBON METABOLISM  
In the one-carbon metabolism cycle, folate is utilised along with other cofactors, 
including pyridoxine (vitamin B6) and cobalamin (vitamin B12), to mediate one-
carbon transfer reactions, which are necessary for DNA repair, amino acid 
metabolism and the biosynthesis of nucleotides and amino acids.260, 352 Methionine, 
an essential amino acid, can be remethylated from homocysteine through this 
cycle and be further metabolised to form S-adenosylmethionine (SAM), which is 
the primary methyl group donor in transmethylation reactions.356, 452 The activities 
of the one-carbon metabolism cycle are affected by variations in dietary folate 
supply; in the rat, dietary folate deficiency for four weeks decreased the hepatic 
ratio of SAM/S-adenosylhomocysteine (SAH).16, 284 A decreased ratio of SAM/SAH 
ratio has been found to impede methyltransferase activities.311 
 
Hepatic SAM/SAH ratio was lower in pregnant rats that were fed a folic acid 
deficient diet (0 mg folic acid /kg feed) as compared to those fed a folic acid 
supplemented diet.208 In contrast, the hepatic SAM/SAH ratio of pregnant and 
virgin rats that were fed a diet containing high levels of folic acid (40 mg folic acid 
/kg) was markedly increased in comparison to those fed a control diet.4 In 
hyperhomocysteinemic pregnant rats, folic acid supplementation was shown to 
increase hepatic SAM/SAH ratio in comparison to those that were fed a folic acid 
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deficient diet.161 Cumulatively, results from these studies are in agreement with the 
rationale that folic acid supplementation during pregnancy increases maternal 
hepatic SAM/SAH ratio.  
 
In contrast, maternal folic acid deficiency, from two weeks prior to mating and 
throughout gestation in the rat, reduced the hepatic SAM/SAH ratio in adolescent 
offspring.54 This suggests that maternal intake of folic acid during gestation can 
alter the hepatic SAM/SAH ratio of offspring long term after birth and may affect 
their capacity for DNA methylation in postnatal life.  
 
However, the association between folic acid intake and hepatic SAM/SAH ratio in 
postnatal life is less consistent. In aged rats, folic acid supplementation (40 mg 
folic acid/kg feed) for 29 days did not alter the hepatic SAM/SAH ratio.4 A cohort 
study of 111 human subjects also reported no differences in the serum SAM/SAH 




Figure 1.1 The Role of Folate in One-Carbon Metabolism. 
Folate is a key cofactor in one-carbon metabolism, in which it serves as a shuttle 
for methyl groups utilised in methylation reactions, de novo synthesis of purines 
and thymidylate and S-adenoysl methionine metabolism. DHFR, dihydrofolate 
reductase; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidylate 
monophosphate; MAT, methionine adenosyltransferase; MS, methionine synthase; 
MTHFD, methylenetetrahydrofolate dehydrogenase; MTHFR, 
methylenetetrahydrofolate reductase; MTRR, methionine synthase reductase; 
SAH, S-adenosyl homocysteine; SAHH, S-adenosyl homocysteine hydrolase; 
SAM, S-adenosyl methionine; THF, tetrahydrofolate; TYMS, thymidylate 
synthetase. Schematic illustration adapted from Lee, Bonner228.  
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1.1.3. MATERNAL ONE-CARBON METABOLISM AND THE ESTABLISHMENT 
OF FOETAL METHYLATION PATTERNS  
Gametogenesis and embryogenesis are two major stages of development during 
which epigenetic patterns are dynamic and may become established.288 Initially, 
primary epigenetic patterns, comprised of DNA methylation and histone 
modifications, are established on imprinted and non-imprinted genes in gametes 
over the course of gametogenesis.238 
 
Following fertilization, inner cell mass of the pre-implantation mouse embryo 
undergoes global demethylation at E3.5.139 Recent studies suggest that not all 
genomic regions are equally affected by global demethylation in the pre-
implantation mouse embryo; imprinted gene loci, imprinting control regions, a 
majority of oocyte-specific CpG islands, a subset of sperm-specific CpG islands as 
well as a selection of transposable elements, including intracisternal A particle, 
appear to be exempt from this wave of DNA methylation erasure.33, 432 These 
variations in the degree of demethylation across different genetic element classes 
may reflect the need to ensure correct transcriptional activation in the early 
embryo as well as the need to repress expression of potentially hazardous 
transposition activities adequately.355  
 
Upon implantation, de novo remethylation commences in the inner cell mass of the 
blastocyst, allowing which to develop into an epiblast layer.355 This remethylation 
process has been found to be largely complete by E6.5.139 As a result, epiblasts 
with lineage-specific methylome are established, allowing these cells to specialise 
into organs, tissues and particular cell types, including primordial germ cells, such 
that they are able to maintain their cellular identity and genomic stability. 
 
At later stages of foetal development, a second wave of erasure of epigenetic 
patterns occurs solely in primordial germ cells.336 This erasure of epigenetic 
patterns in primordial germ cells in mice is known to occur at two stages: the first 
11 
 
at E8.5 and the second from E10.5.355 In effect, genome-wide DNA demethylation 
and the erasure of imprints are achieved by E13.5.287 It is worthy to note that not 
all genomic regions are equally demethylated, with repeats such as IAP and ERV-
1 as well as a subset of single copy sequences shown to escape embryonic 
reprogramming.138, 328 Genomic regions, which escape embryonic reprogramming, 
have been suggested as candid facilitators for transgenerational epigenetic 
inheritance.138, 328 By E16.5, DNA methylation patterns are re-established in 
mouse primordial germ cells along with unique patterns of histone modification, in 
accordance to the sex of the foetus.355 
 
1.1.4. FOLATE AND DNA METHYLATION 
S-adenoyslmethionine homeostasis is essential for the cell, as it partly determines 
the rate at which cellular methylation occurs.132 One of the key cellular methylation 
processes integral to gene expression regulation during development is DNA 
methylation, which is primarily established at the 5’ position of a cytosine residue 
in CpG dinucleotide (CpG). Two types of DNA methylation are known to occur in 
the mammalian genome: maintenance methylation and de novo methylation. The 
replication of DNA methylation patterns during and subsequent to mitosis is 
described as maintenance methylation in which DNA methyltransferase 1 (Dnmt1) 
plays a prominent role.82 With a predilection for hemi-methylated DNA, Dnmt1 
perpetuates the methylation pattern of the parental DNA strand onto the newly 
synthesised daughter strand.26 In addition, Dnmt1 is found to be localised to the 
DNA replication foci during S-phase and interacts closely with MeCP2, a methyl 
binding protein, for the purpose of preserving methylation patterns with high fidelity 
through multiple rounds of cell division.212, 232 
 
De novo methylation is the establishment of new methylation patterns, which is 
catalysed by DNA methyltransferase 3a (Dnmt3a) and 3b (Dnmt3b), particularly 
during early embryogenesis305, 337; therefore, embryonic stem cells (ESCs) with 
Dnmt3a and 3b deficiencies have limited abilities to differentiate and proliferate 
and culminate in embryonic lethality.62 Collectively, these observations illustrate 
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the necessity for de novo methylation during early embryonic development. 
Moreover, de novo methylation has been shown to be required in genomic 
imprinting, through which imprinted genes become expressed exclusively from one 
of the parental alleles. Dnmt3a and DNA methyltransferase 3-like (Dnmt3L) are 
specifically required in genomic imprinting.150, 190 Thus, offspring of Dnmt3a 
conditional mutant female mice die in utero and display allele-specific expression 
at maternally imprinted loci, including Igf2r and Peg, as well as a lack of DNA 
methylation.190 Embryos nullizygous for Dnmt3L similarly display demethylation at 
various maternally imprinted gene loci, including Peg1 and Peg3.150 These 
observations show that the establishment of maternal methylation imprints 
requires Dnmt3L.  
 
1.1.5. DNA METHYLATION AND THE REGULATION OF GENE EXPRESSION  
DNA methylation, at the 5’ position of a cytosine residue in the regulatory CpG 
island of a protein-coding gene, establishes a distinctive epigenetic signature of 
inactive expression.294 The presence of such signature in the regulatory promoter, 
also known as the differentially methylated region (DMR), can alter the interaction 
between DNA-binding proteins and their targets, cis-acting DNA elements.368 
Methylation-sensitive DNA-binding transcription factors cannot access promoter 
regions, which contain a high ratio of 5-methyl cytosine to non-methylated 
cytosine.224 In turn, transcription initiation is impeded, leading to repressed gene 
expression.179 
 
Methylated DNA in the CpG island of a regulatory region can also silence gene 
expression via an alternative mechanism. The presence of a methylation signature 
in the regulatory promoter of a gene can attract methyl CpG binding proteins, in 
turn, recruiting chromatin remodelling enzymes to the local region.188 Recruitment 
of such enzymes to the methylated DNA region instigates the formation of a 
heterochromatin, which is a highly condensed chromatin structure that does not 
allow transcription factors and RNA polymerase II to bind.238 As a result, 
13 
 
transcription initiation complexes cannot assemble at the promoter region, and 
initiation of gene transcription is obstructed.408 
 
Genomic imprinting is a specific type of epigenetic regulation by which a gene 
becomes exclusively expressed from a single allele in accordance to parental 
origin.21 This form of epigenetic regulation is established in the imprint control 
region (ICR) of an imprinted gene via DNA methylation, which prevents the 
imprinted gene from being expressed from the methylated parental allele.265 Thus, 
deletion of ICR of imprinted genes, either naturally or experimentally, results in the 
loss of imprinting.372 With a number of imprinted genes encoding specific solute 
channels and transporters, including the paternally imprinted Slc22a2, Slc22a3 
and Ata3, aberrant genomic imprinting may affect placental expression of 
imprinted genes and may consequently alter the rate of transplacental exchange 
of nutrient substrates and foetal growth.335 
 
1.1.5.1. DNA METHYLATION AND GENOMIC STABILITY  
In addition to the regulatory region of protein-coding genes, CpG islands are also 
found to occur in intergenic regions that regulate genomic stability, including 
imprint domains and repeat elements. The activation and translocation of 
transposable elements and satellite repeats are highly disruptive to genomic 
stability, as these initiate chromosomal rearrangements and chromosomal 
abnormalities. Numerous studies have shown that the inactivation and 
immobilisation of these nuclear elements in plants and mammals are mediated by 
DNA methylation.195, 343 Thus, the partial loss of function in Dnmt3b, as seen in 
immunodeficiency, centromeric region instability, facial anomalies (ICF) syndrome 
in human, has been attributed to an increased incidence of chromosomal 
rearrangements in the hypomethylated centromeric regions.436 Moreover, deletion 
of Dnmt1 and Dnmt3b in human cell lines have been shown to induce 




X-chromosome inactivation is a mechanism of dosage compensation by which one 
of two X chromosomes becomes silenced in the female.233 This process prevents 
the overexpression of X-linked genes, as females possess two copies of the X-
chromosome, while males possess one copy.90 Promoter regions of the inactive X 
chromosome are methylated to a greater extent than those of the active X; hence, 
DNA methylation is crucial for establishing the transcriptional repressed state of 
the inactive X chromosome.304 
 
1.1.5.2. DNA METHYLATION, LINEAGE SPECIFICATION, AND MAINTENANCE 
OF CELLULAR IDENTITY  
Distinctive DNA methylation patterns appear to be instrumental in developmental 
progression and lineage specification. During early development, ESCs undergo 
dynamic methylation changes. As indicated by genome-wide DNA methylation 
analyses, key developmental and house-keeping genes in pluripotent ESCs are 
hypomethylated at their CpG promoter regions, while tissue-specific genes are 
hypermethylated.110, 278, 286 Through the course of differentiation, pluripotency 
genes are progressively down-regulated, while markers of differentiated lineages 
are up-regulated in ESCs.353 Deletion of the three key DNMTs had negligible 
effects on the self-renewal capacity of ESCs, while differentiation of ESCs was 
unable to be maintained without the presence of DNMTs.178, 240, 305, 395 These 
observations suggest that DNA methylation is integral to lineage specification. In 
agreement, DNA methylation is required in the silencing of Oct4, a transcription 
factor responsible for maintaining pluripotency of ESCs.102 Moreover, DNMT 
deficiency prevents ESCs from committing to a specific developmental fate during 
differentiation, in turn, enabling ESCS to revert back to their undifferentiated state. 
353 
 
1.1.6. PHYSIOLOGICAL REQUIREMENTS OF FOLATE DURING 
PERICONCEPTION, PREGNANCY AND LACTATION  
Given the deleterious consequences of periconceptional folate deficiency, the 
World Health Organization (WHO) currently recommends women of reproductive 
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age to consume 0.4 mg of folic acid supplements on a daily basis during the 
periconceptional period until 12 weeks of gestation.431 For women who have had a 
previous birth affected by a NTD, the WHO recommends a daily dosage of 5 mg of 
folic acid supplements.431  
 
The daily dietary folate requirements and intake for women at other stages of 
reproduction are also important, including those for non-pregnant women and 
lactating women, as their needs for folate vary largely. The Australian Department 
of Health and Ageing and the Institute of Medicine in the United States 
recommend the daily folate intake of non-pregnant women to be 0.4 mg.12, 176 
Consistently, the Institute of Medicine in the US also recommends the dietary 
allowance for folate to be 0.4 mg in non-pregnant women over the age of 19 and 
0.6 mg for pregnant women.176 The recommended daily intake (RDI) of folate for 
pregnant women is 0.6 mg, while that for lactating women is 0.5 mg.12  
 
To investigate whether non-pregnant women meet this dietary requirement, 
several studies have assessed the dietary folate intake of women prior to their 
pregnancy. An observational study reported that the median dietary folate intake of 
non-pregnant women in Italy was 0.266 mg, with a median folate serum level of 
5.9 ng/mL.321 For non-pregnant women in the United Kingdom, their median folate 
intake was found to be 0.384 mg, with a medium folate serum level of 9.3 
ng/mL.321 Among the 66,014 women in the Norwegian Mother and Child Cohort 
study, the median total folate intake was reported as 0.313 mg per day in the 
overall population, while that for supplement users was 0.530 mg per day.358 A 
study in Northern China reported that 99% of non-pregnant women had a dietary 
intake of folate below the estimated average requirement of 0.320 mg per day.281 
These studies provide indicative evidence that folate intake from dietary sources of 
typical diets alone may not be sufficient in meeting the RDI for women of 
reproductive age; consequently, there is an increasing need for the practice of 




1.1.7. PERICONCEPTIONAL FOLIC ACID SUPPLEMENTATION AND 
PREGNANCY OUTCOMES IN HUMANS 
The periconceptional period is the time over which preconception, conception, 
implantation, placentation and embryogenesis occur.375 For women, the 
preconceptional phase of this period is considered to begin around 26 weeks prior 
to conception, at which meiosis resumes in the oocytes, with primordial follicles 
leaving their resting state.375 The postconceptional phase of this period is defined 
as the time at which conception is initiated up until the secondary palate of the 
embryo closes at 10 weeks postconception.407 
 
For the purpose of this review, periconceptional folic acid supplementation will be 
defined as MFAS commencing prior to the last menstrual cycle; preconceptional 
folic acid supplementation will be defined as the initiation and termination of MFAS 
commencing prior to the last menstrual cycle; and postconceptional folic acid 
supplementation will be defined as the initiation of MFAS subsequent to the last 
menstrual cycle.  
 
Each of these stages of periconception is highly sensitive to maternal nutrition, 
especially micronutrients,105 with studies indicating that folic acid intake during the 
periconceptional period may affect development of the oocyte and its 
microenvironment.35 In women who underwent in vitro fertilisation or cytoplasmic 
sperm injection, folic acid use was associated with increased folate concentration 
in monofollicular fluid.35 This study only investigated whether women were using 
folic acid supplements on the day of ovum pick up, but it did not report on the 
period for which these women were taking folic acid supplements nor the dosage 
of folic acid supplements consumed. A case-control study reported that mothers 
above the age of 35 years, who used folic acid supplements during postconception, 
from two weeks after her last menstrual cycle, showed a reduced incidence of 
chromosome 21 non-disjunction meiotic II errors in the aging oocyte (OR = 
2.00).159 These findings suggest that periconceptional folic acid supplementation 
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may impact upon oocyte development, with potential implications for chromosomal 
integrity and the maintenance of genomic stability.  
 
In terms of spermatogenesis, the effects of folic acid supplementation on this 
meiotic process has recently been investigated, with folic acid supplementation of 
5 mg per day for 6 months in idiopathic infertile men found to increase blood folate 
concentrations but provided no improvements in sperm parameters, including 
sperm concentration, semen volume, sperm motility and sperm chromatin 
integrity.1 However, folic acid supplementation was found to result in a global loss 
of DNA methylation across the sperm methylome, particularly in intergenic regions 
containing a high number of DNA repeats and transposable elements as well as in 
low-density CpG regions.1 In a double-blind randomised controlled study, no 
significant differences in DNA methylation levels were found in the sperm DNA 
methylome between healthy men who were supplemented with 0.4 mg for 3 
months and those who were not supplemented.55 The sample size of this 
randomised controlled study was relatively small; it might be possible for small 
changes to exist in the DNA sperm methylome of these subjects; therefore, further 
studies with larger sample sizes are needed to ascertain the effects of folic acid 
supplementation on sperm DNA methylome and other reproductive outcomes 
such as embryo quality and growth.  
 
Several lines of evidence also indicate that periconceptional folic acid 
supplementation may affect early embryogenesis. A systematic review found that 
periconceptional folic acid supplementation, alone or with other vitamins and 
minerals, reduced the prevalence of NTDs as compared to no intervention, 
intervention with placebo or intervention with multivitamin supplementation 
deprived of folic acid (Table 1.2).225 Despite recommendations being in place for 
the practice of periconceptional folic acid supplementation, it has been recognised 
that attaining 0.4 mg of folic acid daily intake through an unfortified diet is 
challenging and requires substantial behavioural and dietary changes among 
women of reproductive age.107 To facilitate the implementation of periconceptional 
folic acid supplementation, food fortification has been recommended.29 
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Accordingly, 53 countries, including the United States, Canada, Chile and 
Australia, have adopted policies by which wheat flour is mandatorily fortified with 
folic acid of concentration from 0.946 to 3.08 parts per million.53 The impact of folic 
acid fortification has been evaluated in the United States and has been found to 
reduce the prevalence of NTDs by 19%.160 In Canada, the introduction of folic acid 
fortification resulted in a 46% reduction in the prevalence of NTDs, from 1.58 per 
1000 births before fortification to 0.86 per 1000 births, during the full-fortification 
period.79 A 42% reduction in the birth prevalence rates of anencephaly was also 
observed in Chile during the fortified period as compared to the immediate pre-
fortified period.257 Furthermore, the incidence of low red blood cell folate levels 
among Australian women between the ages of 15 to 50 was reduced to 0.16% 
after the introduction of mandatory folic acid fortification.39  
 
Given the effectiveness of periconceptional folic acid supplementation in 
preventing NTDs, recent research has focused on whether this nutritional 
intervention may have additional benefits, especially on foetal and neonatal 
outcomes as well as other congenital defects. A systematic review reported that 
maternal folic acid supplementation during preconception but not in any other 
periods of gestation was associated with a reduced risk for the neonate of being 
born SGA.156 The dosage of folic acid supplements used by the majority of the 
included subjects (99%, 40,526 women) was between 0.4 and 5 mg, while 1% 
(429 women) used supplements of other dosages.156  
 
Recent studies have also examined the relationship between periconceptional folic 
acid supplementation and preterm birth. A recent large prospective cohort study 
on 207,936 pregnancies found that MFAS of 0.4 mg per day in the 
periconceptional period to be associated with a 14% reduction in the risk of 
spontaneous preterm birth.242 Similarly, a review of observational studies has 
reported MFAS to be associated with a slight reduction in preterm birth.268 On the 
contrary, a recent systematic review has found MFAS during pregnancy to have 
no effects on preventing preterm birth less than 37 weeks.346 At present, it appears 
MFAS may not be an effective intervention for reducing preterm birth.  
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It is well established that being born SGA, as defined by birth weight less than the 
10th centile for gestational age, is associated with an increased susceptibility to 
chronic diseases in later life, including Type 2 Diabetes Mellitus,141 hypertension,19 
obesity306 and cardiovascular diseases.20 Periconceptional folic acid 
supplementation may reduce developmental programming of adult disease on a 
population basis by reducing the incidence of SGA, which is associated with an 













Exposure Time Observed Effects in Offspring 
Embryonic, foetal and neonatal development 
6,105 women 




MFAS prevented the occurrence of NTDs.78 
188,796 infants 
0.4 - 5 
mg/day 
Preconception MFAS was associated with reduced risk of SGA neonate.156 
207,936 infants 0.4 mg/day 
Preconception to 
end of 1st trimester 
MFAS was associated with a 14% decrease in risk of spontaneous 
preterm birth.242 
780 women 0.4 mg/day 
Periconception to 
mid-1st trimester 
MFAS was associated with reduced risk of congenital heart defects.241 
2,104 women 0.8 mg/day 
Preconception to 
mid-1st trimester 
MFAS was associated with reduced risk of congenital malformations.76 
3,987 infants Unspecified 
Preconception to 
end of 1st trimester 
MFAS was associated with reduced risk of non-syndromic cardiac 
defects.34 






MFAS was associated with 30-35% decrease in risk of conotruncal heart 







MFAS was associated with 18% decrease in risk of congenital heart 




1.1.8. MATERNAL FOLIC ACID SUPPLEMENTATION AND PREGNANCY 
OUTCOMES IN HUMANS 
In terms of other adverse pregnancy outcomes, a systematic review of randomised 
controlled, cluster-randomised and cross-over controlled trials did not find MFAS 
to have significant effects on miscarriages, stillbirths, preterm births and mean 
birth weight.225 The dosage of folic acid and the period in which these mothers 
were supplemented across these trials were not consistent; however, these 
heterogeneities in study design were identified and acknowledged as two major 
limitations of the systematic review.225 As with embryonic size, the Rotterdam 
Predict study failed to detect for the presence of any significant associations 
between embryonic crown-rump length and the timing at which maternal folic acid 
use was initiated at preconception or at postconception.403 Furthermore, a number 
of inconsistencies were found between studies examined in this review, 
particularly in relation to the dosage and the period at which folic acid was 
supplemented. Future well-powered studies with unified dosage and timing in 
exposure of folic acid supplements are needed to assess possible relationships 
with pregnancy outcomes.  
 
1.1.9. FOLATE AND MATERNAL PHYSIOLOGY AND METABOLISM  
Maternal and foetal requirements for folate increase markedly over the course of 
gestation. This stems from an increased rate in the biosynthesis of nucleotides 
and amino acids, which are needed to support foetal growth, placental 
development, uterine enlargement and the expansion of blood volume.378, 382 
Consistently, a systematic review has found folic acid supplementation to be 
preventative against maternal megaloblastic anaemia.225  
 
As a cofactor in the one-carbon metabolism cycle, folate facilitates the 
remethylation of methionine and through which reduces the concentration of 
homocysteine.292 It is well recognised that the oxidation of homocysteine gives rise 
to reactive oxygen species, which induce oxidative stress; hence, high levels of 




characterised by disrupted oxidative balance such as pre-eclampsia and 
intrauterine growth retardation.210, 292 Hyperhomocysteinemia has been reported in 
pregnant women with intrauterine growth retardations as compared to their 
pregnant control counterparts.308 Given the role of folate in the remethylation of 
methionine, it may be possible for folic acid supplementation to reduce maternal 
homocysteine levels as a prophylactic means against oxidative stress and its 
associated pregnancy complications. There is supportive evidence for this, the 
introduction of mandatory folic acid fortification in flour in Iran reduced 
hyperhomocysteinemia in women of childbearing age from 38.8% to 7.3%.2, 3 In 
two separate clinical trials, MFAS in the second trimester is found to reduce 
maternal serum homocysteine levels276 and maternal plasma homocysteine in the 
third trimester.424 Furthermore, in a randomised controlled trial, MFAS throughout 
pregnancy reduced the level of maternal plasma homocysteine in the third 
trimester as compared to controls.94 At present, few studies have examined the 
effects of folic acid supplementation on maternal physiology and metabolism. It is 
also unclear if folic acid supplementation could modulate maternal physiological 
and metabolic adaptations that occur in response to pregnancy.  
 
1.1.10. FOLATE IN EMBRYONIC AND FOETAL DEVELOPMENT IN NON-
HUMAN STUDIES 
Despite periconceptional folic acid supplementation being known to prevent NTDs 
and other congenital defects in humans, the underlying molecular mechanisms 
remain largely unknown. A number of in vitro and in vivo studies in non-human 
species have identified potential pathways by which folate may affect development 
of embryos and foetuses (Table 6.1). 
 
Maternal folic acid supplementation, from two weeks before conception and 
throughout pregnancy, reduced global methylation in the brain and liver of mouse 
embryos that were either homozygous or heterozygous deficient for Folbp1, an 
intracellular folate transporter, at gestational day 15.106 However, in another study, 




methylation of 253 genes, including Igf2r, in the liver of both Folbp1 homozygous 
and Folbp1 heterozygous deficient embryos at gestational day 18.394 Thereby, 
these observations provide evidence that MFAS may alter the course of embryonic 
and foetal development through various changes to foetal epigenome, in particular, 
the foetal methylome. Further studies are needed to elucidate whether any 
epigenetic changes induced by MFAS during foetal development can have 
consequences on metabolic and physiological function of offspring after birth.  
 
1.1.11. FOLATE AND EPIGENETIC REGULATION: HUMAN STUDIES  
Several lines of evidence in humans suggest that MFAS alters epigenetic 
regulation in offspring after birth (Table 6.2). Periconceptional folic acid 
supplementation (0.4 mg per day), from one month prior to conception until two 
months after conception, was associated with higher levels of methylation in the 
DMR of IGF2 in the blood of children at the age of 17 months.374 Maternal use of 
folic acid supplements (0.4 mg per day), from 13 week of gestation until term, was 
also associated with a higher level of methylation in the DMR of IGF2 in umbilical 
cord blood of newborn infants.140 Conversely, in the same cohort, reduced 
methylation levels in the DMR of PEG3 and LINE-1 in the cord blood of infants 
were strongly associated with MFAS after 12 weeks of gestation.140 A cohort study 
found no association between maternal use of folic acid supplements before or 
during pregnancy and the level of methylation in the DMR of IGF2 in infant cord 
blood.166 However, this study did report that MFAS, before and throughout 
gestation, decreased methylation levels in the DMR of H19 in the cord blood of 
newborn infants, with this being more pronounced in male infants.166 Similarly, 
higher maternal intake of folic acid during the periconceptional period was reported 
to be associated with lower levels of methylation in the DMR of IGF2 in the buccal 
epithelial cells of infants.309 Recently, MFAS (5 mg per day), from 17 weeks of 
gestation to term, was reported to be associated with decreased methylation levels 
in the 5’ untranslated region of PDGFRA, HLA-DPB2, HLA-DPB1, PAX8 and 
VTRNA2-1 in adult human offspring.341 Taken together, these observations 
indicate that MFAS, before and throughout gestation, can alter the epigenetic state 




specific hypermethylation and hypomethylation. It remains unknown as to whether 
these changes in DNA methylation may occur at multiple CpG sites and whether 
factors such as ethnicity, age and sex could further impact upon these methylation 
signatures.  
 
Also, it remains unknown if MFAS may affect other forms of epigenetic regulation 
such as expression and action of non-coding miRs, chromatin modifications and 
others in offspring. Given the role of epigenetic dysregulation in the manifestation 
of metabolic phenotype and the pathogenesis of chronic diseases, further 
investigation is warranted to advance current understanding on the mechanistic 
basis for the developmental programming effects of MFAS.  
 
1.1.12. FOLATE AND DEVELOPMENTAL PROGRAMMING: HUMAN 
STUDIES 
Clinical studies have reported inconsistent findings on the associations between 
maternal folate status and metabolic health of the offspring after birth. Effects of 
maternal folate status on offspring phenotype have been reported, with these 
effects to vary in accompaniment of maternal vitamin B12 status during gestation 
(Table 6.3).217, 376, 440  
 
Insulin resistance in children, between the ages of nine and a half and thirteen and 
a half, was associated with higher maternal plasma folate between 28 and 32 
weeks of gestation.217 However, in another study, maternal folate status, at 18 to 
32 weeks of gestation, was not found to be related to key parameters of body 
composition in children at the age of nine years, including body weight, total fat 
mass and lean mass.376 Furthermore, a randomised controlled trial did not find any 
associations between maternal blood folate during gestation and insulin resistance 
in Nepali children at six to eight years of age.237 In addition, maternal intake of folic 
acid supplements during first trimester was not associated with blood pressure in 




maternal erythrocyte folate concentrations combined with low maternal erythrocyte 
vitamin B12 concentrations, between 18 and 28 weeks of gestation, were 
associated with a higher risk of insulin resistance and adiposity in six years old 
children.440 Any associations between maternal folate status and intake with 
phenotype in offspring may depend upon the prevailing vitamin B12 status of the 
population, which was not always examined. Equally, maternal folate status, 
dietary folate intake or use of folic acid supplements, from before and throughout 
pregnancy, was not consistently documented in all studies; such limitations in the 
studies to date may contribute to heterogeneity in observed outcomes of maternal 
folate status during pregnancy on body composition, metabolic state and their 
regulation in human offspring. 
 
The effects of maternal folate status during gestation on body composition and 
metabolic state and regulation in offspring in adulthood also remain unexamined; 
other developmental programming effects evident in childhood are also known to 
become amplified and emerge subsequently with increasing exposure to 
challenges by lifestyle factors in adulthood.127, 149  
 
1.1.13. FOLATE AND DEVELOPMENTAL PROGRAMMING: NON-
HUMAN STUDIES 
Recent studies in non-human species have examined the effects of MFAS on 
metabolic health of offspring, with marked perturbations reported in the regulation 
of lipid and glucose homeostasis (Table 6.4). In rodents, MFAS, of 5 mg per day 
from conception to term, reduced plasma cholesterol in the adolescent and adult 
offspring and reduced plasma glucose in adolescent offspring.67 Maternal folic acid 
supplementation, of 5 mg per day from conception to term, increased plasma TAG 
and non-esterified fatty acids (NEFAs) in adult offspring.43, 67 When challenged by 
a post-weaning diet of high fat content, plasma glucose was increased to a greater 
extent in adult offspring of folic acid supplemented dams than in controls.43 




susceptible to impaired metabolic regulation, when challenged with a high fat 
content diet.  
 
Our research group has recently shown that MFAS, of 6 mg per day from two 
weeks prior to conception until term, in the normal pregnant rat improves whole 
body insulin sensitivity and maximal insulin action in the adult male offspring but 
increases plasma glucose in the adult female offspring (Professor Julie Owens, 
oral communication). Consistently, another study has shown that plasma glucose 
in adult female offspring is increased by MFAS relative to controls.158 These 
observations indicate that MFAS in the rat can alter glucose as well as lipid 
homeostasis in offspring postnatally.  
 
Despite the underlying mechanisms for these metabolic changes being elusive, 
several lines of evidence suggest that epigenetic modifications may be one 
pathway by which MFAS affects expression of key metabolic regulators in the 
offspring after birth. One study reported that MFAS, of 5 mg per day from 
conception to term, decreased the hepatic expression of Ppara, Pparγ and LXRα 
in adult offspring.67 Another study showed that MFAS altered hepatic expression of 
a key gluconeogenic regulator, Pepck, in a sex-specific manner, with its 
expression being increased in adult female offspring but unchanged in adult male 
offspring.158 This disparity in hepatic expression of Pepck was found to correlate 
with sex-specific differences in epigenetic regulation, with methylation at CpG site 
-248 in the hepatic promoter of Pepck being substantially modified by MFAS in the 
female offspring.158 As a consequence of an altered DNA methylation signature at 
CpG site -248, there was an increase in binding of CCAAT-enhancer binding 
protein β to the hepatic promoter of Pepck, in turn, hepatic expression of Pepck 
was increased.158  
 
Maternal folic acid supplementation in the rat, of 5 mg per day from three weeks 
before conception to the end of lactation, reduced global DNA methylation in the 




was also observed at specific gene loci in the liver of 14 weeks old offspring of 
folic acid supplemented dams, including the promoter region of Pparγ and ERα, 
exon 6 and 7 of p53 and exon 15 of Apc.365 Increased methylation also occurred at 
selected CpG sites of Pparγ, p16 and exon 6 and 7 of p53 in the liver of adult 
offspring of folic acid supplemented dams as compared to controls.365 Besides 
DNA methylation, the activity of various DNMTs in the liver of weaned and adult 
rat offspring following MFAS were reduced.365 These observations show that 
MFAS can attenuate the capacity of offspring to maintain DNA methylation 
patterns after birth, which may have additional consequences for epigenetic state 
longer term.  
 
1.1.14. MICRORNAS 
MicroRNAs are small non-coding RNA molecules consisted of 20 to 22 
nucleotides; these constitute a novel class of epigenetic regulation.427 Functionally, 
miRs bind to the 3’ untranslated region (3’ UTR) of their target mRNA through 
complementary base pairing and attenuate translation or promote mRNA 
degradation.45, 59 Given a single human miR has been shown to be capable of 
down-regulating the post-transcriptional expression of multiple genes 
simultaneously, it is postulated that a single miR is capable of eliciting changes to 
multiple genes in many different molecular networks and biological pathways.251  
 
1.1.15. MICRORNA BIOGENESIS 
Primary microRNAs (pri-miRs) are produced by transcription of miR genes from 
independent genomic transcription units or from introns of protein-coding genes by 
RNA polymerase II (Figure 1.2).45 Once transcribed, pri-miRs are completed with 
polyadenylation and a 5’ methylguanosine cap.45, 349 These pri-miR molecules are 
further processed into shorter intermediates, also known as precursor miRs (pre-
miRs); thereafter, these shorter intermediates are cleaved by a nuclear 
microprocessor complex, which is comprised of Drosha and DGCR8.145, 229 The 
double-stranded stem and the unpaired flanking region of the pri-miR are 




DGCR8 is responsible for determining the precise cleavage site on the pri-miR, 
while Drosha conducts the cleavage at 11 base pairs away from the double-
stranded RNA junction at the base of the stem.145, 146 
 
Subsequent to nuclear processing, Exportin-5 coupled with Ran-GTP exports the 
pre-miR into the cytoplasm in which the pre-miR becomes further refined into a 
single-stranded mature miR by RNA-induced silencing complex (RISC).31, 444 
Recognition of pre-miR by Exportin-5 occurs through identifying 3’ overhangs and 
the length of the double-stranded stem on the pre-miR.262, 447 The final maturation 
stages of miR in the cytoplasm involves RISC loading complex, which is 
composed of RNase III Dicer, Tar RNA binding protein (TRBP), protein activator of 
protein kinase receptor (PACT) and Argonaute-2 (Ago2).64, 130, 230 A core 
component of RISC loading complex, Ago2, cleaves the 3’ arm of the hairpin-
shaped pre-miR in the middle, releasing a nicked hairpin, otherwise known as the 
Ago2-cleaved precursor miR (ac-pre-miR).84 This step facilitates subsequent 
strand dissociation and microRNA-induced silencing complex (miRISC) 
activation.273, 329 Thereafter, RNase III Dicer cleaves the loop of the ac-pre-miR 
and produces a miR duplex with two nucleotides overhanging at its 3’ end. To 
activate the mature miR, the miR duplex is first required to be separated into the 
functional guide strand and the passenger strand, with the former being 
complementary to the mRNA target, while the latter becomes degraded. 
Thermodynamic stability of the two ends of the duplex plays a key role in 
determining the strand, which reaches full maturation. The functional mature 
strand is characterised by low internal stability at the 5’ end, which becomes 
incorporated into the miRISC.206, 386 
 
As the effector of mature miRs, miRISC can be consisted of Argonaute-bound 
GW182 and one of four Argonaute proteins (Ago1-4).85, 101 All Argonaute proteins 
have been demonstrated to be capable of enhancing the stability and abundance 
of mature miRs.84 For GW182, this protein is known to facilitate the mobilisation of 
miRISCs into P-bodies wherein post-transcriptional expression of the target gene 





Figure 1.2 Canonical Pathway for MicroRNA Biogenesis and Maturation.  
This pathway involves the production of the primary miR transcript via RNA 
polymerase II and the subsequent nuclear cleavage of the transcript by Drosha-
DGCR8. The resultant precursor miR is exported by Exportin-5-Ran-GTP from the 
nucleus to the cytoplasm in which it becomes processed by RNase Dicer and the 
double-stranded RNA binding protein TRBP. The functional strand of the mature 
miR (as shown in red) is incorporated into RNA-induced silencing complex (RISC), 
which is constituted of Argonaute (Ago2) proteins, while the passenger strand (as 
shown in black) is degraded. Through complementary binding, the mature miR 
strand guides the RISC complex to silence its mRNA target through mRNA 
cleavage, mRNA deadenylation or translational repression. Schematic illustration 





1.1.15.1. MECHANISMS OF MICRORNA ACTION  
MicroRNAs achieve their gene silencing effects through two primary mechanisms: 
translational repression173 and mRNA decay.101, 433 Translational repression is the 
result of interference between miRISC-associated proteins and translation 
initiation factors.213 To repress translation, miRs inhibit the assembly of 60S 
subunits on their target mRNAs, with the presence of a 5’ cap on the target mRNA 
deemed as an essential enabling feature for this gene silencing effect.316, 412 As a 
result, microRNAs repress protein expression of their target during the initiation 
stages of translation. Additionally, miRs may also elicit its gene silencing effects 
during the elongation stages of translation, as the deletion of elF6, an elongation 
factor, has been observed to abrogate miR-mediated regulation of target protein 
expression.63 
 
Recent evidence has provided molecular insights into the ways by which miRs 
may instigate decay of their mRNA target. Precedent to mRNA decay, the target 
mRNA transcript first undergoes miR-mediated deadenylation, which is facilitated 
by the CCR4-NOT complex and the PAN2-PAN3 complex.409, 428 One of the key 
constituents in miRISC, GW182, acts as a docking platform for these two protein 
complexes required in miR-mediated deadenylation.37, 100 Following removal of the 
poly(A) tail, the 5’cap of the target mRNA is cleaved off by DCP1-DCP2 complex, 
allowing mRNA decay to occur.24, 334 The degradation of the target mRNA is 
conducted by Xrn1 5’-3’ exonuclease.295 
 
Besides post-transcriptional gene silencing, miRs have recently been postulated to 
have other mechanistic actions, with these being functionally related to their roles 
as mature nuclear miRs and activators of translation.172 Mature miRs have been 
observed to be present in the nucleus,182, 319, 342 with CRM1/Exportin 1 and 
Importin 8 found to mediate the shuttling of mature miRs from the cytoplasm into 
the nucleus. 51, 422 Therefore, mature miRs may regulate gene expression at levels 
other than post-transcriptionally in the nucleus. Consistently, miRs play a cis-
regulatory role in transcription, in which they bind to the promoter region of their 




region of POLR3D; hence, their sequences share perfect complementary.207 
Interestingly, increased expression of miR-320 reduced that of POLR3D through 
the enrichment of transcriptional silencing proteins, including AGO1 and EZH2, at 
its promoter.207 
 
MicroRNAs can also activate transcription of their target genes through promoter 
binding. A putative target site for miR-373 occurs within the promoter region of E-
cadherin.318 Transfection with miR-373 in PC-3 cells increased mRNA expression 
of E-cadherin and facilitated the enrichment of RNA polymerase II in its promoter 
region.318 Besides transcriptional activation, miRs can also activate the translation 
of their target mRNA through interactions with its 5’UTR and 3’UTR.152, 307, 405, 406 
Transfection of miR-10a was found to increase protein expression of Rps16, a 
ribosomal protein, through binding to its 5’UTR.307 Consequently, total protein 
synthesis was increased.307 Under serum starvation conditions, fragile X-related 
protein 1 (FXR1) was recruited by the Ago2-miR-369-3p complex, which was 
docked onto the 3’UTR of TNFα mRNA transcript.406 Through this series of 
interactions, translation of TNFα was greatly increased.406 Overall, the exact 
mechanisms by which these alternative actions occur remain to be further 
delineated.  
 
1.1.15.2. MICRORNA BINDING SITES  
Three main types of miR binding sites are known to exist: seed; canonical; and 3’ 
compensatory (Figure 1.3).38 Seed binding is known to be most evolutionarily 
conserved, with binding between the seed region, which is defined as the 2-7 
nucleotides in the 5’ region of a mature miR, and the seed binding site in the 
3’UTR of the target mRNA being of perfect complementarity.236 This type of seed 
binding occurs with little or in the complete absence of 3’ pairing to the mature 
miR.38 Canonical binding sites in the 3’UTR are characterised by strong binding to 
both the 5’ and 3’ end of a mature miR.38 For 3’ compensatory binding sites, strong 




Computational approaches have identified miRs in plants use a single and highly 
complementary base pairing site to silence gene expression of their target.339 
Perfect or near perfect base pairing between a mature miR and its target site is 
common in plants, with it shown to promote endonucleolytic cleavage of the target 
mRNA.255 In contrast, perfect base pairing between a mature miR and its target 






Figure 1.3 Three Classes of MicroRNA Target Sites. 
Three target site models: (A) canonical; (B) seed; and (C) 3’ compensatory. (A) 
Mode of pairing between a canonical target site (as shown in black) and a miR (as 
shown in green). Canonical target site is characterised by firm pairing to both 5’ 
and 3’ ends of the miR. (B) Mode of pairing between a seed target site (as shown 
in black) and a miR (as shown in red). A seed target site displays predominant 
pairing to the 5’ end of the miR. (C) Mode of pairing between a 3’ compensatory 
target site (as shown in black) and a miR (as shown in blue). 3’ compensatory 
target site demonstrates predominant pairing to the 3’ end of the miR. Schematic 





1.1.15.3. MICRORNAs AND FOLATE 
Folate deficiency can substantially modify miR expression in mouse embryonic 
stem cells (mESCs) and human lymphoblastoid cells.271 Folate deficiency up-
regulated the expression of 60 miRs and down-regulated that of 34 in mESCs.243 
Among the differentially expressed miRs, miR-302a, which regulates cell cycle 
progression via targeting a negative regulator in G1/S transition, Lats2, was down-
regulated.243 This suggests that embryonic and foetal expression of miRs may be 
sensitive to folate availability in utero and may act as a pathway by which 
environmental challenges alter developmental gene cascades. Moreover, in 
another model system, cellular folate deficiency increases expression of miR-22 
and miR-125/351 in human lymphoblastoid cells; these miRs are predicted to 
target a wide range of regulatory genes involved in one-carbon metabolism, 
including Mthfr, Mmab, Dhfr, Tcbir, Tch2, Slc19a1, Mat2a and Mthfd2.377 
Therefore, it is feasible that altered maternal folate intake, before and during 
gestation, could modify miR expression in the foetus as one mechanism by which 
MFAS initiates developmental programming effects in offspring. There may also 
be indirect effects, which may be mediated via an altered capacity for DNA 
methylation.  
  
1.1.15.4. MICRORNA EXPRESSION AND DNA METHYLATION 
Recently, DNA methylation has emerged as a novel mechanism by which miR 
expression is regulated.261, 350 When human bladder cancer cells were treated with 
the DNA demethylating agents, 5-aza-2'-deoxycytidine and 4-phenylbutric acid, 17 
miRs were up-regulated by more than three-fold, with miR-127 being the most 
differentially expressed.350 Consistently, the genomic location of miR-127 is 
encoded within a CpG island and treatment with these agents reduced DNA 
methylation level around the promoter region of miR-127.350  
 
Using an alternative approach, a double knockout (DKO) of DNMT1 and DNMT3b 
in the colon cancer cell line, HCT116, reduced genomic methylation by 95% and 




CpG islands of the two most overly expressed miRs, miR-10a and 200, were 
largely unmethylated in DKO cells, while those in control cells were methylated.147 
 
More importantly, miRs and the regulation of DNA methylation have recently been 
shown to formulate an intriguing relationship in ESCs. Knockout of Dicer, a key 
processing complex in miR maturation, inhibited the differentiation of mESCs.369 
Coincidentally, expression of de novo DNA methyltransferases, Dnmt3a, Dnmt3b 
and Dnmt3L, were also down-regulated in Dicer DKO mESCs, implicating the 
involvement of miRs in their regulation.369 From these observations, it is evident 
that functional and co-ordinated regulation by miRs and DNA methylation are 
pivotal to mESC differentiation.  
 
Recent studies have reported DNA methylation to alter expression of miRs in 
human cancer cells, suggesting DNA methylation to modulate miR expression 
levels as a means of maintaining cellular identity.177, 231, 261, 389 In human ovarian 
carcinoma, miR-21, miR-203 and miR-205 were hypomethylated as compared to 
healthy ovarian tissues.177 Down-regulation of miR-34b and miR-34c in human 
colorectal cancer cells were strongly associated with hypermethylation of their 
neighbouring CpG islands.389 In 34-86% of all primary human breast cancers, miR 
genes, including miR-9-1, miR-124a3, miR-148a, miR-152 and miR-663, displayed 
aberrant DNA methylation.231  
 
From these observations, it is apparent that the expression of a subset of miRs is 
subjected to regulation by DNA methylation. It is also clear that a number of miRs 
may affect this process themselves by targeting the repressors of DNMTs. Given 
the complex dynamic interplay between DNA methylation and miRs, it is possible 
for these two epigenetic mechanisms to coordinate changes in the expression of 
the transcriptome. With MFAS shown to affect DNA methylation in the offspring 
previously, it remains to be determined whether this nutritional intervention may 
impact upon miR expression in the offspring via changes to their regulation of DNA 




1.1.16. MATERNAL ADAPTATIONS DURING PREGNANCY AND THE 
ROLE OF MICRORNAS 
Following conception, maternal physiology and metabolism undergoes extensive 
adaptations to accommodate the growing needs of the developing embryo, 
placenta and foetus.222 With miRs being capable of regulating networks of genes, 
emerging evidence suggests that they may contribute towards the maternal 
physiological and metabolic adaptations that occur during pregnancy.425 As a key 
organ that orchestrates obligatory processes for foetal development, the placenta 
expresses more than 600 miRs abundantly, with distinctive expression patterns 
observed under normal and pathological conditions.97, 244, 417 At term, marked 
alterations in placental miR expression occurred in human pregnancies that were 
complicated by foetal growth restriction as compared to uncomplicated 
pregnancies.153 In human placenta, expression of miR-517b inversely correlated 
with placental weight in the first trimester.413 Four differentially expressed placental 
miRs (hsa-miR: 518b, 1323, 520h and 519d) were specific to foetal growth 
restriction, with these being encoded within the same cluster on chromosome 
19.153 For preeclamptic pregnant women, higher placental expression of miR-182 
and 210 were detected at delivery.317 Predicted targets of both of these miRs were 
related to immune response, with those of miR-182 being over-represented in anti-
apoptosis, while those of miR-210 were enriched in the regulation of 
transcription.317 Consistently, several other studies have also reported increased 
placental expression of miR-210 as a prominent characteristic of preeclampsia, 
which is known to reduce the migration and invasion capacity of human 
trophoblast cells in the first trimester.97, 291, 449, 454 
 
Placental-specific miRs have recently been detected in maternal plasma, with the 
abundance of miR-141 in maternal plasma increasing with gestational age, while 
seven placental specific miRs (hsa-miR: 516-5p, 517*, 518b, 520a*, 520h, 525 
and 526a) in blood appears to be unique to pregnancy.66, 216 These observations 
pose the question of whether placental-specific miRs may modify maternal 
functional characteristics, in particular, those related to metabolism, immune 




optimal environment for the foetus. It is possible for other maternal tissues that 
adapt during pregnancy to contribute towards the expression of pregnancy-specific 
circulating miRs.425 A recent study reported that pregnant women with low B12 
levels in late gestation had increased gene expression of adipogenesis and 
lipogenesis as well as perturbed expression of 12 miRs in their subcutaneous 
adipose tissue as compared to pregnant women with normal B12 levels.5 
 
During pregnancy, the maternal insulin axis undergoes major adaptations, with 
onset of maternal insulin resistance being an important process to support the 
redistribution of maternal nutrients to the growing foetus.47 In pregnant women with 
excessive insulin resistance and impaired glucose tolerance, 17 miRs were found 
to be differentially expressed in their omental adipose tissues as compared to 
pregnant women with normal glucose tolerance.362 Of these, adipose expression 
of miR-222 was up-regulated, while the protein expression of ERα and glucose 
transporter 4 (GLUT4) were reduced.362 Using luciferase assays in 3T3-L1 
adipocytes, ERα was validated to be a direct target of miR-222362; hence, 
increased expression of miR-222 may facilitate estrogen-induced insulin 
resistance in gestational diabetic women through decreasing the protein 
expression and activities of ERα and GLUT4.  
 
Overall, these observations support that miRs modulate cellular processes 
underlying maternal metabolic adaptations during pregnancy. However, little is 
known about whether miR expression may be modified in other key maternal 
metabolic tissues such as the liver, skeletal muscle and adipose tissues, which are 
known to undergo adaptations during pregnancy. More importantly, low maternal 
folate status in the third trimester has been shown to be associated with impaired 
foetal growth, placental dysfunction as well as increased maternal plasma 
expression of miR-222-3p, miR-141-3p and miR-34b-5p.15 Thereby, these 
emerging observations postulate altered miR expression as a potential underlying 
mechanism by which maternal intake of folate may perturb maternal metabolic 




1.1.17. FOETAL DEVELOPMENT AND THE ROLE OF MICRORNAS: 
NON-HUMAN SPECIES 
Several lines of evidence are supportive of non-coding miRs to be indispensable in 
the embryonic and foetal development of non-human species. Mouse embryos 
deficient of the miR processing enzyme, Dicer, were found to die at E7.5, with a 
lack of detectable pluripotent stem cells.27 Dicer deficiency also abolished 
expression of markers for endodermal and mesodermal differentiation in mESCs, 
while expression of centromeric repeat sequences such as those of major and 
minor satellite repeats were more abundant.191 In addition, histone methylation 
marks, namely dimethylation and trimethylation of histone 3 at lysine 9, were 
decreased in mESCs with Dicer deficiency.191 These observations illustrate that 
expression of non-coding miRs are indispensable for sustaining embryo survival, 
silencing centromeric repeat sequences and maintaining histone methylation 
marks. 
 
Silencing of Dicer in four days old mouse blastocysts reduced expression of miR-
181a, miR-34a and EGC receptors.65 EGC receptors confer the ability for 
blastocysts to implant into the endometrium; as a result, mouse blastocysts 
electroporated with Dicer siRNA had a lower implantation rate as compared with 
controls.65  
 
In Dicer knock out (KO) mESCs, expression of the miR-290 cluster was abolished; 
this cluster plays an important role as a mediator in the differentiation of ESCs.369 
Concomitantly, Dicer acts to repress mRNA expression of de novo DNMTs, 
Dnmt3a and Dnmt3b, and protein expression of DNMT3A2, DNMT3B1 and 
DNMT3B6.369 Transfection with all miR members in the miR-290 cluster or miR-
291a-3p alone was able to rescue expression of de novo DNMTs in these Dicer 
KO mESCs, at both mRNA and protein levels.369 The miR-290 cluster may not 
target these de novo DNMTs directly; however, it was predicted that this cluster 
targets transcriptional repressors of de novo DNMTs. This suggests that the miR-




for the differentiation of mESCs. Besides Dicer, DGCR8 is another key enzyme in 
the biogenesis of non-coding miRs. DGCR8 KO mESCs are not capable of 
differentiation, this may possibly be due to their inability to silence pluripotency 
markers, Nanog and Oct4.418  
 
Foetal hepatogenesis is orchestrated by dynamic changes in gene networks that 
involve non-coding miRs. During murine embryonic development, the specification 
of liver progenitor cells is initiated in definitive endoderm at E8.5, with hepatoblasts 
residing in the liver domain undergoing rapid proliferation in preparation for the 
formation of the liver bud at E9.5.383, 411 Between E14.5 and E15.5, hepatoblasts 
undergo differentiation into hepatocytes or cholangiocytes, which are further 
developed into functional liver cells.364 Distinctive miR and mRNA expression 
patterns were observed between endoderm and hepatoblasts throughout these 
stages, with 5,227 transcripts enriched in the endoderm but none in hepatoblasts; 
miR-302b was among one of the enriched transcripts identified.421 This microRNA 
was confirmed to be highly expressed in endoderm at E8.5; by E10.5, it became 
rapidly down-regulated in hepatoblasts.421 Target prediction for miR-302b included 
six mRNA transcripts related to TGF-β signalling, with miR-302b directly shown to 
reduce post-transcriptional expression of Tfgbr2 and Kat2b. This suggests that 
through down-regulating post-transcriptional expression of murine Tgfbr2 and 
Kat2b, miR-302b represses TGF-β signalling, in turn, promoting hepatoblast 
proliferation. Hence, it is evident that dynamic changes in miR expression patterns 
occur during hepatogenesis to facilitate proliferation and differentiation of 
hepatoblasts.  
 
Development of another key metabolic tissue, skeletal muscle, also appears to be 
extensively regulated by non-coding miRs during foetal development of non-
human species.171, 324, 367 Eighty-six miRs were differentially expressed in the 
longissimus dorsi muscle of Landrace porcine embryos between early- and mid-
gestation (gestational day 35 and 77).324 From mid-gestation to neonatal stages 
(gestational day 77 to postnatal day 28), 120 differentially expressed miRs were 




predicted targets being over-represented in the MAPK signalling, axon guidance 
and ErbB signalling pathways.  
 
Moreover, expression of miR-378 in the longissimus muscle of TongCheng 
porcine foetuses changes over gestation, with it being minimal at early-gestation 
and increasing steadily from mid-gestation to term.165 Using luciferase reporter 
assays, miR-378 was confirmed to target BMP2 and MAPK1, which are 
responsible for proliferation.165 Hence, miR-378 may affect foetal myogenesis by 
inhibiting BMP2 and MAPK1, resulting in accelerated differentiation of skeletal 
muscle progenitor cells.165  
 
Taken together, these studies show that miR expression patterns undergo 
dynamic changes over the course of myogenesis and may affect the proliferation 
and differentiation of foetal skeletal muscle fibres. Disturbance of these myogenic 
miR expression patterns may inflict long-term consequences on the functionality 
and metabolism of skeletal muscle fibres in adulthood; however, limited research 
has examined this aspect, which warrants further investigation.  
 
1.1.17.1. MATERNAL MICRORNAS AND NUTRITIONAL EXPOSURES IN 
PREGNANCY  
The impact of paternal and maternal nutrition on the expression of miRs in the 
progeny during prenatal and postnatal remains incompletely understood.434 
Maternal undernutrition increases placental expression of miR-149 in mice; this 
increase in placental miR-149 expression is correlated with a decrease in the 
protein expression of LAT2, which is an amino acid transporter.60 These 
observations suggest that maternal undernutrition may attenuate the capacity for 
transplacental leucine transport, which may compromise foetal growth via altering 
placental expression of miRs. Despite the role of DNA methylation in the 
regulation of miR expression, no studies to date have examined the impact of 





1.1.17.2. FOETAL MICRORNAS AND NUTRITIONAL EXPOSURES IN 
PREGNANCY 
Foetal tissue expression of miRs has been shown to be sensitive to nutritional 
signals in utero.302 Maternal undernutrition during the periconceptional period 
altered miR expression in the liver of the ovine foetus in singleton and in twin 
pregnancies separately.245 In singleton pregnancies, periconceptional maternal 
undernutrition up-regulated the hepatic expression of miR-142-5p and miR-146b-
5p but down-regulated miR-339-5p in ovine foetus.245 In twin ovine foetuses, 
periconceptional maternal undernutrition up-regulated the hepatic expression of 
miR-122-5p and down-regulated the expression of six miRs (miR: 142-5p; let-7a-
5p; let-7b-5p; 130a-3p; 16-2-3p; and 34c-5p.245 In twins, expression of a subset of 
differentially expressed miRs correlated inversely with the expression of insulin-
signalling proteins, including miR-126-5p and AMPKα1; miR-335-5p and PDPK-1; 
and miR-379-30 and PDK4.245, 246 The effects of these inverse relationships on 
insulin action of ovine foetuses of undernourished ewes remain to be determined. 
Furthermore, a number of these differentially expressed miRs are predicted to 
target insulin-signalling proteins; hence, experimental verification is required to 
validate these insulin-signalling proteins as direct targets.  
 
Maternal undernutrition in the periconceptional period also altered miR expression 
in the skeletal muscle of the ovine foetus in singleton and in twin pregnancies 
disparately.247 In singleton pregnancies, periconceptional maternal undernutrition 
reduced foetal skeletal muscle expression of miR-126-5p and miR-125a-5p, which 
were both predicted to target IRS1, an insulin-signalling protein.247 In twin ovine 
foetuses, periconceptional maternal undernutrition increased skeletal muscle 
expression of miR-30a-5pk, which was predicted to target IRS1.247  
 
Maternal obesity during the periconceptional period was also observed to increase 
hepatic expression of miR-103, miR-107 and miR-29b in the 4 months old lamb, 
with these differentially microRNAs known to target constituents in the hepatic 




Maternal deficiency of methyl group donors in rats, including folate and vitamin 
B12, resulted in growth restriction and reduced foetal brain weight near term.202 
Maternal deficiency of methyl group donors also decreased expression of Stat3 
but increased expression of miR-124 in the hippocampus, cerebellum and 
neurogenic subventricular zone of foetuses.202 These changes were associated 
with decreased Stat3 signalling, which is known to reduce brain weight via the 
promotion of cell apoptosis.202  
 
Taken together, these observations suggest variations in maternal nutrition during 
pregnancy can alter foetal hepatic and neural expression of miRs. Given the 
recent evidence on the interactions between folate and miR expression,271, 363 
MFAS may modify foetal miR expression. Particularly, MFAS may impact upon 
miR expression and DNA methylation capacity in key foetal metabolic tissues, in 
turn, inducing further consequences on the metabolic functionality of offspring after 
birth; however, these hypotheses remain to be investigated.  
 
1.1.18. MICRORNAS IN METABOLIC REGULATION 
In response to metabolic stimuli, regulatory and functional protein expression 
adapts to maintain cellular homeostasis through a series of acute and prompt 
changes at the post-transcriptional level. MicroRNAs are increasingly recognised 
as key regulators in the development and function of metabolic tissues that are 
involved in insulin secretion and sensitivity, glucose and lipid homeostasis and 
cholesterol metabolism.104 Several microRNAs with functions in these essential 
metabolic pathways and in early development have been extensively investigated 
and reported; hence, key experimental findings on these microRNAs are 
presented herein.  
 
1.1.18.1. MICRORNAS IN PRENATAL METABOLIC REGULATION  
It has been shown that miR-122 affects hepatic cellular proliferation and 




ESCs; moderate in human definitive endoderm cells and human foetal liver 
between nine and 12 weeks of gestation; and abundant in human primary 
hepatocytes.114, 189, 211 In mESCs, acute overexpression of miR-122 promoted the 
differentiation and maturation of hepatocyte progenitor cells, with 323 genes down-
regulated and 59 genes up-regulated.81 Of these, two liver-specific transcription 
factors, FoxA1 and HNF4a were up-regulated in parallel.81 Concomitantly, 
increased FoxA1 expression was associated with reduced expression of E-
cadherin, which suppressed the proliferation of hepatic precursor cells.81 
Consistently, overexpression of miR-122 in human ESCs was associated with an 
inability to partake in self-renewal and proliferation.189 Based on these 
observations, miR-122 may facilitate hepatic development through regulating the 
balance between proliferation and differentiation of hepatic precursor cells. Overall, 
it is evident that maintaining adequate levels of miR-122 expression is vital for 
hepatic function, while its ablation disrupts the regulation of cell growth and 
migration and can promote the development of hepatocellular carcinoma.189, 301, 396 
 
Recent findings are beginning to shed light on the ways in which maternal nutrition 
can affect foetal development via changes in foetal miR expression.50 In sheep, a 
maternal obesogenic diet increased expression of hsa-miR-381, but it decreased 
expression of hsa-let-7g and bta-miR-376d in the foetal longissimus dorsi 
muscle.441 Moreover, in baboons, a maternal diet of high fat and high fructose 
content increased expression of four miRs (miR: 30a, 1, 198 and 484) in the foetal 
heart.266 It remains to be determined whether other perturbations of maternal 
nutrition such as MFAS may also induce aberrant expression of miRs in foetal 
organs and tissues and, in effect, contribute towards an increased susceptibility of 
offspring to metabolic disorders after birth.  
  
1.1.18.2. MICRORNAS IN POSTNATAL DEVELOPMENT AND FUNCTION 
OF GLUCOREGULATORY ORGANS AND TISSUES 
The insulin-signalling pathway is a key biological process by which glucose uptake 
becomes stimulated subsequent to insulin activation in major glucoregulatory 




signalling proteins within this pathway are highly regulated by miRs at the post-
transcriptional level. In adult human skeletal muscle, miR-128a, which is 
expressed in high abundance, targets the mRNA transcripts of IRS1, INSR and 
PIK3R1 directly (Table 6.5).227, 289 In the skeletal muscle of diabetic Goto-Kakizaki 
rats, expression of miR-24, which directly targets p38 MAPK, is down-regulated.170 
Of interest, p38 MAPK activates myocyte-enhancer factor 2, the transcription 
factor responsible for inducing the expression of GLUT4.203 Changes in expression 
of miR-24 could potentially alter the actions of the p38 MAPK pathway and disrupt 
insulin-stimulated glucose uptake in the skeletal muscle.170  
 
Aberrant miR expression profiles have been observed in the skeletal muscle of 
human patients with Type 2 Diabetes Mellitus.80 A recent study compared global 
miR expression in the skeletal muscle between Type 2 diabetic patients and 
healthy controls, with 29 miRs up-regulated and 33 miRs, including miR-133a, 
down-regulated.116 In particular, expression of miR-133a was reduced by five-fold 
in the skeletal muscle of Type 2 diabetic patients as compared to controls; this 
decrease in expression was associated with plasma glucose at fasting and at two 
hours post glucose tolerance test.116 Another study has reported expression of let-
7a and let-7d were lower in skeletal myotubes from Type 2 diabetic patients 
relative to controls184; these two miRs target IL-13, which promotes glucose uptake, 
oxidation and glycogen synthesis in the skeletal muscle.184 From these 
observations, it appears that metabolic homeostasis and glucose tolerance of 
Type 2 diabetes patients may be altered in part via changes in skeletal muscle 
miR expression.  
 
There is increasing evidence for a role of miRs in the regulation of lipid and 
cholesterol metabolism and their dysregulation in metabolic syndrome (Table 6.5). 
Studies on miR-33 and miR-122 have provided tantalising insights into the 
influence which miRs may exert on lipid and cholesterol metabolism.331 Multiple 
genes involved in cellular cholesterol trafficking, including ABCA1 and ABCG1, 
have been experimentally validated as a direct target of miR-33.270, 297, 331 In miR-




increased as compared to wild type mice.164 Deficiency of miR-33 reduced the 
progression of atherosclerosis and lipid accumulation in atherosclerotic areas of 
apoE-deficient mice by increasing the availability and function of high-density 
lipoproteins for cholesterol efflux.163 In human hepatic cell lines, overexpression of 
miR-33 also inhibited endogenous expression of ABCA1 and the cellular export of 
cholesterol.125 Additionally, miR-33 suppressed the expression of CPT1A, in turn, 
attenuated the rate of fatty acid oxidation in human HepG2 cells.125 Thereby, 
changes to hepatic expression of miR-33 may alter the regulation of cholesterol 
metabolism and may impose consequences on susceptibility to metabolic 
disorders such as atherosclerosis, Type 2 Diabetes Mellitus and Non-Alcoholic 
Fatty Liver Disease (NAFLD). 
 
It has been reported that miR-122 is most abundant in the liver and has recently 
emerged as a key regulator of hepatic function,98, 220 cell differentiation,211 hepatic 
circadian regulation,120 systematic iron homeostasis52 and gene networks and 
pathways (Table 6.5).169, 380, 423 The mature sequence of miR-122 has been 
reported to be identical between 12 different species, including human, mouse and 
frog, suggesting that it is evolutionarily conserved.56 Transient inhibition of miR-
122 using antisense oligonucleotides in normal mice decreased the rate of fatty 
acid synthesis and cholesterol synthesis as well as decreased plasma cholesterol. 
98 Inhibition of miR-122 in mice also reduced hepatic expression of HMG-CoA 
reductase (Hmgcr), a rate-limiting enzyme in cholesterol synthesis.98 Furthermore, 
acute miR-122 inhibition in mice down-regulated Hmgcr and Fdps, which are 
genes involved in hepatic cholesterol biosynthesis.220  
 
In contrast, miR-122 KO mice displayed an increase in lipid biosynthesis, with 
increased hepatic cholesterol and triglycerides.168, 392 In these mice, up-regulation 
of enzymes involved in lipid biosynthesis and storage, including Agpat1, Cidec and 
Mogat1, were observed.168 Moreover, miR-122 KO mice displayed reduced serum 





In juvenile miR-122 KO mice, pathways with functions in steroid biosynthesis and 
bile acid biosynthesis were down-regulated.391 Consistently, these mice were more 
susceptible to the development of steatohepatitis, fibrosis and hepatocellular 
carcinoma.392 
 
Interestingly, adult rats fed a diet deficient of methyl group donors, including 
methionine and choline, for eight weeks displayed reduced hepatic expression of 
miR-122.75 This decrease in expression of miR-122 was accompanied by 
increased activation of nuclear factor kappa B and up-regulation of mitogen-
activated protein kinase kinase kinase 3, hypoxia inducible factor-1 alpha and 
vimentin, suggesting miR-122 to have a pro-fibrogenic role that propels the 
development of steatohepatitis.75 Overall, these observations indicate miR-122 is a 
major regulator of hepatic lipid and cholesterol homeostasis and mediates its 
regulatory effects through direct and indirect targeting of genes involved in these 
metabolic pathways.  
 
1.1.19. SUMMARY AND GENERAL CONCLUSION 
Several lines of evidence in animals and humans have established that MFAS 
perturbs metabolic homeostasis in the offspring after birth; however, the 
underlying molecular mechanisms remain largely elusive.  
 
Maternal folic acid supplementation has been shown to perturb metabolic 
regulation in the adult offspring through altering hepatic expression of key 
metabolic regulatory genes.67, 158 Maternal folic acid supplementation, from 
conception to term, decreases hepatic expression of Ppara, Pparγ and LXRα in 
the adult offspring, which are suggested to contribute towards a decrease in 
plasma cholesterol.67 In contrast, MFAS specifically increases hepatic expression 
of Pepck, a key gluconeogenic regulator, in adult female offspring only.158 This 
increase in hepatic Pepck expression may contribute towards an increase in 




compared to controls.158 Therefore, these observations suggest one mechanism 
by which MFAS perturbs metabolic homeostasis of adult offspring through altering 
hepatic expression of key metabolic regulatory genes.  
 
Another mechanism by which MFAS may alter metabolic regulation in offspring 
after birth is perturbed DNA methylation. Recent studies have shown that MFAS 
before and during gestation increases DNA methylation in the regulatory region of 
IGF2 in blood of the newborn infant.140, 374 In rodents, MFAS decreases the activity 
of DNA methyltransferases, which are key regulatory enzymes for maintaining and 
establishing DNA methylation, in the liver of adult offspring.365 Thereby, these 
observations indicate two mechanisms by which MFAS affects epigenetic state 
and metabolic phenotype of offspring long term through altering DNA methylation 
and its regulation. In particular, methylation status of genes, which are susceptible 
to the effects of MFAS, in the offspring after birth remain incompletely understood 
and are in need of further elucidation.  
 
In addition to protein-coding genes, DNA methylation can also regulate short non-
coding miRs. These short single-stranded miR molecules can repress post-
transcription expression of their mRNA targets and elicit changes to cellular and 
biochemical pathways. It is known that mRNA targets of miRs are involved in 
metabolic pathways, including glucose, lipid and cholesterol metabolism; hence, 
miRs can act in concert to coordinate changes to multiple regulatory networks that 
affect metabolic phenotype. A fourth mechanism by which MFAS may potentially 
alter gene expression and metabolic regulation is through altering non-coding miR 
expression. At present, no studies have examined the effects of MFAS on the 
expression of non-coding miRs in the offspring after birth.  
 
Besides offspring, limited studies have investigated the effects of MFAS on 
metabolic homeostasis of the pregnant mother, particularly in relation to her 
expression of metabolic regulatory genes, DNA methyltransferases and non-




is unknown whether MFAS may have unforeseen consequences on maternal 
physiological and metabolic adaptations that occur in response to pregnancy.  
 
To summarise, this review has identified a number of gaps in knowledge present 
in the current literature regarding MFAS and its consequences for mother and 
offspring: 
 
 The effects of MFAS, from preconception to term, on the expression of 
metabolic regulatory genes in key glucoregulatory organs and tissues, 
including liver and skeletal muscle, of offspring during prenatal and 
postnatal stages of development are unexplored;  
 
 The effects of MFAS, from preconception to term, on the expression of 
DNMTs in key glucoregulatory organs and tissues, including liver and 
skeletal muscle, of offspring during prenatal and postnatal stages of 
development are unexplored; 
 
 The effects of MFAS, from preconception to term, on the expression of non-
coding miRs in key glucoregulatory organs and tissues, including liver and 
skeletal muscle, of offspring during prenatal and postnatal stages of 
development are unexplored; and 
 
 No studies to date have examined the effects of MFAS, from preconception 
to term, on metabolic regulatory genes, DNMTs and non-coding miRs in 
key glucoregulatory organs and tissues, including liver and skeletal muscle, 
of the rodent dam during gestation.  
 
Collectively, it is unknown whether MFAS may affect metabolic homeostasis and 
chronic diseases susceptibility of offspring after birth through a number of 
interrelated molecular mechanisms, including metabolic regulatory genes, DNMTs 




1.2. GENERAL HYPOTHESES 
The present thesis proposes two general hypotheses:  
 Maternal folic acid supplementation, from preconception to term, initiates 
changes to the expression of metabolic and epigenetic regulatory genes in 
key organs and tissues of offspring at prenatal and postnatal stages of 
development; and  
 
 Maternal folic acid supplementation, from preconception to term, initiates 
changes to the expression of key metabolic and epigenetic regulatory 
genes in key organs and tissues of the pregnant mother. 
 
1.2.1. SPECIFIC HYPOTHESES  
The present thesis proposes three specific hypotheses: 
 
1. Maternal folic acid supplementation, from preconception to term, alters 
expression of the hepatic mRNA transcriptome in adult offspring;  
 
2. Maternal folic acid supplementation, from preconception to term, alters 
hepatic expression of metabolic and epigenetic regulatory genes in the 
foetus and in the pregnant mother in late gestation; and 
 
3. Maternal folic acid supplementation, from preconception to term, alters 





The present thesis proposes four aims:  
1. To determine the effects of MFAS in the rat, from preconception to term, on 
the expression of the hepatic mRNA transcriptome in adult offspring; 
 
2. To determine the effects of MFAS in the rat, from preconception to term, on 
the hepatic expression of metabolic and epigenetic regulatory genes in the 
foetus and in the pregnant dam in late gestation; 
 
3. To determine the effects of MFAS in the rat, from preconception to term, on 










Maternal Folic Acid Supplementation Induces 
Differential Changes in the Hepatic 






Periconceptional folic acid supplementation is widely recognised for its 
effectiveness in reducing the occurrence of NTDs.290 To promote optimal neonatal 
outcomes, currently, more than 80 countries around the world have introduced 
mandatory food fortification by which wheat flour becomes fortified with folic acid 
compulsorily.108 As a result, marked reductions in the prevalence of NTDs have 
been observed in the United States, Canada and Chile following its introduction.79, 
160, 257 Recently, a systematic review has found that periconceptional folic acid 
supplementation reduces the risk of the neonate of being born SGA.156 From 
epidemiological studies, it is known that SGA infants have an increased 
susceptibility to metabolic diseases in later life, including Type 2 Diabetes 
Mellitus,142 obesity,306 hypertension19 and cardiovascular diseases.20 Thereby, 
these studies indicate folic acid supplementation before and during pregnancy 
may affect susceptibility of offspring to metabolic diseases after birth. In line with 
this hypothesis, higher maternal plasma folate concentrations at 30 weeks of 
gestation have been reported to be associated with higher levels of insulin 
resistance in children aged 9.5 and 13.5 years.217 In animals, maternal deficiency 
of folate and other methyl group donors throughout pregnancy is reported to 
increase fasting blood glucose and to impair glucose tolerance in adult male 
offspring, indicating marked perturbations in glucose homeostasis.370 These 
studies, together with findings from a recent literature review,42 strongly postulate 
that maternal intake of folate before and during pregnancy plays a pivotal role in 
the developmental programming of metabolic diseases.  
 
Additionally, folic acid is known to impact on one-carbon metabolism, DNA 
methylation and epigenetic state; hence, periconceptional folic acid 
supplementation may affect offspring phenotype via epigenetic modifications.166, 
374 In newborn pups, MFAS in periconceptional period and throughout pregnancy 
reduces global DNA methylation in the brain relative to controls; however, no 
differences in global DNA methylation are observed in their liver, kidney or 
colon.263 These findings suggest that the effects of MFAS on the epigenetics of 
newborn offspring appear to be highly organ-specific. Moreover, changes to 




in effect, influence offspring phenotype long term. Maternal folic acid 
supplementation in periconceptional period and throughout pregnancy reduces 
hepatic expression of Ppara, Gr and Er-α of newborn rat pups at birth, but does 
not affect that of Igf2 or Pparγ.263 Expression of these genes in the brain, kidney 
and colon are not affected by MFAS in the newborn pup.263 In three weeks old rat 
pups, MFAS in the periconceptional period and throughout pregnancy reduces 
hepatic expression of ATGL relative to controls.442 To date, transcriptomic 
changes in the adult offspring, as induced by MFAS in the periconceptional period 
and throughout pregnancy, have not been examined.  
 
Maternal folic acid supplementation alters plasma metabolite profile of adolescent 
rat offspring, with plasma cholesterol markedly reduced.67 Plasma cholesterol and 
TAG are also markedly reduced in the adult offspring following MFAS.67 
Concomitantly, MFAS reduces hepatic expression of a number of key regulators in 
lipid homeostasis, including LXRα, Ppara and Pparγ, in the adolescent rat 
offspring.67 It has been previously shown that LXRα regulates hepatic lipid 
biosynthesis through enhancing expression of SREBP-1c, a transcription factor of 
numerous lipogenic enzymes.18 In effect, a reduction in LXRα hepatic expression 
leads to a decrease in TAG levels in adult offspring following MFAS; hence, these 
changes in plasma lipids in offspring following MFAS may result from alterations to 
their hepatic expression of key regulators that control different aspects of lipid 
metabolism.  
 
Furthermore, MFAS reportedly alters metabolic homeostasis in adult offspring in a 
sex-specific manner, with females being more markedly affected.158 Maternal folic 
acid supplementation increases plasma glucose levels specifically in adult female 
offspring, while those in adult male offspring remain unaffected.158 Consistently, 
hepatic expression of Pepck, a key regulator of gluconeogenesis, is significantly 
up-regulated by MFAS in the adult female offspring, but this in the adult male 
offspring remains unaffected.158 In light of these sexually dimorphic differences, 
MFAS may alter expression of the hepatic mRNA transcriptome in male and 




susceptibility to chronic diseases in later life. To assess the effects of MFAS, from 
preconception to term, on the hepatic mRNA transcriptome of adult male and 






2.2.1. ANIMALS AND TISSUE COLLECTION 
This study was designed in accordance with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes and was approved by the 
University of Adelaide Animal Ethics Committee. Virgin female Wistar rats (aged 
98 ± 5 days) and Lewis/SNN male rats (aged 84 ± 5 days) were purchased from 
Animal Resources Centre (Perth, Australia). Virgin female Wistar rats were 
randomly allocated to one of two groups: control (C) or maternal folic acid 
supplementation (MFAS), with each group consisted of nine virgin female Wistar 
rats. Control group was fed a standard rodent diet (AIN93G, Speciality Feeds, 
Australia) comprised of 2 mg folic acid/kg feed from two weeks prior to conception 
until term; this dosage of folic acid is generally accepted as meeting the basal 
dietary requirements for rats and closely assembles the recommended dietary 
allowance of 0.4 mg dietary folate equivalent in humans.12, 410 Maternal folic acid 
supplementation group was fed a standard rodent diet (SF07-018, Speciality 
Feeds, Australia) comprised of 6 mg folic acid/kg feed from two weeks prior to 
conception until term. This dosage of folic acid is three fold greater than basal 
dietary requirements for rats and mimics the level of folate to which women are 
exposed through average dietary intake, food fortification and supplementation 
during the periconceptional and gestational period.382 Standardised rodent diets 
containing different levels of folic acid are a common method of providing 
supplementary dietary folate to rodents and this method has been used and 
documented extensively in previous experimental studies.43, 67, 263 Folate 
concentrations achieved by this method in the plasma, liver, brain, kidney and 
colon of rodent models have been described previously in detail.263 
 
Virgin female Wistar rats were mated with Lewis/SNN male rats. Upon 
confirmation of pregnancy, pregnant dams were housed singly. At birth, each litter 
was reduced to eights pups. Throughout lactation, dams were given free access to 
a standard rodent diet and water and were weighed on a weekly basis. At 
postnatal day 21, all offspring were weaned onto a standard rodent diet. At 




followed by cardiac puncture, with their liver collected, frozen in liquid nitrogen and 
stored at -80ºC. The effects of MFAS on litter size, birthweight and organ and 
relative weight of postnatal offspring have been reported separately (Saidatul 
Naziah Mohammad, oral communication).  
 
2.2.2. RNA EXTRACTION AND QUALITY ANALYSIS 
Total RNA from the liver was extracted by TRIzol®  reagent (Invitrogen, USA) on 
Precellys®  24 Homogeniser (Bertin Technologies, France). Total RNA was isolated 
using standard RNA extraction procedures.310 To eliminate potential DNA from 
RNA samples, Ambion DNA-free Kit (Life Technologies, USA) was used in 
accordance to manufacturer’s instructions. Total RNA quality was assessed on 
Agilent 2100 Bioanalyzer (Agilent Technologies, USA) using RNA 6000 Nano 
Chips (Agilent Technologies, USA), which determined the UV 260/280 absorbance 
ratio and the RNA size distribution of each RNA sample. All analysed samples had 
a RIN score of 8 or above. Any samples with a RIN of less than 8 were excluded 
from further analysis.  
 
2.2.3. AFFYMETRIX GENECHIP®  RAT GENE 1.0 ST ARRAY PREPARATION 
Affymetrix GeneChip®  Rat Gene 1.0 ST Array (Affymetrix, USA) was used to 
examine the hepatic mRNA transcriptome in adult offspring of the two maternal 
dietary groups (C: 14, male = 7, female = 7; MFAS: 14, male = 8, female = 6). 
Probe sequence design and gene annotations were based on content derived 
from sources including RefSeq (National Center for Biotechnology Information, 
http://www.ncbi.nlm.nih.gov/refseq/), GenBank (National Institute of Health, 
http://www.ncbi.nlm.nih.gov/genbank/) and Ensembl (European Bioinformatics 
Institute, http://www.ensembl.org/). 
 
Briefly, using 300 ng of total RNA from individual liver samples, cDNA synthesis 
and the purification and synthesis of biotin-labelled cRNA were performed in 




hours at 45ºC, 5.5 µg of fragmented cRNA was hybridised with Affymetrix 
GeneChip®  Rat Gene 1.0 ST Array. The slides were washed and stained with 
Affymetrix GeneChip®  Fluidics Station 400 (Affymetrix, USA). Following staining, 
slides were scanned with Gene Array Scanner (Affymetrix, USA). Using the 
manufacturer’s standard protocols, cRNA synthesis and labelling, hybridisation to 
the Rat Gene 1.0 ST array, post-hybridisation washes, staining, array image 
generation, segmentation and quality control analysis were performed by the 
Adelaide Microarray Centre (Adelaide, Australia).  
 
2.2.4. AFFYMETRIX MICROARRAY DATA NORMALISATION AND ANALYSIS 
Affymetrix microarray data analyses were performed with Biometric Research 
Branch (BRB) ArrayTools version 4.2.0 (National Cancer Institute, 
http://linus.nci.nih.gov/BRB-ArrayTools.html) developed by Dr. Richard Simon and 
the BRB-ArrayTools development team. BRB-ArrayTools is an excel add-in that 
processes and analyses microarray data through the utilisation of the R version 
2.12 environment (The R Foundation for Statistical Computing, http://www.R-
project.org). Of the 27,342 transcripts represented on the array, those with 
variance in the 75th percentile were excluded and those with more than 80% of 
expression values displaying a fold change of 1.5 or above were further analysed. 
Robust Multichip Average (RMA) normalisation was performed prior to class 
comparison analysis, which uses an independent samples t-test with a random 
variance model to detect significant variance in gene expression between the two 
groups of samples. To identify genes with a significance threshold of P < 0.05 for 
univariate tests, a total of 10,000 permutations were completed. Differential 
expression was considered significant at P < 0.05. For unsupervised average 
linkage hierarchical cluster analysis, Pearson’s centred correlation was utilised as 
a distance metric to stratify samples in accordance to their expression profiles 





2.2.5. QUANTIFICATION OF MRNA EXPRESSION 
Based on their differential expression and vast fold changes, as observed on 
Affymetrix GeneChip®  Rat Gene 1.0 ST Array, hepatic expression of eleven genes 
(Abcd2, Acaca, Acsm3, Akr1b10, Akr1b7, Idi1, Pck1, Ppara, Ppargc1a, Sc4mol 
and Sqle) were selected for independent validation by qRT-PCR in an expanded 
cohort (C: 18, male = 9, female = 9; MFAS: 18, male = 9, female = 9).  
 
To synthesise cDNA, reverse transcription was performed with 5 μg of total RNA 
using TaqMan®  Reverse Transcription reagents (Life Technologies, USA). Each 
100 μL reverse transcription reaction contained 5 μg of total RNA in 50 μL of 
nuclease-free water, 10 μL of 10X Reverse Transcription buffer, 4 μL of 25X dNTP 
(100 mM), 10 μL of random hexamer (50 μM), 21 μL of nuclease–free water and 5 
μL of MultiScribe™ Reverse Transcriptase (50 U/μL). Reaction was carried out on 
GeneAmp®  PCR system 9700 (Life Technologies, USA) at 25°C for 10 minutes 
and 37°C for 120 minutes. All cDNA products were stored at -20°C until use. 
  
Quantitative PCR of gene expression was performed on Applied Biosystems 
7900HT Fast Real-Time PCR System (Life Technologies, USA) using TaqMan®  
Universal PCR Master Mix (Life Technologies, USA) in accordance to 
manufacturer’s instructions. Each PCR amplification reaction contained 10 μL of 
2X TaqMan®  Universal PCR Master Mix (Life Technologies, USA), 1 μL of 
TaqMan®  Gene Expression Assay (Table 6.6; Life Technologies, USA), 7 μL of 
nuclease-free water and 2 μL of cDNA. On Applied Biosystems 7900HT Fast Real-
Time PCR System (Life Technologies, USA), cycling conditions were set as 
follows: 50°C for 2 minutes; 95°C for 10 minutes; and 45 cycles of 95°C for 15 





2.2.6. DATA PROCESSING AND STATISTICAL ANALYSIS FOR MRNA 
EXPRESSION 
Potential reference genes were assessed with Normfinder,226 which provides a 
stability ranking through determining the intra- and inter-group variation. 
Normalisation of qRT-PCR data was performed with the most stable reference 
gene, peptidylprolyl isomerase A (Ppia), as reflected by its minimal intra- and inter-
group variations on Normfinder. In accordance to the Applied Biosystems Relative 
Quantification Methodology (Applied Biosystems, United Kingdom), 2-∆∆Ct method 
was performed to depict gene expression levels as means and fold changes. 
 
Independent samples t-test was performed on SPSS version 20 (IBM, USA) to 
determine for significant differences in normalised gene expression values 
between offspring of the two maternal dietary groups. For data that was not 
normally distributed, Kruskal-Wallis H test was performed. Analyses were 
performed in compliance with the guidelines provided by Livak and Schmittgen254. 
Associations between hepatic expression of metabolic regulatory genes were 
assessed by Pearson’s one-tailed correlation analysis on SPSS version 20 (IBM, 
USA). 
 
2.2.7. BIOINFORMATICS ANALYSIS 
Information on the gene symbol, gene name and gene ontology of the differentially 
expressed genes was obtained from NCBI Gene (National Center for 
Biotechnology Information, http://www.ncbi.nlm.nih.gov/gene). The presence of 
CpG islands, 20 kilobase upstream or downstream, from the coding region of a 
differentially expressed gene was identified using an enabled CpG island track on 
Ensembl (European Bioinformatics Institute, http://www.ensembl.org/), which 
allowed for close inspection of cis-acting elements within a specified chromosomal 
region. Imprinting status of the differentially expressed genes was obtained from 





2.2.8. INGENUITY PATHWAY ANALYSIS  
To interpret Affymetrix microarray data in the context of biological functions, 
diseases, canonical pathways, upstream regulators and molecular networks, ‘Core 
Analysis’ was performed using Ingenuity Pathway Analysis (IPA; Ingenuity 
Systems, www.ingenuity.com), with all 'Identifier Types' selected. Based on the 
degree of overlap between the uploaded dataset and the gene-set within the IPA 
database, an overlap P-value was generated with adjustments for Benjamini-
Hochberg (B-H) multiple testing. For molecular networks, an IPA score ≥ 3 was 
considered as significant. For biological functions and diseases, B-H P < 0.05 was 
accepted. For canonical pathways, –log (B-H) P ≥ 1.3 was considered as 
significant. Upstream regulators for the differentially expressed genes were also 
identified with an activation z-score, which determined the directional change of an 
upstream regulator by comparing the uploaded dataset against the mediator 
dataset within the IPA database. An upstream regulator with an activation z-score 
≥ 2 was interpreted as activated, while an activation z-score ≤ -2 was interpreted 






2.3.1. EFFECTS OF MATERNAL FOLIC ACID SUPPLEMENTATION ON 
GLOBAL TRANSCRIPTOMIC CHANGES IN THE LIVER OF ADULT 
OFFSPRING 
Maternal folic acid supplementation altered expression of 13 genes (P < 0.05) in 
the liver of adult offspring, irrespective of sex (Figure 2.1), with seven up-regulated 
(1.21 to 1.61 fold; Table 2.1) and six down-regulated (-0.25 to -0.58 fold; Table 
2.1).  
 
Maternal folic acid supplementation altered hepatic expression of 22 genes (P < 
0.05) in adult male offspring (Figure 2.2), with 10 up-regulated (1.19 to 1.76 fold; 
Table 2.2) and 12 down-regulated (-0.15 to -0.57 fold; Table 2.2). 
 
In adult female offspring, MFAS altered hepatic expression of 36 genes (P < 0.05; 
Figure 2.3), with eight up-regulated (1.16 to 1.38 fold; Table 2.3) and 28 down-





Figure 2.1 Hierarchical Clustering Analysis and Heat Map Comparison of Global Hepatic 
Gene Expression between Adult Offspring of Folic Acid Supplemented and Control Dams. 
Top Panel: Hierarchical Clustering Analysis of Global Gene Expression in the Liver of Adult 
Offspring of Folic Acid Supplemented and Control Dams. Dendrogram depicts unsupervised 
hierarchical clustering analysis performed on the normalised log intensities of 28 samples (C: 14, 
male = 8, female = 6; MFAS: 14, male = 8, female = 6) using Pearson’s correlation with average 
linkage. Bottom Panel: Hepatic Transcriptome Profiles of Adult Offspring of Folic Acid 
Supplemented and Control Dams. Expression of the 13 differentially expressed genes (P < 0.05) 







Table 2.1 Effects of Maternal Folic Acid Supplementation on Global Gene Expression in the Liver of Adult Offspring. 









Up-regulated genes of all offspring 
10710295 Acsm3 
acyl-CoA synthetase medium-chain family 
member 3 
1.61 0.0024 1q35 No 
10858370 Usp18 ubiquitin specific peptidase 18 1.36 0.0286 4q42 No 
10866142 Klra7 
killer cell lectin-like receptor, subfamily A, member 
7 
1.34 0.0221 4q42 No 
10750454 Kcnj15 
potassium inwardly-rectifying channel, subfamily J, 
member 15 
1.28 0.0352 11q11 No 
10730349 Scd1 stearoyl-Coenzyme A desaturase 1 1.25 0.0260 1q54 No 
10738196 Ttc25 tetratricopeptide repeat domain 25 1.23 0.0408 10q32 Yes 
10714903 Ifit3 
interferon-induced protein with tetratricopeptide 
repeats 3 
1.21 0.0225 1q52 No 
  
     
  
Down-regulated genes of all offspring 
10768998 Tor3a torsin family 3, member A -0.58  0.0437 13q22 Yes 
10865300 Klrg1 
killer cell lectin-like receptor subfamily G, member 
1 
-0.42  0.0117 4q42 No 
10847922 Rpl21 ribosomal protein L21 -0.32  0.0293 12p11 Yes 
10831308 Slc44a4 solute carrier family 44, member 4 -0.30  0.0348 20p12 No 
10730599 Cyp17a1 
cytochrome P450, family 17, subfamily a, 
polypeptide 1 
-0.30  0.0479 1q55 No 








Fold change was determined from the median expression across all the arrays between offspring of folic acid supplemented and control dams. P-values were 
calculated by class comparison analysis, which used an independent samples t-test, computed with a random univariate permutation of 10,000. Distal CpG 







Figure 2.2 Hierarchical Clustering Analysis and Heat Map Comparison of Global Hepatic 
Gene Expression between Adult Male Offspring of Folic Acid Supplemented and Control 
Dams. 
Top Panel: Hierarchical Clustering Analysis of Global Gene Expression in the Liver of Adult Male 
Offspring of Folic Acid Supplemented and Control Dams. Dendrogram depicts unsupervised 
hierarchical clustering analysis performed on the normalised log intensities of 15 samples (C: 7, 
MFAS: 8) using Pearson’s correlation with average linkage. Bottom Panel: Hepatic Transcriptome 
Profiles of Adult Male Offspring of Folic Acid Supplemented and Control Dams. Expression of the 
22 differentially expressed genes (P < 0.05) are shown; green indicates decreased expression and 







Table 2.2 Effects of Maternal Folic Acid Supplementation on Global Gene Expression in the Liver of Adult Male Offspring. 










Up-regulated genes of male offspring 
10710295 Acsm3 acyl-CoA synthetase medium-chain family member 3 1.76 0.005 1q35 No 
10869010 Zfp189 zinc finger protein 189 1.39 0.028 5q22 No 
10862694 Inmt indolethylamine N-methyltransferase 1.36 0.032 4q24 No 
10926098 Sult1c2 sulfotransferase family, cytosolic, 1C, member 2 1.34 0.007 9q11 Yes 
10866142 Klra7 killer cell lectin-like receptor, subfamily A, member 7 1.33 0.044 4q42 No 
10804281 Spink3 serine peptidase inhibitor, Kazal type 3 1.27 0.042 18p No 
10918368 Aph1b anterior pharynx defective 1 homolog B (C. elegans) 1.26 0.003 8q24 Yes 
10937624 Mid1 midline 1 1.24 0.049 Xq21 Yes 
10789857 Il17rb interleukin 17 receptor B 1.22 0.026 16p16 Yes 
10838130 Slc1a2 solute carrier family 1, member 2 1.19 0.042 3q31 Yes 
  
     
  
Down-regulated genes of male offspring 
10854427 Akr1b7 aldo-keto reductase family 1, member B7 -0.57 0.034 4q22 No 
10768998 Tor3a torsin family 3, member A -0.51 0.025 13q22 Yes 
10847922 Rpl21 ribosomal protein L21 -0.44 0.048 12p11 Yes 
10770807 G0s2 G0/G1switch 2 -0.43 0.027 13q27 No 
10870429 Dab1 disabled homolog 1 (Drosophila) -0.34 0.042 5q34 No 
10713496 Rcor2 REST corepressor 2 -0.33 0.027 1q43 Yes 
10854291 Cpa2 carboxypeptidase A2 (pancreatic) -0.31 0.024 4q22 No 
10901531 Ascl1 achaete-scute complex homolog 1 (Drosophila) -0.29 0.043 7q13 Yes 
10824439 Efna1 ephrin A1 -0.28 0.034 2q34 No 
10731686 Rogdi rogdi homolog (Drosophila) -0.19 0.035 10q12 Yes 
10786338 Arhgef3 Rho guanine nucleotide exchange factor (GEF) 3 -0.18 0.005 16p16 Yes 







Fold change was determined from the median expression across all the arrays between male offspring of folic acid supplemented and control dams. P-values 
were calculated by class comparison analysis, which used an independent samples t-test, computed with a random univariate permutation of 10,000. Distal 






Figure 2.3 Hierarchical Clustering Analysis and Heat Map Comparison of Global Hepatic 
Gene Expression between Adult Female Offspring of Folic Acid Supplemented and Control 
Dams. Top Panel: Hierarchical Clustering Analysis of Global Gene Expression in the Liver of Adult 
Female Offspring of Folic Acid Supplemented and Control Dams. Dendrogram depicts 
unsupervised hierarchical clustering analysis performed on the normalised log intensities of 13 
samples (C: 7, MFAS: 6) using Pearson’s correlation with average linkage. Bottom Panel: Hepatic 
Transcriptome Profiles of Adult Female Offspring of Folic Acid Supplemented and Control Dams. 
Expression of the 36 differentially expressed genes (P < 0.05) are shown; green indicates 







Table 2.3 Effects of Maternal Folic Acid Supplementation on Global Gene Expression in the Liver of Adult Female 
Offspring. 










Up-regulated genes of female offspring 
10730349 Scd1 stearoyl-Coenzyme A desaturase 1 1.38 0.035 1q54 No 
10889148 Ubxn2a UBX domain protein 2A 1.36 0.016 6q14 Yes 
10854417 Akr1b10 
aldo-keto reductase family 1, member B10 (aldose 
reductase) 
1.34 0.042 4q22 No 
10933479 S100g S100 calcium binding protein G 1.31 0.018 Xq21 No 
10723822 Tsku tsukushin 1.27 0.004 1q32 Yes 
10907793 Mettl7a methyltransferase like 7A 1.18 0.044 7q36 Yes 
10878170 Cyp2j3 
cytochrome P450, family 2, subfamily j, 
polypeptide 3 
1.16 0.022 5q33 No 
10728494 Slc22a25 solute carrier family 22, member 25 1.16 0.025 1q43 No 
  
     
  
Down-regulated genes of female offspring 
10773115 Prom1 prominin 1 -0.75  0.004  14q21 Yes 
10906428 Abcd2 
ATP-binding cassette, sub-family D (ALD), 
member 2 
-0.71  0.036  7q35 No 
10865300 Klrg1 
killer cell lectin-like receptor subfamily G, member 
1 
-0.70  0.004  4q42 No 
10760760 LOC288521 
similar to Leukosialin precursor (Leucocyte 
sialoglycoprotein) (Sialophorin) (CD43) (W3/13 
antigen) 
-0.58  0.018  12q11 No 
10799241 Idi1 isopentenyl-diphosphate delta isomerase 1 -0.57  0.007  17q12 Yes 
10885871 Acot5 acyl-CoA thioesterase 5 -0.49  0.033  6q31 No 







10896772 Sqle squalene epoxidase -0.48  0.009  7q33 Yes 
10929128 Ptprn protein tyrosine phosphatase, receptor type, N -0.45  0.010  9q33 Yes 
10831308 Slc44a4 solute carrier family 44, member 4 -0.42  0.031  20p12 No 
10783537 Slc7a7 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 7 
-0.40  0.022  15p13 Yes 
10824188 Ntrk1 neurotrophic tyrosine kinase, receptor, type 1 -0.38  0.012  2q34 Yes 
10869010 Zfp189 zinc finger protein 189 -0.33  0.030  5q22 No 
10838130 Slc1a2 
solute carrier family 1 (glial high affinity glutamate 
transporter), member 2 
-0.31  0.011  3q31 Yes 
10898456 Creld2 cysteine-rich with EGF-like domains 2 -0.31  0.037  7q34 Yes 
10911145 Car12 carbonic anyhydrase 12 -0.30  0.032  8q24 No 
10919354 Pls1 plastin 1 (I isoform) -0.28  0.003  8q31 Yes 
10829927 Dnajc12 DnaJ (Hsp40) homolog, subfamily C, member 12 -0.27  0.043  20p11 No 
10813445 Lifr leukaemia inhibitory factor receptor alpha -0.26  0.009  2q16 Yes 
10759488 Zinki Arg3.1/Arc mRNA-binding zinc finger protein -0.26  0.025  12p11 No 
10819644 Ddah1 dimethylarginine dimethylaminohydrolase 1 -0.24  0.006  2q44 Yes 
10923338 Coq10b coenzyme Q10 homolog B (S. cerevisiae) -0.24  0.019  9q31 Yes 
10903987 A1bg alpha-1-B glycoprotein -0.23  0.007  7q33 No 
10792832 F7 
coagulation factor VII (serum prothrombin 
conversion accelerator) 
-0.23  0.037  16q12 No 
10813628 Prlr prolactin receptor -0.22  0.008  2q16 No 
10833635 Slc16a10 
solute carrier family 16 (monocarboxylic acid 
transporters), member 10 
-0.20  0.032  20q12 No 
10714745 Il33 interleukin 33 -0.13  0.039  1q52 No 
10793310 Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 1  -0.11  0.023  17p14 Yes 
Fold change was determined from the median expression across all the arrays between female offspring of folic acid supplemented and control dams. P-
values were calculated by class comparison analysis, which used an independent samples t-test, computed with a random univariate permutation of 10,000. 





2.3.2. HIERARCHICAL CLUSTERING AND INGENUITY PATHWAY ANALYSIS 
FOR THE DIFFERENTIALLY EXPRESSED GENES IN ADULT 
OFFSPRING 
Hierarchical clustering identified two significant gene clusters (r > 0.7) among the 
differentially expressed genes in the liver of adult offspring following MFAS, with 
each cluster containing two differentially expressed genes (Table 6.7). In Cluster 1, 
the expression of Ifit3 and Usp18 were most positively correlated; Ifit3 encodes for 
interferon-induced protein with tetratricopeptide repeats 3, which is responsive to 
interferon and mediates antiviral response,453 while Usp18 encodes for ubiquitin 
specific peptidase 18, an enzyme that potentiates the antiviral activity of 
interferon.330 In Cluster 2, expression of Tor3a and Klrg1 were positively correlated, 
with the former known to encode for a cofactor required in protein folding, while 
the latter encodes for a membrane glycoprotein that interferes with mast cell 
secretory response. 
 
The major biological functions and diseases affected by MFAS in the liver of adult 
offspring were lipid metabolism (B-H P = 0.011), molecular transport (B-H P = 
0.011) and small molecule biochemistry (B-H P = 0.011), with these being 
associated with the up-regulated gene of Scd1 (Table 6.8). The up-regulated gene, 
Scd1, encodes for stearoyl-CoA desaturase, an enzyme involved in the 
biosynthesis of monounsaturated fatty acids such as palmitoleic acid.157  
 
Four canonical pathways (-log (B-H) P ≥ 1.3) were identified as over-represented 
in the liver of adult offspring following MFAS (Table 6.9). Among these, androgen 
biosynthesis and glucocorticoid biosynthesis were closely associated with the 
down-regulated gene of Cyp17a1, which encodes a steroid hydroxylase central to 
glucocorticoid and androgen production (Table 6.9).320 Furthermore, oleate 
biosynthesis II and interferon signalling were identified as affected canonical 
pathways in the liver of adult offspring following MFAS, with the former being 
closely associated with the up-regulated gene of Scd1, while the latter was 




A molecular network (IPA score = 32; Table 6.10) with functions in lipid 
metabolism and molecular transport was affected by MFAS in the liver of adult 
offspring (Figure 2.4). Additionally, tumour necrosis factor (TNF; P = 0.007, z-
score = 0.625) was found to be an activated upstream regulator for four of the 
differentially expressed genes in the liver of adult offspring following MFAS (Table 
6.11). Tumour necrosis factor is known for its role as a systemic cytokine that 
stimulates acute inflammation and regulates cell proliferation and apoptosis.197 
This systemically abundant cytokine is associated with the development of liver 





Figure 2.4 Molecular Network Affected by Maternal Folic Acid Supplementation in the Liver 
of Adult Offspring. 
Up-regulated genes are represented as nodes in red. Down-regulated genes are represented as 
nodes in green. Biological relationship between two nodes is represented as a line, with solid lines 
representing direct interactions, while dashed lines indicate indirect interactions. All biological 
relationships are substantiated by findings in at least one academic journal reference or from 
canonical information present in the Ingenuity Knowledge Base. Functions associated with this 




2.3.3. HIERARCHICAL CLUSTERING AND INGENUITY PATHWAY ANALYSIS 
FOR THE DIFFERENTIALLY EXPRESSED GENES IN ADULT MALE 
OFFSPRING 
Six significant gene clusters (r > 0.7) were identified in the altered hepatic 
transcriptome of male offspring following MFAS. Two clusters were exclusively 
constituted of up-regulated genes (Cluster 1 and 2), with Cluster 2 indicating the 
expression of Acsm3 and Spink3 to be positively correlated (Table 6.7). Acsm3 
encodes for an acyl-CoA synthetase, which is involved in fatty acid synthesis,32 
while Spink3 encodes for a serine peptidase inhibitor that affects trypsin.129 For the 
down-regulated genes, four significant clusters were identified, with the expression 
of Akr1b7 being positively correlated with that of Cpa2 (Table 6.7). It is known that 
Akr1b7 encodes a member of aldo-keto reductase that is targeted by FXR and 
plays a regulatory role in lipid and glucose homeostasis, while Cpa2 encodes a 
carboxypeptidase that is involved in protein catabolism.122 
 
The major biological functions affected by MFAS in liver of adult male offspring 
include organismal development (B-H P = 0.019) and tissue morphology (B-H P = 
0.019), with these both being associated with the down-regulated gene of Ascl1 
(Table 6.8). Ascl1 encodes for achaete-scute family bHLH transcription factor 1, 
which has been established to play a pivotal role in neurogenesis.420 No canonical 
pathway was associated with the differentially expressed genes in liver of male 
offspring; however, differentially expressed genes in liver of male offspring were 
found to be over-represented in two molecular networks (Table 6.10). A molecular 
network (IPA score = 27) was found to be involved in lymphoid tissue structure 
and development (Figure 2.5A), while another (IPA score = 24) was found to be 
involved in cellular development (Figure 2.5B). No upstream regulator was 
















Figure 2.5 Molecular Networks Affected by Maternal Folic Acid Supplementation in the Liver of Adult Male Offspring. 
(A) Functions associated with this network include lymphoid tissue and development, organ morphology and tissue morphology; IPA score = 27. (B) 
Functions associated with this network include cellular development, nervous system development and function and organismal injury and abnormalities; IPA 
score = 24. Up-regulated genes are represented as nodes in red. Down-regulated genes are represented as nodes in green. Biological relationship between 
two nodes is represented as a line, with solid lines representing direct interactions, while dashed lines indicate indirect interactions. All biological relationships 




2.3.4. HIERARCHICAL CLUSTERING AND INGENUITY PATHWAY ANALYSIS 
FOR THE DIFFERENTIALLY EXPRESSED GENES IN ADULT FEMALE 
OFFSPRING 
Seven significant gene clusters (r > 0.7) were identified in the altered hepatic 
transcriptome of adult female offspring following MFAS, with several members in 
these clusters predicted to be co-regulated or co-expressed (Figure 2.3). Of these, 
Cluster 6 was identified as the largest cluster, containing 12 down-regulated genes 
including three cholesterogenic genes, Idi1, Sc4mol and Sqle. Hepatic expression 
of these three cholesterogenic genes were found to be positively correlated with 
each other within Cluster 6 (Table 6.7).  
 
In terms of biological functions, lipid metabolism (B-H P = 0.024) and small 
molecular biochemistry (B-H P = 0.024) were affected in the liver of adult female 
offspring following MFAS. Steroid metabolism was identified as common to both of 
these biological functions (Table 6.8). In addition, three cholesterogenic genes, 
Idi1, Sc4mol and Sqle, were enriched within these two biological functions.  
 
Ingenuity pathway analysis identified six canonical pathways (-log (B-H) P ≥ 1.3) 
as being affected by the differentially expressed genes in the liver of adult female 
offspring following MFAS (Table 6.9). Moreover, the differentially expressed genes 
in liver of female adult offspring following MFAS, including the three 
cholesterogenic genes, Idi1, Sc4mol and Sqle, were closely related to cholesterol 
and epoxysqualene biosynthesis (Table 6.9). Also, LXR/RXR activation (-log (B-H) 
P = 1.84) was revealed as one of the affected canonical pathways, with it being 
enriched for the up-regulated gene of Scd1 and the down-regulated genes of Il33 
and A1bg. Il33 is known to encode a proinflammatory cytokine, while A1bg 
encodes alpha-1-B glycoprotein, which is a member of the high-density lipoprotein 





Three molecular networks were associated with the differentially expressed genes 
in the liver of adult female offspring following MFAS (Table 6.10). The top network 
(IPA score = 42) was functionally relevant to lipid metabolism (Figure 2.6A), while 
the other two networks (IPA score ≥ 3) were associated with energy production 
(Figure 2.6B) and small molecule biochemistry (Figure 2.6C). Furthermore, 11 
upstream regulators were identified for the differentially expressed genes in the 
liver of adult female offspring (Table 6.11), including SREBP1, SREBP2 and 
PPARA, which are known to be transcription regulators for genes involved in lipid 





















Figure 2.6 Molecular Networks Affected by Maternal Folic Acid Supplementation in the Liver of Adult Female Offspring. 
(A) Functions associated with this network include lipid metabolism, molecular transport and small molecule biochemistry; IPA score = 42. (B) Functions 
associated with this network include energy production, lipid metabolism and small molecule biochemistry; IPA score = 33. (C) Functions associated with this 
network are unidentified; IPA score = 3. Up-regulated genes are represented as nodes in red. Down-regulated genes are represented as nodes in green. 
Biological relationship between two nodes is represented as a line, with solid lines representing direct interactions, while dashed lines indicate indirect 
interactions. All biological relationships are substantiated by findings in at least one academic journal reference or from canonical information present in the 





Figure 2.7 Transcriptional Network Affected by Maternal Folic Acid Supplementation in the 
Liver of Adult Female Offspring. 
Differentially expressed genes/gene products are represented as nodes in grey. Nodes in purple 
indicate key upstream regulators of the differentially expressed genes. Biological relationship 
between two nodes is represented as a line, with solid lines representing direct interactions, while 
dashed lines indicate indirect interactions. The type of interaction between two nodes is 
represented by alphabet letters: A, activation; E, expression; PD, protein-DNA binding; T, 
transcription. All biological relationships are substantiated by findings in at least one academic 




2.3.5. BIOINFORMATICS ANALYSIS  
Bioinformatics analysis was undertaken to determine the chromosomal location of 
the differentially expressed genes in the liver of adult offspring following MFAS 
(Table 2.1). All of the differentially expressed genes were found to be encoded on 
a somatic chromosome, with chromosome 1 identified as the host of four 
differentially expressed genes, including Acsm3, Ifit3, Scd1 and Cyp17a1. Three 
differentially expressed genes, Klra7, Usp18 and Klrg1, were found to be encoded 
in the genomic region of chromosome 4q42. With the potential for MFAS to alter 
DNA methylation of genes in offspring, it was also determined whether regulatory 
CpG islands were present within 20kb upstream of the transcription start site of the 
differentially expressed genes. In terms of methylation regulatory regions, three 
differentially expressed genes, Tor3a, Rpl21 and Ttc25, are encoded within 20kb 
from a distal CpG island. 
 
Bioinformatics analysis revealed the chromosomal location of the differentially 
expressed genes in the liver of adult male offspring following MFAS (Table 2.2). All 
of the differentially expressed genes, except for Mid1, were found to be embedded 
in a somatic chromosome. X chromosome encodes the up-regulated gene of Mid1. 
Chromosome 4 was the most enriched for the differentially expressed genes in the 
adult male offspring, encoding four (18%) of the differentially expressed genes. 
Two genomic regions, 4q22 and 16p16, were found to encode more than one 
differentially expressed gene, with the former region encoding two of the down-
regulated genes (Akr1b7 and Cpa2), while the latter region encodes one up-
regulated (Il17rb) and one down-regulated gene (Arhgef3). 
 
In terms of methylation regulatory regions, five up-regulated and six down-
regulated genes were found to be flanked by a distal CpG island within 20kb 
upstream of their transcription start site (Table 2.2). The regulatory CpG island for 
one of the six down-regulated genes, Ascl1, is amalgamated with its coding region 




the differentially expressed genes in the liver of offspring is currently known to be 
paternally or maternally imprinted in the rat. 
 
The chromosomal location of the differentially expressed genes in the adult female 
offspring following MFAS are summarised in Table 2.3. Chromosome 7 was the 
most significantly enriched for the differentially expressed genes, with five (14%) 
found to be encoded on this chromosome. All of the differentially expressed genes 
are encoded on a somatic chromosome, with the exemption of S100g, which is 
encoded on the X chromosome. Bioinformatics analysis further revealed two 
genomic regions encoding more than one differentially expressed gene, 2q16 and 
7q33; the former region encodes two down-regulated genes, Prlr and Lifr, while 
the latter region encodes another two down-regulated genes, A1bg and Sqle.  
 
CpG islands were found to be present within 20kb from the coding region of three 
up-regulated genes in the liver of adult female offspring following MFAS (Table 
2.3). Of the down-regulated genes, fourteen are encoded within 20kb from a distal 
CpG island, including three cholesterogenic genes, Idi1, Sc4mol and Sqle (Table 
2.3). In addition, a CpG island is located within 20kb downstream of the down-
regulated gene, Pls1 (Table 2.3). None of the differentially expressed genes 
following MFAS is currently known to display paternal or maternal imprinted 
inheritance in the rat.  
 
2.3.6. INDEPENDENT QUANTIFICATION OF MRNA EXPRESSION IN LIVER 
OF ADULT OFFSPRING  
To validate the hepatic transcriptomic differences found in adult offspring following 
MFAS using microarrays, eleven genes, including Abcd2, Acaca, Acsm3, Akr1b7, 
Akr1b10, Idi1, Pck1, Ppara, Ppargc1a, Sc4mol and Sqle, were selected for 
analysis by qRT-PCR. Ingenuity Pathway Analysis identified putative upstream 
regulators of these genes in lipid homeostasis (Table 6.11); therefore, expression 




determined. Expression of upstream regulators that were examined included 
Ppara, a transcription factor for enzymes involved in the oxidation and uptake of 
fatty acids; Ppargc1a, a transcriptional coactivator of PPARA; Acaca, the rate 
limiting enzyme in de novo lipogenesis; and Pck1, a pivotal regulator of 
gluconeogenesis. 
 
Consistent with microarray findings, MFAS up-regulated hepatic expression of 
Acsm3 in adult offspring (4.28 fold, P = 0.010; Table 2.4; Figure 2.8A). Acetyl-CoA 
carboxylase alpha (Acaca), the rate limiting enzyme in de novo fatty acid synthesis, 
was similarly up-regulated in the liver of adult offspring by MFAS (1.53 fold, P = 
0.029; Figure 2.8B). On the other hand, MFAS down-regulated hepatic expression 
of Ppara in adult offspring (-0.41 fold, P = 0.002; Figure 2.8C). Moreover, hepatic 
expression of two cholesterogenic genes, Idi1 (-0.43 fold, P = 0.003; Figure 2.8D) 
and Sqle (-0.31 fold, P = 0.042; Figure 2.8E), were also down-regulated by MFAS 
in adult offspring. Pearson’s one-tailed correlation analysis indicated that hepatic 
expression of Ppara and Sqle were positively correlated (r = 0.443, P = 0.003) in 
the adult offspring, in contrast to those of Ppara and Idi1 (r = 0.196, P = 0.127). 
 
In the adult male offspring, hepatic expression of Acaca was up-regulated by 
MFAS (1.56 fold, P = 0.011; Table 2.5; Figure 2.8B), while that of Ppara was 
reduced (-0.52 fold, P = 0.010; Table 2.5; Figure 2.8C). 
 
Consistent with microarray findings, MFAS up-regulated hepatic expression of 
Akr1b10 in adult female offspring (2.41 fold, P = 0.024; Table 2.5; Figure 2.8F) but 
down-regulated that of Idi1 (-0.64 fold, P < 0.0001; Table 2.5; Figure 2.8D). 
Furthermore, hepatic expression of Ppara was down-regulated by MFAS in adult 
female offspring (-0.25 fold, P = 0.001; Table 2.5; Figure 2.8C). Consistent with 
IPA upstream regulator analysis, Pearson’s one-tailed correlation analysis showed 
hepatic expression of Ppara was positively correlated with that of Idi1 (r = 0.434, P 




expression of Akr1b10 and Acaca (r = 0.846, P < 0.0001) were also positively 













CA vs FAA (P) 
Ppara  0.089 ± 0.010 0.054 ± 0.008  0.002 
      
Abcd2 
 













































0.046 ± 0.006 0.031 ± 0.004 
 
0.042 
Eighteen offspring per maternal dietary group were analysed (C: 18, male = 9, female = 9; FA: 18, 
male = 9, female = 9). Normal distributed data was analysed with independent samples t-test. Non-
normal distributed data was analysed with Kruskal-Wallis H test. Expression values of the genes of 
interest are normalised to hepatic Ppia expression and are presented as mean ± SEM. CA, all 













CM FAM CM vs FAM (P) CF FAF CF vs FAF (P) 
Ppara   0.100 ± 0.016 0.046 ± 0.007 0.010  0.083 ± 0.007 0.048 ± 0.006 0.001  
 
              
Abcd2   0.05 ± 0.01 0.05 ± 0.01 0.816  1.12 ± 0.14 0.91 ± 0.25 0.277  
Acaca   0.142 ± 0.014 0.211 ± 0.017 0.011 0.171 ± 0.028 0.204 ± 0.029 0.386  
Acsm3   1.356 ± 0.672 2.303 ± 0.414 0.149  0.392 ± 0.121 0.624 ± 0.151 0.242  
Akr1b7   1.68 ± 0.50 3.97 ± 0.98 0.065  0.06 ± 0.01 0.06 ± 0.02 0.830  
Akr1b10   0.029 ± 0.007 0.041 ± 0.008 0.315  0.439 ± 0.079 1.386 ± 0.366 0.024  
Idi1   0.288 ± 0.038 0.233 ± 0.043 0.349  0.425 ± 0.017 0.182 ± 0.028 0.000  
Pck1   7.39 ± 1.74 8.21 ± 2.20 0.691  5.74 ± 1.97 2.87 ± 0.67 0.508  
Ppargc1a   0.07 ± 0.01 0.09 ± 0.02 0.062  0.23 ± 0.03 0.40 ± 0.09 0.109  
Sc4mol   0.55 ± 0.04 1.08 ± 0.26 0.129  1.01 ± 0.19 0.86 ± 0.13 0.512  
Sqle 
 
0.025 ± 0.003 0.020 ± 0.003 0.372  0.054 ± 0.007 0.040 ± 0.007 0.122  
Eighteen offspring per maternal dietary group were analysed (C: 18, male = 9, female = 9; FA: 18, male = 9, female = 9). Normal distributed data was 
analysed with independent samples t-test. Non-normal distributed data was analysed with Kruskal-Wallis H test. Expression values of the genes of interest 
are normalised to hepatic Ppia expression and are presented as mean ± SEM. CM, male offspring of control dams; CF, female offspring of control dams; 









Figure 2.8 Maternal Folic Acid Supplementation Alters Hepatic Gene Expression in the Adult Offspring. 
Relative hepatic expression of (A) Acsm3; (B) Acaca; (C) Ppara; (D) Idi1; (E) Sqle; and (F) Akr1b10 in adult offspring of folic acid supplemented and control 
dams. Eighteen offspring per maternal dietary group were analysed (C: 18, male = 9, female = 9; MFAS: 18, male = 9, female = 9). Normally distributed data 
was analysed by independent samples t-test. Non-normally distributed data was analysed by Kruskal-Wallis H test. Expression values are normalised to 





In the present study, we have shown for the first time that MFAS, from 
preconception to term, differentially alters the hepatic transcriptome of adult 
offspring. Genes with major functions in lipid metabolism and cholesterogenesis 
are altered markedly in adult offspring following MFAS. Cumulatively, these 
hepatic transcriptomic changes may contribute towards an altered capacity for lipid 
homeostasis in the adult offspring following MFAS and, in turn, may affect hepatic 
lipid balance and susceptibility to chronic diseases.  
 
De novo lipogenesis is a key biochemical pathway by which excess dietary 
carbohydrates or fats are converted to fatty acids in the liver.183, 379 The resultant 
fatty acid products are subsequently incorporated into triglycerides, which are then 
exported to the peripheral tissues for energy storage.92, 99 In the present study, two 
genes involved in de novo lipogenesis, Acaca and Acsm3, are up-regulated by 
MFAS in the liver of adult offspring. Being a critical rate limiting determinant of de 
novo lipogenesis, ACACA facilitates the conversion of acetyl-CoA to malonyl-CoA, 
which is processed by ACSM3 to produce acyl-CoA.115 Consistently, MFAS, from 
conception to term, has been shown to up-regulate hepatic expression of genes, 
which are closely associated with fatty acid metabolic pathways in adult rat 
offspring.250 Taken together, these observations suggest that MFAS may 
accentuate the capacity for de novo lipogenesis in the liver of adult offspring and, 
in effect, may increase hepatic abundance of lipids, particularly fatty acids.  
 
Being a key transcription regulator, PPARA is responsible for co-ordinating 
changes to the expression of genes involved in fatty acid uptake, cholesterol 
biosynthesis and mitochondrial fatty acid oxidation.113, 234 Previously, MFAS in the 
rat, from postconception to term, has been shown to down-regulate hepatic 
expression of Ppara in offspring after birth.67 Consistently, we have observed in 
the present study that MFAS, from preconception to term, down-regulates the 
hepatic expression of Ppara in the adult offspring, irrespective of sex. Down-
regulation of Ppara has been shown to reduce constitutive hepatic beta-oxidation 




wild type mice; thereby, this indicates a reduced capacity for mitochondrial fatty 
acid oxidation.10 Collectively, these observations suggest that MFAS may diminish 
the capacity for mitochondrial fatty acid oxidation in the postnatal offspring, 
irrespective of sex, and may have consequences on hepatic concentration of fatty 
acids. In addition, PPARA has previously been shown to function as an anti-
inflammatory regulator that inhibits the hepatic expression of inflammatory 
cytokines and acute-phase proteins, including interleukin-6, C-reactive protein, 
fibrinogen and TNFα.272 In light of this, reduced hepatic expression of Ppara in the 
adult offspring of folic acid supplemented dams may increase hepatic expression 
of inflammatory cytokines and acute-phase proteins, in turn, potentiating hepatic 
inflammation and affecting susceptibility to hepatic steatosis.272 However, this 
aspect of consequence for adult offspring following MFAS requires further 
investigation.  
 
An inability to maintain lipid homeostasis has been identified as an underlying 
cause for increased hepatic lipid accumulation, which is a well-established 
pathophysiological characteristic of NAFLD.196, 293 From the hepatic transcriptional 
profiles of patients with NAFLD, aberrations to the expression of genes related to 
the regulation of lipid homeostasis have been shown to be prominent.214, 299 As 
reported in clinical studies, patients with NAFLD have been shown to display 
markedly higher expression of genes involved in de novo lipogenesis, including 
ACACA.154, 214, 299 On the other hand, hepatic expression of genes involved in fatty 
acid oxidation and transport, including PPARA and CPT-1, have been found to be 
greatly reduced in patients with NAFLD.214, 299 Cumulatively, these distinctive 
hepatic gene expression patterns are closely associated with the pathogenesis of 
NAFLD and have been suggested to increase the propensity for hepatic lipid 
accumulation.214, 299 Of concern, the hepatic gene expression patterns observed in 
patients with NAFLD and those observed in the adult offspring of folic acid 
supplemented dams are highly similar. This close resemblance in hepatic 
transcriptional profiles suggests that MFAS may increase susceptibility of offspring 
to NAFLD in adulthood through hepatic transcriptomic changes; however, to date, 




Besides hepatic lipid imbalance, disruption to the composition of hepatic fatty 
acids is also a key characteristic of NAFLD.7 Patients with non-alcoholic 
steatohepatitis have been reported to possess markedly higher hepatic 
concentrations of monounsaturated fatty acids, including palmitoleic acid and oleic 
acid, relative to healthy controls.7, 11 In the present study, accumulation of 
palmitoleic acid has been identified as a biological function affected by MFAS in 
the liver of adult offspring. Also, oleate biosynthesis has been observed to be a 
canonical pathway affected by MFAS in the liver of adult offspring, with it being 
closely associated with the up-regulated gene of Scd1. Overall, these observations 
suggest that MFAS, from preconception to term, may increase the synthesis and 
accumulation of monounsaturated fatty acids in the adult offspring and, in effect, 
perturb hepatic fatty acid composition and susceptibility to NAFLD. Often, 
disruptions in hepatic fatty acid composition of patients with NAFLD are also 
accompanied by an aberrant inflammatory response. As observed previously, 
serum levels of proinflammatory cytokines and adipokines, including TNFα and IL-
8, are notably higher in patients with NAFLD as compared to obese and non-
obese controls.181 Increased expression of TNFα has been found to contribute 
towards liver injuries that propel hepatocyte apoptosis.86, 280 Of relevance, TNF is 
identified as an upstream regulator for four of the differentially expressed genes in 
the liver of adult offspring following MFAS in the present study. Taken together, 
these observations suggest that MFAS may augment proinflammatory activity of 
TNF in the liver of adult offspring, consistent with an increased susceptibility to 
NAFLD. 
 
In the present study, hepatic expression of two cholesterogenic genes, Idi1 and 
Sqle, are shown to be down-regulated by MFAS in adult offspring. Reduced 
expression of these two cholesterogenic genes suggest that MFAS may diminish 
the capacity for adult offspring to undertake cholesterogenesis. Consistently, a 
previous study has reported MFAS to lower plasma cholesterol markedly in the 
adult rat offspring.67 As cholesterol may originate from either endogenous 
biosynthesis or through diet, down-regulation of genes involved in 
cholesterogenesis may in part contribute to the reduced plasma cholesterol of 




that of glucocorticoid, androgens and estrogen, also requires cholesterol as a 
precursor285; hence, decreased expression of cholesterogenic genes may also 
attenuate the capacity for steroid biosynthesis in the adult offspring following 
MFAS. Furthermore, the biosynthesis of glucocorticoid and androgen are identified 
as canonical pathways affected by MFAS in the liver of adult offspring. Also, with 
steroid hormones having diverse roles and actions in metabolic regulation, the 
extent to which biosynthesis of glucocorticoid and androgen may be perturbed and 
if this also relates to altered lipid homeostasis in adult offspring of folic acid 
supplemented dams require further investigation.  
 
Moreover, in the present study, we have shown that MFAS induces sexually 
dimorphic changes in the hepatic transcriptome of adult offspring. Hepatic 
expression of Akr1b10, a gene known to promote de novo lipogenesis via 
increasing protein stability of ACACA, is found to be highly up-regulated by MFAS 
in the adult female offspring only. Coincidentally, steroid metabolism is identified 
as a biological function affected by MFAS in the adult female offspring only. In 
agreement, hepatic expression of Idi1, a cholesterogenic gene, is also markedly 
reduced in the female offspring. Thereby, these observations suggest that MFAS 
may perturb de novo lipogenesis and steroid biosynthesis to a greater extent in 
adult female offspring than in males via sex-specific mechanisms. Recent studies 
have reported sexually dimorphic differences in DNA methylation of offspring of 
folic acid supplemented dams, including the differentially methylated region of H19, 
which has been shown to be less methylated in the cord blood of male newborns 
than in females.140, 158, 166 Characterisation of DNA methylation changes that occur 
in the liver of offspring following MFAS during prenatal and postnatal development 
are key priorities of research. It is also of paramount importance to determine 
whether any of these epigenetic changes may relate to the alterations in gene 
expression observed herein. These studies would inform the extent to which 
epigenetics may contribute towards the observed sex-specific differences in 





In conclusion, our observations have shown that MFAS induces marked changes 
to the hepatic transcriptome of adult offspring, with genes related to de novo 
lipogenesis being up-regulated, while those related to fatty acid oxidation and 
cholesterogenesis are down-regulated. These changes may confer an increased 
capacity for de novo lipogenesis but an attenuated capacity for fatty acid oxidation 
and cholesterogenesis in the adult offspring following MFAS. In effect, hepatic lipid 
balance and homeostasis may be perturbed by MFAS in the adult offspring, 
leading to excessive hepatic lipid accumulation, which may modify their 
susceptibility to chronic diseases, particularly NAFLD. Given the prevalence of 
MFAS worldwide, future studies in humans are needed to clarify the effects of this 











Maternal Folic Acid Supplementation and Its 
Effects on Maternal and Foetal Hepatic 
Expression of Metabolic and Epigenetic 





Periconceptional folic acid supplementation is well recognised for its efficacy in 
reducing the risk of NTDs.290 To minimise the incidence of NTDs, over 80 
countries in the world, including the United States, Canada and Chile, have 
adopted public health policies that mandatorily fortify wheat flour with folic acid.79, 
160, 257 Despite credible benefits to folic acid fortification, concerns have been 
raised regarding the merits and long-term consequences of prolonging this 
practice beyond periconception may confer upon metabolic health of offspring.74 
 
Recently, periconceptional folic acid supplementation has been reported in a 
systematic review to reduce the risk of the neonate of being born SGA.156 From 
existing epidemiological studies, it is known that a strong association exists 
between being born SGA and susceptibility to chronic diseases in later life, 
including Type 2 Diabetes Mellitus,142 obesity,306 hypertension19 and 
cardiovascular diseases.20 Thereby, these observations suggest that maternal 
intake of folic acid during periconception is a key determinant of prenatal growth, 
neonatal outcomes and susceptibility of offspring to chronic diseases in adult life. 
Besides the periconceptional period, maternal intake of folate in other gestational 
period may also alter metabolic homeostasis and susceptibility of offspring to 
chronic diseases after birth. Higher maternal plasma folate concentrations at 30 
weeks of gestation has been associated with higher levels of insulin resistance of 
children, aged between 9.5 and 13.5 years.217 In rodents, higher levels of fasting 
blood glucose and impaired glucose homeostasis in adult male offspring are 
associated with maternal deficiency of folate and other methyl group donors 
throughout pregnancy.370 Taken together, these studies suggest maternal intake of 
folate in the periconceptional and gestational period may alter susceptibility of 
offspring to chronic diseases after birth; however, the underlying molecular 
mechanisms are incompletely understood. 
 
One molecular mechanism by which folic acid availability during periconception 
may influence susceptibility of offspring to chronic disease after birth is 




occur without alterations to the DNA nucleotide sequence.127 Key epigenetic 
processes known to be involved in the regulation of gene expression and 
development include DNA methylation, histone modification and non-coding 
RNAs.179 Emerging findings from a comparative study in humans suggest that 
MFAS before or during pregnancy perturbs methylation levels at the differentially 
methylated region of IGF2 in the umbilical cord blood of infants.374 A prospective 
study in human has also identified maternal use of folic acid supplements during 
late gestation to be associated with increased methylation in the promoter region 
of IGF2 in the cord blood of infants.140  
 
Experimental studies in rodents have shown that MFAS from periconceptional 
period and throughout pregnancy can alter epigenetic regulation and gene 
expression in the offspring at birth and thereafter.158, 263, 365, 442 Global DNA 
methylation in the brain of newborn pups are reduced by MFAS; however, no 
differences in global DNA methylation are observed in the liver, kidney or colon.263 
Hepatic expression of Ppara, Gr and Er-α in the newborn pups are also reduced 
by MFAS.263 In postnatal life, MFAS reduces hepatic expression of ATGL in the 
three weeks old offspring.442  
 
Moreover, MFAS throughout pregnancy and lactation can also alter epigenetic 
regulation and gene expression in the postnatal offspring, with it shown to reduce 
global DNA methylation in the liver of weaning rat pups as compared to 
controls.365 Maternal folic acid supplementation throughout pregnancy and 
lactation also reduces the activity of DNMTs in the liver of weaning and adult rat 
offspring.365 In addition, another study has reported that MFAS during gestation 
increases hepatic expression of Pepck, a key regulator of gluconeogenesis, in the 
adult female offspring but not in the adult male offspring, indicative of a sexually 
dimorphic effect.158 Increased hepatic expression of Pepck in the adult female 
offspring of folic acid supplemented dams is also associated with altered CpG 
methylation in its promoter region as well as increased fasting plasma glucose.158 




birth via changes in DNA methylation; however, it is unknown whether such 
changes may become established in early foetal development. 
 
Intriguingly, one class of non-coding gene known as miRs has been found to be 
particularly responsive to cellular availability of folate and the dysregulation of DNA 
methylation.134, 271 These short single-stranded RNA molecules are known to play 
a key regulatory role in post-transcription, as they possess the ability to repress 
post-transcriptional expression of their target mRNA through 3’UTR base-pairing 
interactions.45 MicroRNAs have recently been reported to target genes involved in 
glucose, lipid and cholesterol metabolism; hence, this indicates that aberrant miR 
expression in glucoregulatory organs and tissues may disrupt metabolic 
homeostasis.104 To date, the role of miRs in foetal development remains largely 
elusive; hence, to elucidate a molecular mechanism by which MFAS may affect 
susceptibility of offspring to chronic disease during foetal development, this study 
examined the effects of MFAS on foetal hepatic expression of non-coding miRs in 
late gestation.  
 
As reported in Chapter 2, MFAS alters hepatic expression of key genes in lipid 
homeostasis in adult offspring, it is unknown whether these changes may emerge 
in prenatal life and, therefore, require further investigation. In addition, there exists 
the potential for MFAS to elicit genome-wide transcriptomic changes through 
altering expression of DNMTs, which are known to regulate the expression of key 
metabolic regulators and miRs. As another molecular mechanism, MFAS may 
affect susceptibility of offspring to chronic disease in part through perturbing 
hepatic expression of DNMTs during foetal development.17 Collectively, this study 
examined the effects of MFAS on foetal hepatic expression of key metabolic 
regulators and DNMTs in late gestation.  
 
Moreover, it is well established that maternal metabolism undergoes extensive 
adaptations during gestation in order to facilitate placental and foetal 




through a series of changes in maternal hepatic gene expression.46 However, 
failure to undertake maternal metabolic adaptations during gestation, as in the 
case of gestational diabetes, has been shown to increase susceptibility of offspring 
to glucose intolerance and obesity in later life.333 At present, it is unknown whether 
MFAS may alter maternal metabolic adaptations in late gestation through changes 
in hepatic gene expression; hence, this study also examined the effects of MFAS 
on maternal hepatic expression of key metabolic regulatory genes, DNMTs and 







3.2.1. ANIMALS AND TISSUE COLLECTION 
This study was designed in accordance with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes and was approved by the 
University of Adelaide Animal Ethics Committee. Virgin female Wistar rats (aged 
98 ± 5 days) and Lewis/SNN male rats (aged 84 ± 5 days) were purchased from 
Animal Resources Centre (Perth, Australia). Virgin female Wistar rats were 
randomly allocated to one of two groups: control (C) or maternal folic acid 
supplementation (MFAS), with each group consisted of nine virgin female Wistar 
rats. Control group was fed a standard rodent diet (AIN93G, Speciality Feeds, 
Australia) comprised of 2 mg folic acid/kg feed from two weeks prior to conception 
until term; this dosage of folic acid is generally accepted as meeting the basal 
dietary requirements for rats and closely assembles the recommended dietary 
allowance of 0.4 mg dietary folate equivalent in humans.12, 410 Maternal folic acid 
supplementation group was fed a standard rodent diet (SF07-018, Speciality 
Feeds, Australia) comprised of 6 mg folic acid/kg feed from two weeks prior to 
conception until term. This dosage of folic acid is three fold greater than basal 
dietary requirements for rats and mimics the level of folate to which women are 
exposed through average dietary intake, food fortification and supplementation 
during the periconceptional and gestational period.382  
 
Standardised rodent diets containing different levels of folic acid are a common 
method of providing supplementary dietary folate to rodents; this method has been 
used previously in a number of experimental studies.43, 67, 263 Folate concentrations 
achieved by this method in the plasma, liver, brain, kidney and colon of rodent 
models have been reported previously in detail.263  
 
All dams were sacrificed by isoflurane inhalation followed by cardiac puncture at 
gestational day 20. All foetuses were sacrificed by cervical dislocation. Maternal 
and foetal livers were collected, frozen in liquid nitrogen and stored at -80ºC. 
Maternal and foetal organ weight, including liver, lung, kidney, heart and pancreas, 
were normalised and expressed as percentages of total body weight. Gestational 




gestational day 20. Differences in body weight, gestational weight gain and relative 
organ weight between dams of the two maternal dietary groups were compared 
using independent samples t-test on SPSS version 20 (IBM, USA). Differences in 
foetal body weight and relative organ weight were compared using repeated 
measures ANOVA on SPSS version 20 (IBM, USA), with maternal dietary 
treatment as between subject factor, foetal sex as within subject factor and dam as 
covariate. 
 
3.2.2. RNA EXTRACTION AND QUALITY ANALYSIS  
Total RNA from the liver was extracted by TRIzol®  reagent (Invitrogen, USA) on 
Precellys®  24 Homogeniser (Bertin Technologies, France). Total RNA was isolated 
using standard RNA extraction procedures.310 All RNA samples had a 260/280 
absorbance ratio between 1.8 and 2.0, with their final concentration determined on 
Nanodrop ND-1000 spectrophotometer (BioLab Scientific, Canada). Integrity of 
28S and 18S ribosomal RNA was verified using 1% (w/v) agarose gel 
electrophoresis.  
 
3.2.3. QUANTIFICATION OF MRNA EXPRESSION 
As reported in Chapter 2, a number of key metabolic genes (Abcd2, Acaca, Acsm3, 
Akr1b10, Akr1b7, Idi1, Pck1, Ppara, Ppargc1a, Sc4mol and Sqle) displayed 
differential expression in the liver of adult offspring following MFAS. To determine 
if these expressional changes in the offspring were initiated by MFAS in late 
gestation, qRT-PCR analysis was performed on 12 foetuses (male = 6, female = 6; 
1 male and 1 female foetus per dam) from the two maternal dietary groups at 
gestational day 20. To determine whether MFAS altered maternal metabolic 
adaptations in late gestation through changes in hepatic gene expression, qRT-
PCR analysis was also performed on 6 dams from the two maternal dietary groups 





cDNA synthesis was performed with SuperScript™ III Reverse Transcriptase 
(Invitrogen, USA) in accordance to manufacturer’s instructions. Each cDNA 
synthesis reaction contained 2 μg of total RNA in 13 μL of nuclease-free water, 1 
μL of 10 mM dNTP (Life Technologies, USA) and 1 μL of random hexamers (200 
ng/μL) (Life Technologies, USA). The reactions were first incubated at 65°C for 5 
minutes before incubation on ice for 1 minute on GeneAmp®  PCR system 9700 
(Life Technologies, USA). The remaining constituents, including 4 μL of 5X First-
Strand Buffer (Life Technologies, USA), 1 μL of 0.1 M DTT (Life Technologies, 
USA), 1 μL of RNaseOUT™ RNase inhibitor (40 U/μL; Life Technologies, USA) 
and 1 μL of SuperScript™ III Reverse Transcriptase (200 U/μL; Invitrogen, USA) 
were added to each reaction on ice. The reactions were allowed to continue at 
25°C for 5 minutes, 50°C for 60 minutes and 70°C for 15 minutes on GeneAmp®  
PCR system 9700 (Life Technologies, USA). All cDNA reactions were stored at -
20°C until use.  
 
Quantitative PCR of gene expression was performed on Applied Biosystems 
7900HT Fast Real-Time PCR System (Life Technologies, USA) using TaqMan®  
Universal PCR Master Mix (Life Technologies, USA) in accordance to 
manufacturer’s instructions. Each PCR amplification reaction contained 10 μL of 
2X TaqMan®  Universal PCR Master Mix (Life Technologies, USA), 1 μL of 
TaqMan®  Gene Expression Assay (Table 6.12; Life Technologies, USA), 7 μL of 
nuclease-free water and 2 μL of cDNA. On Applied Biosystems 7900HT Fast Real-
Time PCR System (Life Technologies, USA), cycling conditions were set as 
follows: 50°C for 2 minutes; 95°C for 10 minutes; and 45 cycles of 95°C for 15 
seconds and 60°C for 1 minute. Each sample was amplified in duplicates.  
 
3.2.4. DATA PROCESSING AND STATISTICAL ANALYSIS FOR MRNA 
EXPRESSION 
Potential reference genes were evaluated using Normfinder,226 which provides a 
stability ranking through determining the intra- and inter-group variation (Data not 




reference gene, actin beta (Actb), as reflected by its minimal intra- and inter-group 
variations on Normfinder. In accordance to the Applied Biosystems Relative 
Quantification Methodology (Life Technologies, USA), the 2-∆∆Ct method was 
performed to depict gene expression as means and fold changes. Independent 
samples t-test was performed on SPSS version 20 (IBM, USA) to compare the 
differences in maternal hepatic gene expression between the two maternal dietary 
treatment groups. Repeated measures ANOVA was performed on SPSS version 
20 (IBM, USA) to assess the effects of maternal dietary treatment on foetal hepatic 
gene expression, with maternal dietary treatment as between subject factor, foetal 
sex as within subject factor and dam as covariate. For data that was not normally 
distributed, Kruskal-Wallis H test was performed. Associations between maternal 
and foetal hepatic gene expression were assessed by Pearson’s two-tailed 
correlation analysis on SPSS version 20 (IBM, USA).  
 
3.2.5. EXIQON MICRORNA MICROARRAY ANALYSIS 
Global hepatic miR expression was compared between six dams of the two 
maternal dietary groups as well as between 12 foetuses (male = 6, female = 6; 1 
male and 1 female foetus per dam) of the two maternal dietary groups. A total of 
six microarrays were performed for each foetal sex. Briefly, 5 μg of total RNA from 
each sample was labelled using a previously described method.384 To eliminate 
the effect of dye bias, a dye swap design was incorporated, with hepatic RNA from 
each maternal dietary group labelled in a balanced block order.87 Each array 
contained the antisense probes of all known mature miRs for rat, as published in 
the Sanger miRBase release version 11 (Wellcome Trust Sanger Institute, 
http://mirbase.org131; with probes for these printed in duplicates. Included on the 
array were two positive controls, with their capture probes being antisense to that 
of U6-small nuclear spliceosomal RNA 1 and 2 (U6 snRNA 1 or 2). Eight negative 
control probes were present on the microarray, hsa_negative_control (1-8), which 
are each of a synthetic sequence that shares no known homology with any 
mammalian miRs. Hybridisation was performed overnight at 60°C in the dark. 




accordance to manufacturer’s instructions. Microarrays were scanned at 10 μM 
resolution using GenePix®  4000B Scanner (Molecular Devices, USA).  
 
All raw pixel intensities were extracted with GenePix®  Pro 6.0 (Molecular Devices, 
USA) to produce scanned images for each array. The foreground and background 
pixel intensities for all arrays were extracted from the scanned images and 
processed with Spot version 3 plugin (Commonwealth Scientific and Industrial 
Research Organisation, Australia) using R software (The R Foundation for 
Statistical Computing, http://cran.r-project.org). Following background median 
subtraction, spot intensity values were Loess-normalised using Limma plugin 
(Walter and Eliza Hall Institute of Medical Research, Australia) for R software. 
Mean intensities were log2 transformed to produce a single Cy5/Cy3 ratio for each 
probe on the microarray. A linear model was conducted for each probe on the 
microarray to determine for differential expression. With Benjamini-Hochberg (B-H) 
correction for multiple comparisons, statistical significance was accepted at P < 
0.05. 
 
3.2.6. QUANTIFICATION OF SELECTED MICRORNA EXPRESSION 
To validate the differential hepatic miR expression observed in the dams and 
female foetuses following MFAS, qRT-PCR analyses were performed. Male 
foetuses were omitted from further qRT-PCR analyses, as no significant changes 
in hepatic miR expression were detected from Exiqon microRNA microarray 
analysis.  
 
To synthesise cDNA from total RNA extracted from foetal and maternal liver, 
reverse transcription was performed with TaqMan®  MicroRNA Reverse 
Transcription kit (Life Technologies, USA) in accordance to manufacturer’s 
instructions. The reaction was incubated at 16ºC for 30 minutes, 42ºC for 30 
minutes and 85ºC for 5 minutes on GeneAmp®  PCR system 9700 (Life 




To quantify maternal hepatic miR expression (C: 6, FA: 6), the following TaqMan®  
MicroRNA Assays (Life Technologies, USA) were used: rno-miR: 17 (ID: 002308); 
25 (ID: 000403); 122 (ID: 002245); and 191 (ID: 002299). Foetal hepatic miR 
expression (C: 6, female = 6; FA: 6, female = 6) was determined using TaqMan®  
MicroRNA Assays (Life Technologies, USA), which included the following: rno-miR: 
17 (ID: 002308); 20a (ID: 000580); 25 (ID: 000403); 33 (ID: 002135); 103 (ID: 
000439); 122 (ID: 002245); 127 (ID: 000452); 142-3p (ID: 000464); 183 (ID: 
002269); and 191 (ID: 002299). 
 
Quantitative PCR reactions were performed in triplicates using TaqMan®  Universal 
PCR Master Mix II with no AmpErase®  UNG (Life Technologies, USA) in 
accordance to manufacturer’s instructions. In respective order, all reactions were 
incubated at 95ºC for 10 minutes and 50 cycles of 95ºC for 15 seconds and 60ºC 
for 60 seconds. All reactions were performed on Rotor-Gene®  6000 series PCR 
machines (Corbett Research, Australia). Raw Ct data was collected and analysed 
using Rotor-Gene®  Q Series Software version 1.7 (Corbett Research, Australia).  
 
3.2.7. DATA PROCESSING AND STATISTICAL ANALYSIS FOR MICRORNA 
EXPRESSION 
Potential reference miR genes were evaluated using NormFinder226 and GeNorm. 
404 As nominated by the two algorithms, normalisation was performed with the 
most stable candidate, rno-miR-25. Fold change in the expression of a miR gene 
was calculated using the 2-∆∆Ct method in accordance to Applied Biosystems 
Relative Quantification Methodology (Life Technologies, USA). Differences in 
hepatic miR expression between female foetuses of the two maternal dietary 
groups were analysed by independent samples t-test on SPSS version 20 (IBM, 
USA), which was performed in compliance with the guidelines provided by Livak 
and Schmittgen254. To assess for associations between hepatic expression of 
miRs and genes, Pearson’s one-tailed correlation analysis was performed on 




3.2.8. MICRORNA BIOINFORMATICS AND TARGET PREDICTION ANALYSES 
Information on the mature sequence, chromosomal location, cluster status and 
gene family of the miRs presented was obtained from miRBase version 20 
(Wellcome Trust Sanger Institute, http://microrna.sanger.ac.uk/sequences/). The 
presence of CpG islands, 20 kilobase upstream or downstream, from the coding 
region of a miR gene was identified using an enabled CpG island track on 
Ensembl (European Bioinformatics Institute, http://www.ensembl.org/), which 
allowed for close inspection of cis-acting elements within a specified chromosomal 
region. To generate predicted targets for the differentially expressed miRs, three 
prediction algorithms, TargetScan version 6.1 (Whitehead Institute for Biomedical 
Research, http://www.targetscan.org/), miRanda (Memorial Sloan-Kettering 
Cancer Center, http://www.microrna.org/microrna/home.do) and RNAhybrid 
(Bielefeld Bioinformatics Service, http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) 
were consulted. Predicted targets that overlapped between the three different 
prediction algorithms were further analysed. To identify experimentally validated 
targets of the differentially expressed miRs, miRTarBase (National Chiao Tung 
University, http://mirtarbase.mbc.nctu.edu.tw/) and miRWalk (Heidelberg 
University, http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) were first 
consulted, followed by literature searching on PubMed (National Center for 
Biotechnology Information, http://www.pubmed.com/).  
 
3.2.9. INGENUITY PATHWAY ANALYSIS 
To interpret Exiqon miR microarray data in the context of biological functions, 
diseases, canonical pathways, upstream regulators and molecular networks, ‘Core 
Analysis’ was performed using Ingenuity Pathway Analysis (IPA; Ingenuity 
Systems, www.ingenuity.com), with all 'Identifier Types' selected. Predicted targets 
of all the differentially expressed miRs were analysed. Based on the degree of 
overlap between the uploaded dataset and the gene-set within the IPA database, 
an overlap P-value was generated, with adjustments for Benjamini-Hochberg 
multiple testing corrections. For molecular networks, an IPA score ≥ 3 was 
considered as significant. For biological functions and diseases, B-H P < 0.05 was 




significant. Upstream regulators for the differentially expressed genes were also 
identified with an activation z-score, which determined the directional change of 
the upstream regulator by comparing the uploaded dataset against the mediator 
dataset within the IPA database. An upstream regulator with an activation z-score 
≥ 2 was interpreted as activated, while which with an activation z-score ≤ -2 was 






3.3.1. EFFECTS OF MATERNAL FOLIC ACID SUPPLEMENTATION ON 
MATERNAL AND FOETAL MORPHOMETRY 
Maternal folic acid supplementation did not alter body weight of foetuses in late 
gestation (Figure 3.1). Weight of foetal pancreas, kidneys, liver, heart or lungs of 
foetuses relative to total body weight was also unaffected by MFAS (Table 6.13).  
 
Maternal folic acid supplementation did not alter body weight of dams prior to 
pregnancy nor at gestational day 20 (Figure 3.2). Maternal folic acid 
supplementation also did not affect weight of maternal liver, heart, pancreas, 
spleen, lungs or kidneys relative to total body weight at gestational day 20 (Table 





Figure 3.1 Effects of Maternal Folic Acid Supplementation on Foetal Weight in Late 
Gestation. Maternal folic acid supplementation did not alter foetal body weight. Twelve foetuses 
per maternal dietary group were analysed (C: 12, male = 6, female = 6; FA: 12, male = 6, female = 
6). Data was analysed by repeated measures ANOVA, with maternal dietary treatment as between 





Figure 3.2 Maternal Total Body Weight Prior to Pregnancy and at Gestational Day 20. 
Maternal folic acid supplementation did not alter total body weight of dams prior to pregnancy nor 
at gestational day 20 (C: 6, FA: 6). Data was analysed by independent samples t-test. Values are 




3.3.2. EFFECTS OF MATERNAL FOLIC ACID SUPPLEMENTATION ON 
GLOBAL MATERNAL AND FOETAL HEPATIC MICRORNA 
EXPRESSION 
Maternal folic acid supplementation altered foetal hepatic expression of 33 miRs 
(P < 0.05) in late gestation, irrespective of sex (Table 6.15). Of these, eight miRs 
were up-regulated (1.11 to 1.23 fold, P < 0.05) and 25 miRs were down-regulated 
(-0.15 to -0.59 fold, P < 0.05). 
 
In the female foetus, MFAS altered hepatic expression of 36 miRs (P < 0.05) in 
late gestation, with four up-regulated (1.18 to 1.22 fold) and 32 down-regulated (-
0.21 to -1.18 fold; Table 6.16). Down-regulated miRs included rno-miR-122, which 
has been demonstrated previously to regulate lipid metabolism168, 220 as well as 
rno-miR-33, a miR with major regulator effects on cholesterol metabolism.331 
Interestingly, a high degree of overlap (69% concordance) was found between the 
differentially expressed miRs identified in female foetuses and those identified in 
all foetuses irrespective of sex.  
 
Maternal folic acid supplementation did not alter miR expression in the liver of the 
male foetus in late gestation. 
 
Maternal folic acid supplementation reduced maternal hepatic expression of miR-





3.3.3. GENOMICS OF DIFFERENTIALLY EXPRESSED MATERNAL AND 
FOETAL HEPATIC MICRORNAS 
To determine the chromosomal location of the differentially expressed miRs, 
bioinformatics analysis was performed. Of the eight up-regulated miRs in all 
foetuses of folic acid supplemented dams, five are intergenic (Table 6.15) and 
three are intronic (Table 6.15).  
 
It is known several miR genes can be located adjacent to each other on the same 
chromosome to form a cluster from which they are transcribed through a common 
promoter.77 A cluster of miRs share many common mRNA targets within the same 
pathway, thereby enabling them to have regulatory control over several key 
regulators in a metabolic pathway.77 Bioinformatics analysis was also conducted to 
determine if MFAS altered expression of hepatic microRNAs at an individual or 
cluster level. Six up-regulated miRs are clustered (Table 6.15), with each of these 
belonging to a different miR gene cluster. Three up-regulated miRs (37.5%) are 
encoded on the X chromosome (Table 6.15). Four up-regulated miRs (rno-miR: 
34c*, 196a*, 880 and let-7d) are encoded within 20kb from a distal CpG island 
(Table 6.15). 
 
Among the 25 down-regulated miRs in the foetus of folic acid supplemented dams, 
18 are intergenic, six are intronic and one miR is of unknown chromosomal 
location (Table 6.15). Chromosome 6 encodes seven (28%) of the 25 down-
regulated miRs, while 14 are known to be encoded within a miR gene cluster. Five 
over-represented miR gene families (miR-101, miR-142, miR-154, miR-30 and 
miR-368) were identified, with each of these hosting two down-regulated miRs.  
 
Of the four up-regulated miRs in the female foetus of folic acid supplemented 
dams, two are intergenic, while two are intronic (Table 6.16). Two up-regulated 
miRs are encoded within a miR gene cluster, while two up-regulated miRs (rno-




Furthermore, two other up-regulated miRs (50%) are encoded on the X 
chromosome.  
 
Among the 32 down-regulated miRs in the female foetus of folic acid 
supplemented dams, 23 are intergenic, eight are intronic, while one is of unknown 
chromosomal location (Table 6.16). Twenty down-regulated miRs are encoded as 
part of a miR gene cluster. Six down-regulated miRs are encoded on chromosome 
6. Furthermore, an over-representation of seven miR gene families (miR-19, miR-
17, miR-101, miR-103, miR-130, miR-142 and miR-154) was observed, with each 
of these hosting two down-regulated miRs. 
 
The only differentially expressed miR in the liver of the dam in MFAS, rno-miR-33, 
is intronic and unclustered. This miR is known to be encoded on chromosome 7 
(Table 6.17) and a distal CpG island is present within 20kb from the coding region 
of this miR (Table 6.17). 
 
3.3.4. PREDICTED AND VALIDATED TARGETS OF THE DIFFERENTIALLY 
EXPRESSED MICRORNAS IN FOETUSES AND DAMS 
Predicted targets of the differentially expressed miRs were identified using three 
different in silico algorithms including TargetScan 6.1,133 miRanda187 and 
RNAhybrid.218 In order to maximise prediction stringency, only targets that were 
predicted unanimously by all three algorithms were further analysed. Validated 
targets of the differentially expressed miRs were identified by miRTarBase,167 
miRWalk 91 and literature searching on PubMed.  
 
Prediction results for miR-122 returned with 13 mRNA targets (Aldoa, Ankrd13c, 
Bcat2, Brpf1, Ccng1, Cd320, Clic5, Cux1, Epo, Hnrnpu, Lrp10, Ocln and P4ha1; 
Table 6.18). Of these, miRWalk indicated Aldoa,160 Ccng1,415 Cd320,349 Cux1228 




Prediction results for miR-191 returned with six mRNA targets (Plcd1, Tor1aip2, 
Cebpb, Rnf139, Bdnf and Mapre3; Table 6.18). Of these, brain-derived 
neurotrophic factor (Bdnf) was validated experimentally to be a direct target of 
miR-191.296 Intriguingly, expression of miR-191 in human breast cancer cell is 
under the transcriptional control of the estrogen receptor.296  
 
Prediction results for miR-17 returned with 36 mRNA targets (Table 6.19). Of 
these, three predictions, Lhx6,199 Mapk969 and Ptpro439 were confirmed as 
experimentally validated targets of miR-17. 
 
Prediction results for miR-370 returned with 85 mRNA targets, which are 





3.3.5. INGENUITY PATHWAY ANALYSIS FOR THE DIFFERENTIALLY 
EXPRESSED HEPATIC MICRORNAS IN ALL FOETUSES 
To examine the functional significance of the differentially expressed foetal hepatic 
miRs, IPA was performed. Gene expression (B-H P < 0.0001) was one of the 
major biological functions predicted as affected by MFAS in the liver of all foetuses 
in late gestation, irrespective of sex (Table 3.1). Transcription (B-H P < 0.0001) 
and expression of RNA (B-H P < 0.0001) were revealed as the specific functional 
aspects of gene expression that were altered (Table 3.1). An over-representation 
of 68 canonical pathways (-log (B-H) P > 1.3) was observed, with ERK/MAPK 
signalling, dopamine-DARPP32 feedback in cAMP signalling, prolactin signalling, 
p70S6K signalling and calcium-induced T lymphocyte apoptosis being the top five 
affected pathways (Table 3.2). Moreover, 25 molecular networks (IPA score > 3) 
were highly enriched for the predicted targets of the differentially expressed miRs 
(Table 6.21). The top five molecular networks were functionally pertinent to post-
translational modification, organ development and cellular development.  
 
3.3.6. INGENUITY PATHWAY ANALYSIS FOR THE DIFFERENTIALLY 
EXPRESSED HEPATIC MICRORNAS IN FEMALE FOETUSES 
Similar to those observed in all foetuses, IPA indicated gene expression (P < 
0.0001) as one of the major biological functions affected by MFAS in the liver of 
the female foetus (Table 3.1). Forty-nine canonical pathways (-log (B-H) P >1.3) 
were found to be highly enriched for the predicted targets of the differentially 
expressed miRs in female foetuses of folic acid supplemented dams (Table 3.2). 
Of these, the top five pathways were functionally associated with ERK/MAPK 
signalling, dopamine-DARPP32 feedback in cAMP signalling and synaptic long-
term potentiation. Furthermore, an over-representation of 25 networks was found 
(IPA score > 3), with the top five being involved in endocrine system development 





3.3.7. INGENUITY PATHWAY ANALYSIS FOR THE DIFFERENTIALLY 
EXPRESSED HEPATIC MICRORNAS IN DAMS 
Molecular transport of metal ion (P < 0.0001) was predicted as one of the major 
biological functions in liver of dams affected by MFAS (Table 3.1). Ingenuity 
Pathway Analysis revealed two molecular networks (IPA score > 3) as affected by 
miR-33 in the liver of folic acid supplemented dams, with these suggested to be 
involved in metabolic disease and molecular transport (Table 6.23). No canonical 


















Table 3.1 Diseases and Biological Functions Affected in Maternal and Foetal 







Diseases and biological functions of all foetuses 
Gene Expression 3.72E-14 expression of RNA 207 
Gene Expression 7.62E-13 transcription 186 
Cellular Development 7.62E-13 differentiation of cells 190 
Gene Expression 7.62E-13 transcription of RNA 183 
Cell Death and Survival 3.80E-11 apoptosis 234 
    
Diseases and biological functions of female foetuses 
Gene Expression 3.38E-13 transcription 199 
Organismal Survival 6.25E-13 organismal death 239 
Gene Expression 1.44E-12 transcription of RNA 193 
Gene Expression 1.48E-12 expression of RNA 212 






    
Diseases and biological functions of dams 
Molecular Transport 5.55E-03 transport of metal ion 5 
Organismal Functions 5.55E-03 walking 3 
Behaviour 5.55E-03 walking 3 
Behaviour 5.55E-03 locomotion 5 
Molecular Transport 1.00E-02 export of lipid 2 
Diseases or biological functions with Benjamini-Hochberg corrected (B-H) P < 0.05 are considered 
as significant. # Molecules denote the number of differentially expressed gene(s) highly associated 





Table 3.2 Canonical Pathways Affected in Maternal and Foetal Liver by MFAS 
in Late Gestation. 




Predicted targets of the differentially expressed miRs of all foetuses 
ERK/MAPK Signalling 4.44 0.14 
Dopamine-DARPP32 Feedback in cAMP Signalling 3.71 0.14 
Prolactin Signalling 3.23 0.18 
p70S6K Signalling 3.16 0.15 
Calcium-induced T Lymphocyte Apoptosis 2.86 0.19 
   
Predicted targets of the differentially expressed miRs of female foetuses 
Synaptic Long Term Potentiation 2.75 0.16 
Dopamine-DARPP32 Feedback in cAMP Signalling 2.75 0.13 
ERK/MAPK Signalling 2.75 0.12 
nNOS Signalling in Neurons 2.14 0.21 
Cholecystokinin/Gastrin-mediated Signalling 2.06 0.15 
Ingenuity canonical pathways with –log (B-H) P ≥ 1.3 are considered as significant. Ratio 
represents the number of predicted targets over the total number of genes that constitute the 





3.3.8. QUANTIFICATION OF MATERNAL AND FOETAL HEPATIC MICRORNA 
EXPRESSION 
Quantification by qRT-PCR confirmed that MFAS increased hepatic expression of 
miR-122 (1.54 fold, P = 0.037) and miR-191 (1.34 fold, P = 0.045) in the female 
foetus in late gestation (Table 3.3; Figure 3.3A). Additionally, MFAS reduced 
hepatic expression of miR-17 (-0.19 fold, P = 0.009; Table 3.4) and miR-122 (-0.29 












CF vs FAF (P) 
rno-miR-17 
 








































1.270 ± 0.145 1.705 ± 0.108 
 
0.045 
Six female foetuses per maternal dietary group were analysed (C: 6, FA: 6). Data was analysed 
with independent samples t-test. Expression values of the miRs of interest are normalised against 
hepatic miR-25 expression and are mean ± SEM. CF, female foetuses of control dams; FAF, 













C vs FA (P) 
rno-miR-17 
 















6 ± 1 10 ± 2 
 
0.063 
Six dams per maternal dietary group were analysed (C: 6, FA: 6). Data was analysed with 
independent samples t-test. C, control dams; FA, folic acid supplemented dams. Expression values 





Figure 3.3 Maternal Folic Acid Supplementation Alters Hepatic Expression of MicroRNAs in 
Female Foetus and Dam in Late Gestation.  
(A) Relative hepatic expression of miR-122 and miR-191 in female foetus of folic acid 
supplemented and control dams. (B) Relative hepatic expression of miR-17 and miR-122 in folic 
acid supplemented and control dams. Six female foetuses and dams per maternal dietary group 
were analysed (C: 6, FA: 6). Data was analysed by independent samples t-test. Expression values 
are normalised to hepatic miR-25 expression and are presented as mean ± SEM. * indicates P < 





3.3.9. EFFECTS OF MATERNAL FOLIC ACID SUPPLEMENTATION ON 
MATERNAL AND FOETAL HEPATIC EXPRESSION OF METABOLIC 
REGULATORY GENES 
Maternal folic acid supplementation increased foetal hepatic expression of 
Ppargc1a (1.20 fold, P < 0.0001) in late gestation, irrespective of sex (Figure 3.4A). 
For the hepatic expression of this gene, a significant interaction was found 
between maternal dietary treatment and foetal sex (P = 0.028; Table 3.5). Hepatic 
expression of Ppargc1a was increased (1.21 fold, P = 0.010) in male foetuses and 
to a greater extent in female foetuses (1.70 fold, P < 0.0001) of folic acid 
supplemented dams as compared to controls (Table 3.6).  
 
Maternal folic acid supplementation increased foetal hepatic expression of Ppara 
(1.22 fold, P = 0.024) in late gestation, irrespective of sex (Figure 3.4B). Hepatic 
expression of Ppara was increased more markedly in female foetuses of folic acid 
supplemented dams (1.84 fold, P = 0.007) than in male foetuses, wherein it was 
unaltered (Table 3.6).  
 
Maternal folic acid supplementation altered foetal hepatic expression of Acaca and 
Scd1 in a sexual dimorphic manner (Table 3.6). Hepatic expression of Acaca was 
reduced in male foetuses of folic acid supplemented dams relative to controls (-
0.32 fold, P = 0.013), while it was unaffected in female foetuses (Figure 3.4C). 
Conversely, MFAS reduced hepatic expression of Scd1 in female foetuses (-0.37 
fold, P = 0.017), while it was unaffected in male foetuses (Figure 3.4D). 
Irrespective of sex, MFAS did not alter foetal hepatic expression of Acaca nor 
Scd1 in late gestation (Table 3.5).  
 
Maternal folic acid supplementation increased foetal hepatic expression of Sc4mol 
(1.48 fold, P = 0.022; Table 3.5) in late gestation overall (Figure 3.4E). Hepatic 
expression of Sc4mol was increased in female foetuses of folic acid supplemented 




foetal hepatic expression of Sc4mol (P = 0.002; Table 3.5), irrespective of 
maternal dietary treatment. An interaction trending towards statistical significance 
(P = 0.050) was detected between maternal dietary treatment and foetal hepatic 
expression of Sc4mol (Figure 3.4E). Foetal hepatic expression of Sqle was 
decreased (-0.38 fold, P = 0.002) in males, while it was unaffected in female 
foetuses (Figure 3.4F). Furthermore, MFAS did not alter foetal hepatic expression 
of Idi1 in late gestation.  
 
Maternal folic acid supplementation increased foetal hepatic expression of Gapdh 
at late gestation in a sex-specific manner, with it being increased in females (P = 
0.022; Table 3.6) but unaffected in males (Figure 3.4G). A significant interaction (P 
= 0.030) was found between maternal dietary treatment and foetal sex for the 
hepatic expression of Gapdh (Table 3.5).  
 
Maternal folic acid supplementation did not affect hepatic expression of Acaca nor 
Scd1 in the dam in late gestation. Maternal hepatic expression of Ppara was 
unaltered between the two maternal dietary groups. Furthermore, MFAS did not 
alter hepatic expression of cholesterogenic genes, Idi1, Sqle nor Sc4mol in the 
dam in late gestation. 
 
Hepatic expression of Pck1 tended to be lower in folic acid supplemented dams 
relative to controls; however, this was not statistically significant (P = 0.081). 
Maternal folic acid supplementation did not alter hepatic expression of Ppargc1a 
nor Gapdh in dams in late gestation; the effects of MFAS on hepatic gene 
expression of dams in late gestation are summarised in Table 6.24.  
 






Table 3.5 Effects of Maternal Folic Acid Supplementation on Foetal Hepatic Gene Expression in Late Gestation. 
Foetal  Significance 
Relative mRNA Expression 
 
CA FAA  CA vs FAA (P) 
Maternal Diet x 
Foetal Sex (P) 
Foetal Sex (P) 
Dnmt1 
 
0.077 ± 0.009 0.052 ± 0.004  0.443 0.191 0.320 
Dnmt3a 
 
0.0093 ± 0.0006 0.0075 ± 0.0006  0.622 0.335 0.619 
Dnmt3b 
 
0.0027 ± 0.0001 0.0019 ± 0.0001  0.190 0.971 0.378 






0.0047 ± 0.0002 0.0033 ± 0.0004  0.193 0.219 0.247 
Scd1 
 
0.042 ± 0.006 0.026 ± 0.003  0.314 0.148 0.269 






0.021 ± 0.004 0.019 ± 0.003  0.148 0.859 0.716 
Sc4mol 
 
0.020 ± 0.002 0.028 ± 0.002  0.022 0.050 0.002 
Sqle 
 
0.025 ± 0.002 0.018 ± 0.001  0.256 0.602 0.577 






0.021 ± 0.002 0.032 ± 0.003  0.024 0.126 0.059 
Ppargc1a 
 
0.0006 ± 0.00001 0.0009 ± 0.00002  0.000 0.028 0.116 
Gapdh 
 
0.14 ± 0.01 0.14 ± 0.01  0.700 0.030 0.361 
Twelve foetuses per maternal dietary group were analysed (C: 12; FA: 12). Normally distributed data was analysed by repeated measures ANOVA, with 
maternal dietary treatment as between subject factor, foetal sex as within subject factor and dam as covariate. Non-normally distributed data was analysed by 
Kruskal-Wallis H test. Expression values of the genes of interest are normalised to hepatic Actb expression and are mean ± SEM. CA, all foetuses of control 
dams; FAA, all foetuses of folic acid supplemented dams.  
 














  CM FAM 
CM vs FAM 
(P) 
CF FAF 
CF vs FAF 
(P) 
Dnmt1   0.069 ± 0.007 0.052 ± 0.007 0.103  0.085 ± 0.012 0.051 ± 0.001 0.039  
Dnmt3a   0.0089 ± 0.0011 0.0068 ± 0.0007 0.133  0.0096 ± 0.0002 0.0081 ± 0.0004 0.054  
Dnmt3b   0.0022 ± 0.00011 0.0017 ± 0.00021 0.095  0.0032 ± 0.00008 0.0021 ± 0.00006 0.000  
                
Acaca   0.0048 ± 0.0001 0.0034 ± 0.0003 0.013  0.0045 ± 0.0003 0.0032 ± 0.0005 0.052  
Scd1   0.034 ± 0.004 0.024 ± 0.004 0.116  0.050 ± 0.007 0.028 ± 0.003 0.017  
                
Idi1   0.016 ± 0.002 0.014 ± 0.001 0.623  0.026 ± 0.005 0.024 ± 0.005 0.240  
Sc4mol   0.020 ± 0.002 0.020 ± 0.002 0.954  0.019 ± 0.003 0.036 ± 0.003 0.003  
Sqle   0.023 ± 0.002 0.015 ± 0.001 0.002  0.028 ± 0.003 0.021 ± 0.001 0.081  
                
Ppara   0.020 ± 0.002 0.023 ± 0.001 0.339  0.021 ± 0.003 0.042 ± 0.005 0.007  
Ppargc1a   0.0006 ± 0.000003 0.0007 ± 0.000003 0.010  0.0006 ± 0.00001 0.0011 ± 0.00003 0.000  
Gapdh   0.159 ± 0.013 0.135 ± 0.009 0.186  0.114 ± 0.011 0.155 ± 0.003 0.022  
Twelve foetuses per maternal dietary group were analysed (C: 12, male = 6, female = 6; FA: 12, male = 6, female = 6). Normally distributed data was 
analysed by repeated measures ANOVA. Non-normally distributed data was analysed by Kruskal-Wallis H test. Expression values of the genes of interest are 
normalised to hepatic Actb expression and are mean ± SEM. CM, male foetuses of control dams; CF, female foetuses of control dams; FAM, male foetuses 
of folic acid supplemented dams; FAF, female foetuses of folic acid supplemented dams. 
 














Figure 3.4 Maternal Folic Acid Supplementation Alters Foetal Hepatic Expression of Metabolic Regulatory Genes in Late Gestation.  
Relative hepatic expression of (A) Ppargc1a; (B) Ppara; (C) Acaca; (D) Scd1; (E) Sc4mol; (F) Sqle; and (G) Gapdh in foetuses of folic acid supplemented and 
control dams. Twelve foetuses per maternal dietary group were analysed (C: 12, male = 6, female = 6; FA: 12, male = 6, female = 6). Normally distributed 
data was analysed by repeated measures ANOVA, with maternal dietary treatment as between subject factor, foetal sex as within subject factor and dam as 
covariate. Non-normally distributed data was analysed by Kruskal-Wallis H test. Expression values are normalised to hepatic Actb expression and are mean ± 





3.3.10. EFFECTS OF MATERNAL FOLIC ACID SUPPLEMENTATION ON 
MATERNAL AND FOETAL HEPATIC EXPRESSION OF DNA 
METHYLTRANSFERASES 
Maternal folic acid supplementation altered foetal hepatic expression of Dnmt1 (-
0.36 fold, P = 0.039; Figure 3.5A) and Dnmt3b (-0.21 fold, P < 0.0001; Figure 3.5B) 
in a sex-specific manner, with these being affected in female foetuses exclusively. 
Hepatic expression of Dnmt3a tended to be lower in female foetuses of folic acid 
supplemented dams relative to controls; however, this was not statistically 
significant (P = 0.054). Irrespective of sex, MFAS did not alter foetal hepatic 
expression of Dnmt1, Dnmt3a nor Dnmt3b in late gestation overall (Figure 3.5). 
Furthermore, MFAS did not alter hepatic expression of Dnmt1, Dnmt3a nor 







Figure 3.5 Maternal Folic Acid Supplementation Alters Foetal Hepatic Expression of DNA 
Methyltransferase 1 and 3b in a Sexually Dimorphic Manner.  
Relative hepatic expression of (A) Dnmt1 and (B) Dnmt3b in foetuses of folic acid supplemented 
and control dams. Twelve foetuses per maternal dietary group were analysed (C: 12, male = 6, 
female = 6; FA: 12, male = 6, female = 6). Normally distributed data was analysed by repeated 
measures ANOVA, with maternal dietary treatment as between subject factor, foetal sex as within 
subject factor and dam as covariate. Non-normally distributed data was analysed by Kruskal-Wallis 
H test. Expression values are normalised to hepatic Actb expression and are mean ± SEM. * 




3.3.11. RELATIONSHIPS BETWEEN HEPATIC EXPRESSION OF 
MICRORNAS AND GENES IN FEMALE FOETUSES 
In the female foetus, hepatic expression of miR-122 was positively correlated with 
that of Dnmt3b (r = 0.693, P = 0.009) and Idi1 (r = 0.597, P = 0.020; Table 6.25). 
Hepatic expression of miR-191 was positively correlated with hepatic expression 
of Idi1 (r = 0.630, P = 0.014) and Ppara (r = 0.671, P = 0.017; Table 6.25). In 
contrast, hepatic expression of miR-191 was inversely correlated with that of 
Ppargc1a (r = -0.724, P = 0.021; Table 6.25).  
 
3.3.12. RELATIONSHIPS BETWEEN HEPATIC EXPRESSION OF 
MICRORNAS AND GENES IN DAMS 
In the dam, hepatic expression of miR-33 was inversely correlated with that of Idi1 
(r = -0.728, P = 0.004), Dnmt3a (r = -0.593, P = 0.021) and Sc4mol (r = -0.499, P = 
0.049; Table 6.26). Moreover, maternal hepatic expression of miR-122 was 
inversely correlated with that of Dnmt3b (r = -0.542, P = 0.034) and Gapdh (r = -






In the present study, we have shown for the first time that MFAS, from 
preconception to term, alters hepatic expression of key metabolic regulatory genes, 
DNMTs and non-coding miRs in the foetus in late gestation, with these effects 
being largely sexually dimorphic and predominantly affecting females. The 
resultant changes observed in the foetus following MFAS may contribute towards 
differences in epigenetic and metabolic regulation after birth, including perturbed 
hepatic transcriptomic and metabolomic profiles observed in adulthood. In effect, 
these changes in the foetal hepatic transcriptome may play a key role in eliciting 
the developmental programming effects of MFAS and may in part determine 
metabolic phenotype of offspring long term. We have also demonstrated that 
MFAS, from preconception to term, has minimal effects on maternal hepatic 
expression of metabolic regulatory genes and non-coding miRs, which suggest 
that the effects of MFAS are foetal-specific and are most prominent during early 
development.  
 
Maternal folic acid supplementation markedly increases the hepatic expression of 
Ppargc1a, a key regulator of gluconeogenesis, in foetuses. This indicates MFAS 
may increase the capacity for hepatic gluconeogenesis in the foetus in late 
gestation. Normally, hepatic gluconeogenesis remains relatively inactive in the 
foetus until near term. However, in response to changes in intrauterine 
environment, including prolonged maternal hypoglycaemia and maternal 
hyperglycaemia, gluconeogenesis in the foetus may become induced precociously, 
leading to consequences for metabolic homeostasis after birth.111, 112, 126 Our 
observations indicate that the capacity for gluconeogenesis in the foetus may also 
be affected in part by maternal intake of folate and its abundance during gestation. 
In line with this, we have also observed that MFAS decreases hepatic expression 
of Gapdh in the female foetus in late gestation specifically. Being a key regulatory 
enzyme, the catalytic activity of GAPDH enables glyceraldehyde-3-phosphate 
(GAP) to be converted to 1,3-biphospho-glycerate (1,3-BPG), in turn, promoting 
glycolysis.354 Conversely, inhibition of its enzymatic activity reverses glycolysis and 




capacity for the female foetus to convert GAP to 1,3-BPG by shifting the flow of 
GAP preferentially towards hepatic gluconeogenesis.  
 
In the present study, MFAS increases foetal hepatic expression of Ppara in late 
gestation, particularly in females. As a pivotal transcription factor for enzymes 
involved in fatty acid oxidation and uptake, PPARA promotes fatty acid catabolism 
and the maintenance of hepatic fatty acid balance.267 Increased hepatic 
expression of Ppara in response to MFAS may enhance the capacity for fatty acid 
oxidation and uptake in the liver of foetuses in late gestation. Previously, maternal 
folic acid deficiency has been shown to have negligible effects on hepatic Ppara 
expression in the foetus in late gestation.275 Taken together, these observations 
indicate that MFAS during gestation augments foetal hepatic expression of Ppara 
and, in turn, may affect hepatic fatty acid balance. Interestingly, MFAS decreased 
Ppara expression in the liver of postnatal offspring (See Chapter 2).67, 249 Maternal 
folic acid supplementation is observed herein to increase Ppara expression in the 
liver of foetuses in late gestation; thus, it may induce opposite changes in hepatic 
Ppara expression of offspring between prenatal and postnatal stages of 
development. It remains to be determined whether MFAS may alter epigenetic 
state of Ppara in the liver of the foetus, as reported previously for postnatal 
offspring.249 Altered epigenetic state of Ppara may provide insights into a potential 
mechanism by which MFAS augments hepatic Ppara expression in prenatal and 
postnatal development.  
 
By late gestation, the foetus is capable of synthesising cholesterol to sustain its 
own developmental needs, with placental transfer to be accountable for up to 20% 
of total cholesterol in the foetus only.49, 128, 135 In the present study, we have 
observed that MFAS alters hepatic expression of cholesterogenic genes in the 
foetus in late gestation, with expression of Sc4mol being markedly increased. The 
rate of cholesterol biosynthesis in the foetal liver is in part influenced by maternal 
nutrition, particularly the content and type of fat in the maternal diet.136, 137 
However, other studies have reported that foetal cholesterol biosynthesis occurs 




which influence foetal cholesterol biosynthesis being elusive, increased hepatic 
expression of Sc4mol in the foetus may indicate an enhanced capacity to convert 
lanosterol to cholesterol, which may be used subsequently to support liver growth 
and development as well as for export to other peripheral organs.6, 8, 151  
 
Furthermore, MFAS is observed in the present study to decrease hepatic 
expression of Sqle in male foetuses specifically, while this remains unaltered in 
female foetuses. Down-regulation of Sqle expression suggests that MFAS may 
suppress the capacity for epoxidation of squalene to 2,3-oxidosqualene in male 
foetuses, which may lead to the retention of squalene.68 As an antioxidant, 
squalene has been shown to be protective against lipid peroxidation damage 
induced by alcohol in the retinas of chick embryos57; however, squalene 
abundance in the liver of male foetuses in response to MFAS needs to be 
quantified in order to determine whether it is truly increased and beneficial in 
buffering against lipid peroxidation damage.  
 
In terms of sexually dimorphic effects, MFAS markedly down-regulates the hepatic 
expression of Acaca in male foetuses, while this remains unaltered in female 
foetuses. On the contrary, MFAS attenuates hepatic expression of Scd1 in female 
foetuses specifically. Earlier, we have observed that MFAS accentuates hepatic 
expression of Acaca in adult male offspring only, while hepatic expression of Scd1 
is increased in adult female offspring only (See Chapter 2). These observations 
provide further evidence for MFAS to exert disparate effects on genes involved in 
lipid biosynthesis during prenatal and postnatal stages of development as well as 
in a sex-specific manner, with the capacity for de novo lipogenesis to be 
diminished during late foetal development; however, this subverts to being 
accentuated during adulthood. The roles of sex steroids and epigenetic changes, if 
any, in facilitating this reversal of metabolic phenotype between prenatal and 





DNA methylation is an epigenetic process by which cytosine residue in the CpG 
dinucleotide site becomes methylated. This epigenetic process occurs most 
actively during embryogenesis as DNMTs establish new DNA methylation patterns 
in the developing foetus.336 With DNA methylation being closely involved in the 
developmental regulation of gene expression, global methylation pattern 
established in each foetal organ is found to be highly specific to its own 
developmental trajectory and is maintained after birth.103, 400 Recent studies have 
shown that changes to the maternal intake of folic acid during gestation can 
greatly modify global methylation pattern in various tissues of adult offspring, 
including liver, small intestines and mammary glands.264, 274, 366 In particular, MFAS 
during gestation has been found to reduce gene-specific DNA methylation and 
DNMT activity in the liver of offspring after birth366; however, it is unknown whether 
MFAS may alter the capacity to establish and maintain DNA methylation in the 
developing foetus. In the present study, we observed that MFAS reduces hepatic 
expression of DNMTs, Dnmt1 and 3b, in the female foetus in late gestation, 
indicative of an attenuated capacity for the female foetus to establish and maintain 
DNA methylation during late stages of foetal development and also potentially 
after birth. Our observation of a reduction in hepatic expression of DNMTs is 
consistent with previous findings in postnatal life. Taken together, these 
observations may reveal a possible mechanism by which MFAS attenuates 
hepatic activity of DNMTs in the offspring after birth.  
 
Dnmt1 is primarily a maintenance methyltransferase, which favours hemi-
methylated CpG sites and replicates the methylation patterns of the parental DNA 
strand onto the newly synthesised daughter strand.185 Inheritance of DNA 
methylation pattern is a key mechanism by which genomic stability and gene 
expression patterns are preserved.325 Reduced expression of Dnmt1 has been 
previously observed to increase the incidence of microsatellite instability,209, 258 bi-
allelic expression of imprinted genes239 and chromosomal translocations.194 As 
observed in the present study, a decrease in hepatic Dnmt1 expression suggests 
that MFAS may reduce the capacity for the female foetus to replicate tissue-
specific methylation patterns that preserve genomic stability. In support of this 




to be strongly associated with reduced methylation of long interspersed nuclear 
element 1 (LINE-1), a transposable element, in the cord blood of human infants.140 
A high level of methylation in LINE-1 has been documented to inhibit transposition 
and is known to be protective against the adverse integration of transposon 
elements during early development.235 Taken together, MFAS may reduce the 
capacity for the female foetus to maintain methylation patterns with high fidelity 
and, in turn, may give rise to genomic instability and the loss of cellular identity. In 
agreement, MFAS has been reported to increase the risk of mammary gland 
tumours in female offspring, in which decreased global DNA methylation and 
increased appearance of mammary gland tumours have been observed.264 The 
consequences of this attenuated capacity to maintain epigenetic patterns, as 
conferred by decreased expression of Dnmt1, on the health of the female offspring 
after birth warrant further investigation. 
 
Dnmt3a and Dnmt3b are critical regulators of genomic imprinting, with these being 
responsible for determining the monoallelic expression of an imprinted gene 
through the establishment of DNA methylation patterns.62, 190 Despite both 
DNMT3A and 3B sharing many common DNA targets in de novo methylation in 
the zygote, these two methyltransferases also have notable differences in 
preference for imprinted genes and satellite repeats.62 Particularly, Dnmt3a is 
capable of methylating the 5’ region of the imprinted gene Xist, while Dnmt3b is 
not, indicative of these two DNA methyltransferases to have highly distinctive DNA 
targets in de novo methylation.62 For satellite repeats, Dnmt3a preferentially 
methylates major satellite repeats, while Dnmt3b displays a preference for minor 
satellite repeats.62 In the present study, we observed that MFAS decreases 
hepatic Dnmt3b expression in female foetuses in late gestation, while this remains 
unaltered in male foetuses. These observations indicate that MFAS may affect the 
capacity for epigenetic regulation in the foetus in late gestation in a sexually 
dimorphic manner. These differences in hepatic DNMT expression between male 
and female foetuses may in part account for sex-specific changes in epigenetic 
inheritance observed after birth. Previously, MFAS has been shown to reduce 
global DNA methylation in the mammary gland of pubertal female offspring.264 




region of Pepck in the liver of adult female offspring but not in adult male offspring 
of folic acid supplemented mothers.158 Moreover, MFAS has also been reported to 
reduce the methylation of H19, the differentially methylated region of the imprinted 
gene IGF2, in the cord blood of infants, with the effects being most prominent in 
male infants.166 Besides IGF2, reduced methylation of the imprinted gene PEG3 in 
the cord blood of newborn infants has also been found to be strongly associated 
with maternal usage of folic acid supplements during late pregnancy.140 
Collectively, these observations along with ours reveal that foetal hepatic 
expression of DNMTs are sexually dimorphic, as are some of the putatively related 
consequences. Therefore, further studies are required to characterise the specific 
genes and transposable elements, if any, at which CpG methylation is disrupted 
by MFAS during foetal development, as changes in epigenetic regulation in the 
foetus may in part contribute to and explain for the aberrant methylation patterns 
observed in adulthood.  
 
In addition, MFAS is observed in the present study to alter global miR expression 
in the liver of the foetus in a sexually dimorphic manner, with it being markedly 
perturbed in females but unaffected in males. The differentially expressed hepatic 
miRs in the female foetuses of folic acid supplemented dams modulate molecular 
networks with functions in endocrine system development and function. In 
agreement, hepatic expression of miR-122 and miR-191 are confirmed by qRT-
PCR as being up-regulated in female foetuses of folic acid supplemented dams 
relative to controls. As one of the predominant miRs in the liver, miR-122 has been 
shown to play a major regulatory role in lipid metabolism and homeostasis.98, 220 In 
miR-122 KO mice, an increase in hepatic triglyceride accumulation occurs as a 
result of elevated de novo lipogenic activities and diminished hepatic secretion of 
triacylglycerides.168 Genes involved in de novo lipogenesis and lipid storage have 
also been found to be more highly expressed in the liver of miR-122 KO mice, 
while expression of Sc4mol is reduced.168 As observed in the present study, an 
increase in hepatic miR-122 expression is consistent with the reduced hepatic 
expression of the lipogenic gene, Scd1, and increased hepatic expression of the 
cholesterogenic gene, Sc4mol, in female foetuses of folic acid supplemented 




de novo lipogenesis in female foetuses through changes to their hepatic gene and 
miR expression. Hepatic triglyceride accumulation may also be reduced in female 
foetuses of folic acid supplemented mothers as a result of up-regulated miR-122 
and Ppara expression. In addition, overexpression of miR-122 in foetal liver 
derived progenitor cells has been shown to enhance hepatic differentiation.88 
Hence, it is plausible for MFAS to promote hepatic differentiation in female 
foetuses through the up-regulation of miR-122; however, this aspect remains to be 
further examined.  
 
Besides miR-122, MFAS is also observed to increase hepatic expression of miR-
191 in the female foetus in late gestation. A recent study has elucidated the role of 
miR-191 in estrogen signalling, with its transcription found to be highly up-
regulated in response to increased levels of estrogen.296 In concordance with this 
effect, miR-191 expression has been experimentally validated to be under the 
direct regulation of the estrogen receptor.83 In terms of functionality, 
overexpression of miR-191 has been observed to promote cellular proliferation in 
a wide range of cancers, including pancreas, liver, breast and the ovaries96, 177, 201, 
361; its oncogenic effects may be attained through the down-regulation of a number 
of mRNA targets, which have been validated to be CDK6, BDNF and SATB1 in the 
human breast tissue and SOX4, IL1A and TMC7 in the human liver tissue.96, 296 
Our observation of a significant up-regulation in hepatic miR-191 expression in the 
present study suggests that MFAS may potentiate estrogen mediated cellular 
proliferation in the liver of female foetus in late gestation through a miR-191 
elicited mechanism. In addition to its effects on cell growth, estrogen also affects 
hepatic lipid biosynthesis, as its administration markedly reduces hepatic 
triglyceride levels and greatly decreases the hepatic expression of lipogenic genes, 
including Scd1 and Fasn.118 On the other hand, estrogen deficiency, as induced by 
estrogen receptor knock out in mice, significantly increases hepatic lipogenic gene 
expression.41 Our observations of a decrease in Scd1 expression but an increase 
in miR-191 expression in the liver of the female foetus are concordant with the 
metabolic effects imparted by estrogen. The causal pathway for these 




To date, several studies have explored the role for miRs in maternal metabolic 
adaptations during gestation, particularly adipogenesis5 and gestational 
hypertension.30 A recent study has shown that low maternal folate status in the 
third trimester is associated with impaired foetal growth, perturbed trophoblast 
proliferation and apoptosis, placental nutrient transport, endocrine function and 
increased maternal plasma expression of miR-222-3p, miR-141-3p and miR-34b-
5p.15 Thereby, these observations suggest maternal miR expression to be 
subjected to the influence of maternal folate intake in late gestation. In the present 
study, we have shown that MFAS decreases hepatic expression of miR-17 and 
miR-122 in the pregnant dam in late gestation. A recent study has identified miR-
17 as one of the up-regulated miRs in the plasma of mothers with Gestational 
Diabetes Mellitus during second trimester.455 Target prediction and pathway 
analysis suggest that miR-17 targets SOS-1 and AKT3, which are known to 
regulate insulin-signalling and the MAPK signalling pathway respectively.455 As for 
miR-122, inhibition of this miR has been demonstrated previously to promote 
triglyceride accumulation.168 These observations collectively suggest that 
availability of maternal nutrition, particularly folic acid, affects maternal hepatic 
expression of miRs, which may impact upon key metabolic and endocrine 
adaptations that occur during late gestation.  
 
Furthermore, MFAS is observed to have negligible effects on cholesterogenic and 
lipogenic gene expression in the liver of pregnant dams in late gestation. In line 
with these observations, serum triglycerides, high-density lipoprotein-cholesterol 
and low-density lipoprotein-cholesterol were not altered by MFAS in pregnant 
ewes during late gestation.269 In addition, MFAS does not affect hepatic Ppara 
expression in the pregnant dams in late gestation in the present study. These 
observations suggest that MFAS has minimal effects on expression of key 
metabolic regulatory genes in the liver of pregnant dams during late gestation.  
 
In conclusion, our observations suggest that MFAS, from preconception to term, 
induces specific changes to foetal hepatic expression of DNMTs, miRs and 




highlight the effects of MFAS on key aspects of epigenetic regulation in the liver of 
offspring at prenatal stages and, in turn, may perturb their epigenetic inheritance 
and metabolic functionality after birth. Further studies are required to examine the 
repercussions of an altered capacity for epigenetic maintenance and inheritance in 









Maternal Folic Acid Supplementation Induces 
Differential Changes in the Skeletal Muscle 





Folic acid supplementation is an antenatal dietary intervention recommended and 
commonly adopted amongst women of reproductive age, as it provides 
prophylaxis against the occurrence of NTDs.225 Being a synthetic analogue of 
folate, folic acid engages in the biosynthesis of nucleotides as well as DNA and 
histone methylation, which are all essential processes for growth and 
development.22 Supplementation with folic acid ensures that these biochemical 
processes essential to foetal growth are not constrained by folate deficiency; 
however, due to differences in receptor affinity for folic acid and naturally bioactive 
folate, supplementation of folic acid may introduce undesirable competition that 
disrupts critical steps in one-carbon metabolism and folate transport with 
unforeseen consequences.58 
 
In a recent systematic review, periconceptional folic acid supplementation has 
been reported to be effective in reducing the risk of the neonate of being born 
SGA.156 From previous epidemiological and experimental studies in humans, it is 
known that being born SGA is strongly associated with an increased susceptibility 
to metabolic diseases in later life, including Type 2 Diabetes Mellitus,142 obesity,306 
hypertension19 and cardiovascular diseases.20 In the gestational period, increased 
maternal plasma folate concentrations at 30 weeks of gestation has been found to 
be associated with increased levels of insulin resistance in children aged 9.5 and 
13.5 years.217 In light of these emerging studies, MFAS in the periconceptional and 
gestational period displays the potential to alter susceptibility of offspring to 
metabolic diseases after birth; however, the underlying molecular mechanisms 
have received limited study to date. 
 
Skeletal muscle is a key tissue that is critical to the systemic regulation of 
metabolic homeostasis. Disruptions to key metabolic processes in the skeletal 
muscle including glucose uptake, glycogen synthesis and peroxisomal beta-
oxidation are known to underlie the aetiology of insulin resistance, which is a 
notable characteristic of Type 2 Diabetes Mellitus and metabolic syndrome.312 




metabolic processes is mediated in part via epigenetics modifications,89 which are 
heritable changes to gene expression that are not encoded within the DNA 
nucleotide sequence itself.248 A comparative study identified eight genes, including 
PPARGC1A, KCNQ1, SLC30A8, DUSP9, CDKN2A, KLF11 and HNF4A, that are 
differentially methylated in the skeletal muscle of Type 2 diabetic and non-diabetic 
monozygotic twins.340 Lipid and carbohydrate metabolic pathways in the skeletal 
muscle, including PPARα activation, pyruvate metabolism and propanoate 
metabolism, are reported as affected in these Type 2 diabetic patients.340  
 
Increasingly, emerging evidence from human and animal studies further suggest 
that epigenetic modifications may serve as a mechanism by which maternal 
nutrition before and during gestation affects metabolic regulation and chronic 
disease susceptibility of offspring long term.248 In rodents, maternal protein 
restriction increases CpG methylation in the promoter of PGC-1α and decreases 
its expression in the skeletal muscle of adult female offspring, suggesting maternal 
nutrition during gestation can lead to changes in epigenetic state and gene 
expression of adult offspring.448 Another study reported that maternal high fat diet, 
from periconception to term, induces hypermethylation in the promoter of PGC-1α 
in the skeletal muscle of offspring at birth and in adulthood.223. These studies 
reveal that maternal nutrition during gestation may elicit epigenetic changes in the 
offspring that influence their gene expression and functionality of metabolic 
pathways in later life. 
 
At present, it is unknown whether MFAS may affect molecular mechanisms and 
pathways in the skeletal muscle of adult offspring that impact upon their metabolic 
homeostasis and susceptibility to chronic diseases. To explore this hypothesis, we 
examined the effects of MFAS, from preconception to term, on the skeletal muscle 





4.2.1. ANIMALS AND TISSUE COLLECTION 
This study was designed in accordance with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes and was approved by the 
University of Adelaide Animal Ethics Committee. Virgin female Wistar rats (aged 
98 ± 5 days) and Lewis/SNN male rats (aged 84 ± 5 days) were purchased from 
Animal Resources Centre (Perth, Australia). Virgin female Wistar rats were 
randomly allocated to one of two groups: control (C) or maternal folic acid 
supplementation (MFAS), with each group consisted of nine virgin female Wistar 
rats. Control group was fed a standard rodent diet (AIN93G, Speciality Feeds, 
Australia) comprised of 2 mg folic acid/kg feed from two weeks prior to conception 
until term; this dosage of folic acid is generally accepted as meeting the basal 
dietary requirements for rats and closely assembles the recommended dietary 
allowance of 0.4 mg dietary folate equivalent in humans.12,410 Maternal folic acid 
supplementation group was fed a standard rodent diet (SF07-018, Speciality 
Feeds, Australia) comprised of 6 mg folic acid/kg feed from two weeks prior to 
conception until term. This dosage of folic acid is three fold greater than basal 
dietary requirements for rats and mimics the level of folate to which women are 
exposed through average dietary intake, food fortification and supplementation 
during the periconceptional and gestational period.382 
 
Standardised rodent diets containing different levels of folic acid are a common 
method of providing supplementary dietary folate to rodents and this method has 
been extensively used in previous experimental studies.43, 67, 263 Folate 
concentrations achieved by this method in the plasma, liver, brain, kidney and 
colon of rodent models have been previously described in detail.263 
 
Virgin female Wistar rats were mated with Lewis/SNN male rats. Upon 
confirmation of pregnancy, pregnant dams were housed singly. At birth, each litter 
was reduced to eights pups. Throughout lactation, dams were given free access to 
a standard rodent diet and water and were weighed on a weekly basis. At 
postnatal day 21, all offspring were weaned onto a standard rodent diet. At 




followed by cardiac puncture, with soleus muscle from their left hind leg collected, 
frozen in liquid nitrogen and stored at -80ºC. The effects of MFAS on litter size, 
birthweight and organ and relative weight of postnatal offspring have been 
reported separately (Saidatul Naziah Mohammad, oral communication).  
 
4.2.2. RNA EXTRACTION AND QUALITY ANALYSIS 
Total RNA from the skeletal muscle was extracted by TRIzol®  reagent (Invitrogen, 
USA) on Precellys®  24 Homogeniser (Bertin Technologies, France). Total RNA 
was isolated using standard RNA extraction procedures.310 To eliminate potential 
DNA from RNA samples, Ambion DNA-free Kit (Life Technologies, USA) was 
performed in accordance to manufacturer’s instructions. Total RNA quality was 
assessed on Agilent 2100 Bioanalyzer (Agilent Technologies, USA) using RNA 
6000 Nano Chips (Agilent Technologies, USA), which determined the UV 260/280 
absorbance ratio and the RNA size distribution of each RNA sample. All samples 
had a RIN score of 7.5 or above. 
 
4.2.3. AFFYMETRIX GENECHIP®  RAT GENE 1.0 ST ARRAY PREPARATION 
Affymetrix GeneChip®  Rat Gene 1.0 ST Array (Affymetrix, USA) was used to 
examine skeletal muscle mRNA transcriptome of adult offspring of the two 
maternal dietary groups (C: 16, male = 8, female = 8; MFAS: 14, male = 8, female 
= 6). Probe sequence design and gene annotations were based on content 
derived from sources including RefSeq (National Center for Biotechnology 
Information, http://www.ncbi.nlm.nih.gov/refseq/), GenBank (National Institute of 
Health, http://www.ncbi.nlm.nih.gov/genbank/) and Ensembl (European 
Bioinformatics Institute, http://www.ensembl.org/). 
 
Briefly, using 300 ng of total RNA from individual skeletal muscle samples, cDNA 
synthesis and the purification and synthesis of biotin-labelled cRNA were 
performed in accordance to manufacturer’s instructions. Using rotation at 60 rpm 




GeneChip®  Rat Gene 1.0 ST Array. The slides were washed and stained with 
Fluidics Station 400 (Affymetrix, USA). Following staining, slides were scanned 
with Gene Array Scanner (Affymetrix, USA). Using the manufacturer’s standard 
protocols, cRNA synthesis and labelling, hybridisation to the Rat Gene 1.0 ST 
array, post-hybridisation washes, staining, array image generation, segmentation 
and quality control analysis were performed by the Adelaide Microarray Centre 
(Adelaide, Australia).  
 
4.2.4. AFFYMETRIX MICROARRAY DATA NORMALISATION AND ANALYSIS 
Affymetrix microarray data analyses were performed with Biometric Research 
Branch (BRB) ArrayTools version 4.2.0 (National Cancer Institute, 
http://linus.nci.nih.gov/BRB-ArrayTools.html) developed by Dr. Richard Simon and 
the BRB-ArrayTools development team. BRB-ArrayTools is an Excel add-in that 
processes and analyses microarray data through the utilisation of the R version 
2.12 environment (The R Foundation for Statistical Computing, http://www.R-
project.org). Of the 27,342 transcripts represented on the array, those with 
variance in the 75th percentile were excluded and those with more than 50% of 
expression values displaying a fold change of 1.2 or above were further analysed. 
Robust Multichip Average (RMA) normalisation was performed prior to class 
comparison analysis, which uses an independent samples t-test with a random 
variance model to detect for significant variance in gene expression between two 
treatment groups. To identify the list of genes with a significance threshold of P < 
0.05 for univariate tests, a total of 10,000 permutations were completed. 
Differential expression was considered as significant at P < 0.05. For unsupervised 
average linkage hierarchical cluster analysis, Pearson’s centred correlation was 
utilised as a distance metric to stratify samples in accordance to their expression 
profiles across the set of differentially expressed genes.  
 
4.2.5. INDEPENDENT QUANTIFICATION OF MRNA EXPRESSION 
To synthesise cDNA, reverse transcription was performed with 2 μg of total RNA 




50 μL reverse transcription reaction contained 2 μg of total RNA in 16.75 μL of 
nuclease-free water, 1.25 μL of MultiScribe™ Reverse Transcriptase (50 U/μL), 5 
μL of 10X Reverse Transcription buffer, 11 μL of 25 mM MgCl, 10 μL of dNTP 
(100 mM), 2.5 μL of random hexamer (50 μM), 2.5 μL of oligo (d)T (50 μM) and 1 
μL of RNase Inhibitor (20 U/μL). Reaction was carried out on the GeneAmp®  PCR 
system 9700 (Life Technologies, USA) at 25°C for 10 minutes, followed by 48°C 
for 30 minutes and 95°C for 5 minutes. All cDNA products were stored at -20°C 
until use. 
 
Preamplification was performed using TaqMan®  PreAmp Master Mix (Life 
Technologies, USA) following manufacturer’s instructions. Automated TaqMan®  
Real Time PCR set up was performed with QIAgility™ (Qiagen, The Netherlands). 
Each PCR amplification reaction was consisted of 10 μL of 2X TaqMan®  Universal 
PCR Master Mix (Life Technologies, USA), 1 μL of TaqMan®  Gene Expression 
Assay (Table 6.27; Life Technologies, USA), 7 μL of nuclease-free water and 2 μL 
of cDNA. TaqMan®  Real Time PCR was performed on Applied Biosystems 
7900HT Fast Real-Time PCR System (Life Technologies, USA) at 50°C for 2 
minutes, 95°C for 10 minutes and 45 cycles at 95°C for 15 seconds and 60°C for 1 
minute. Each sample was amplified in duplicate.  
 
4.2.6. DATA PROCESSING AND STATISTICAL ANALYSIS FOR MRNA 
EXPRESSION 
Potential reference genes were evaluated with Normfinder,226 which provides a 
stability ranking based on intra- and inter-group variation. Normalisation of qRT-
PCR data was performed with the most stable reference gene, peptidylprolyl 
isomerase A (Ppia), as reflected by its minimal intra- and inter-group variations on 
Normfinder. In accordance with Applied Biosystems Relative Quantification 
Methodology (Applied Biosystems, United Kingdom), the 2-∆∆Ct method was used 
to depict gene expression levels as means and fold changes. Independent 
samples t-test was performed using SPSS version 20 (IBM, USA) to identify any 




the two maternal dietary groups. Analyses were performed in compliance with the 
guidelines provided by Livak and Schmittgen254. 
 
4.2.7. BIOINFORMATICS ANALYSIS 
Information on the gene symbol, gene name and gene ontology of the differentially 
expressed genes was obtained from NCBI Gene (National Center for 
Biotechnology Information, http://www.ncbi.nlm.nih.gov/gene). The presence of 
CpG islands, 20 kilobase upstream or downstream, from the coding region of a 
differentially expressed gene was identified using an enabled CpG island track on 
Ensembl (European Bioinformatics Institute, http://www.ensembl.org/), which 
allowed for close inspection of cis-acting elements within a specified chromosomal 
region. Imprinting status of the differentially expressed genes was obtained from 
Geneimprint (Duke University, http://www.geneimprint.com/). 
 
4.2.8. INGENUITY PATHWAY ANALYSIS 
To interpret Affymetrix microarray data in the context of biological functions, 
diseases, canonical pathways, upstream regulators and molecular networks, ‘Core 
Analysis’ was performed using Ingenuity Pathway Analysis (IPA; Ingenuity 
Systems, www.ingenuity.com), with all 'Identifier Types' selected. Based on the 
degree of overlap between the uploaded dataset and the gene-set within the IPA 
database, an overlap P-value was generated, with adjustments for Benjamini-
Hochberg (B-H) multiple testing correction. For molecular networks, an IPA score 
≥ 3 was considered as significant. For biological functions and diseases, P < 0.05 
was accepted. For canonical pathways, –log (B-H) P ≥ 1.3 was considered as 
significant. Upstream regulators for the differentially expressed genes were also 
identified with an activation z-score, which determined the directional change of 
the upstream regulator by comparing the uploaded dataset against the mediator 
dataset within the IPA database. An upstream regulator with an activation z-score 
≥ 2 was interpreted as activated, while any with an activation z-score ≤ -2 was 





4.3.1. EFFECTS OF MATERNAL FOLIC ACID SUPPLEMENTATION ON 
GLOBAL TRANSCRIPTOMIC CHANGES IN THE SKELETAL MUSCLE 
OF ADULT OFFSPRING  
Maternal folic acid supplementation altered expression of six genes (P < 0.05) in 
the skeletal muscle of adult offspring, irrespective of sex, with two up-regulated 
(1.19 to 1.44 fold; Table 4.1) and four down-regulated (-0.19 to -0.53 fold; Table 
4.1). Hierarchical clustering analysis did not identify any significant gene clusters (r 
< 0.7) among the differentially expressed genes (Figure 4.1).  
 
In adult male offspring, MFAS altered skeletal muscle expression of nine genes (P 
< 0.05). Maternal folic acid supplementation up-regulated the expression of five 
genes (1.21 to 1.52 fold; Table 4.2) and down-regulated the expression of four 
genes (-0.26 to -0.51 fold; Table 4.2) in the skeletal muscle of adult male offspring. 
Hierarchical clustering analysis identified one significant gene cluster, in which 
skeletal muscle expression of Actc1 and Tob2 were highly correlated (r > 0.7; 
Figure 4.2).  
 
In the skeletal muscle of adult female offspring, MFAS altered expression of three 
genes (P < 0.05), with two up-regulated (1.24 to 1.35 fold; Table 4.3) and one, 
mitochondrial transcription termination factor (Mterf), down-regulated (-2.16 fold; 
Table 4.3). Hierarchical clustering analysis did not identify any significantly 







Figure 4.1 Hierarchical Clustering Analysis and Heat Map Comparison of Global Gene 
Expression in the Skeletal Muscle of Adult Offspring of Folic Acid Supplemented and 
Control Dams. 
Top Panel: Hierarchical Clustering Analysis of Global Gene Expression in the Skeletal Muscle of 
Adult Offspring of Folic Acid Supplemented and Control Dams. Dendrogram depicts unsupervised 
hierarchical clustering analysis performed on the normalised log intensities of 30 offspring (C: 16, 
male = 8, female = 8; MFAS: 14, male = 8, female = 6) using Pearson’s correlation with average 
linkage. Bottom Panel: Transcriptional Profiles of the Skeletal Muscle of Adult Offspring of Folic 
Acid Supplemented and Control Dams. Expression of the six differentially expressed genes (P < 



















Up-regulated genes of all offspring 
10848315 Actc1 actin, alpha, cardiac muscle 1 1.44 0.0216 3q35 No 
10749874 Gbe1 glucan (1,4-alpha-), branching enzyme 1 1.19 0.0439 11p11 No 
       
Down-regulated genes of all offspring 
10860623 Mterf 
mitochondrial transcription termination 
factor 
-0.53 0.0295 4q13 No 
10824794 RGD1563667 similar to TDPOZ3 -0.34 0.0472 2q34 No 
10812865 Sfrs12ip1 SFRS12-interacting protein 1 -0.30 0.0361 2q13 No 
10759999 Alox5ap 
arachidonate 5-lipoxygenase activating 
protein 
-0.19 0.0497 12p11 No 
Fold change in median expression across all the arrays between adult offspring of folic acid supplemented and control dams. P-values were calculated by 
class comparison analysis, which used an independent samples t-test, computed with a random univariate permutation of 10,000. Distal CpG island present 







Figure 4.2 Hierarchical Clustering Analysis and Heat Map Comparison of Global Gene 
Expression in the Skeletal Muscle of Adult Male Offspring of Folic Acid Supplemented and 
Control Dams. Top Panel: Hierarchical Clustering Analysis of Global Gene Expression in the 
Skeletal Muscle of Adult Male Offspring of Folic Acid Supplemented and Control Dams. 
Dendrogram depicts unsupervised hierarchical clustering analysis performed on the normalised log 
intensities of expression of 16 offspring (C: 8, MFAS: 8) using Pearson’s correlation with average 
linkage. Bottom Panel: Transcriptional Profiles of the Skeletal Muscle of Adult Male Offspring of 
Folic Acid Supplemented and Control Dams. Expression of the nine differentially expressed genes 




















Up-regulated genes of male offspring 
10848315 Actc1 actin, alpha, cardiac muscle 1 1.52 0.0395 3q35 No 
10905645 Tob2 transducer of ERBB2, 2 1.27 0.0397 7q34 Yes 
10889148 Ubxn2a UBX domain protein 2A 1.24 0.0037 6q14 Yes 
10742927 Olr1418 olfactory receptor 1418 1.23 0.0286 10q22 No 
10929656 Kcnj13 
potassium inwardly-rectifying channel, 
subfamily J, member 13 
1.21 0.0185 9q35 No 
       
Down-regulated genes of male offspring 
10783413 LOC691103 rCG38400-like -0.51 0.0325 15p14 No 
10812865 Sfrs12ip1 SFRS12-interacting protein 1 -0.50 0.0315 2q13 No 
10813152 Emb embigin homolog (mouse) -0.40 0.0368 2q15 Yes 
10759999 Alox5ap 
arachidonate 5-lipoxygenase activating 
protein 
-0.26 0.0492 12p11 No 
Fold change in median expression across all the arrays between adult male offspring of folic acid supplemented and control dams. P-values were calculated 
by class comparison analysis, which used an independent samples t-test, computed with a random univariate permutation of 10,000. Distal CpG island 







Figure 4.3 Hierarchical Clustering Analysis and Heat Map Comparison of Global Gene 
Expression in the Skeletal Muscle of Adult Female Offspring of Folic Acid Supplemented 
and Control Dams. Top Panel: Hierarchical Clustering Analysis of Global Gene Expression in the 
Skeletal Muscle of Adult Female Offspring of Folic Acid Supplemented and Control Dams. 
Dendrogram depicts unsupervised hierarchical clustering analysis performed on the normalised log 
intensities of expression of 14 offspring (C: 8, MFAS: 6) using Pearson’s correlation with average 
linkage. Bottom Panel: Transcriptional Profiles of the Skeletal Muscle of Adult Female Offspring of 
Folic Acid Supplemented and Control Dams. Expression of the three differentially expressed genes 


















Up-regulated genes of female offspring 
10817274 Ndufs5 
NADH dehydrogenase (ubiquinone) Fe-S 
protein 5 
1.35 0.0310 5q36 No 
10858370 Usp18 ubiquitin specific peptidase 18 1.24 0.0330 4q42 No 
       
Down-regulated genes of female offspring 
10860623 Mterf mitochondrial transcription termination factor -2.16 0.0233 4q13 No 
Fold change in median expression across all the arrays between adult female offspring of folic acid supplemented and control dams. P-values were 
calculated by class comparison analysis, which used an independent samples t-test, computed with a random univariate permutation of 10,000. Distal CpG 





4.3.2. BIOINFORMATICS ANALYSIS 
None of the differentially expressed genes in the skeletal muscle of adult offspring 
following MFAS is encoded within 20kb from a distal CpG island (Table 4.1). Two 
of the differentially expressed genes, Sfrs12ip1 and RGD1563667, are encoded 
on chromosome 2, while none of the differentially expressed genes is known to be 
encoded on a sex chromosome (Table 4.1).  
 
None of the differentially expressed genes in the skeletal muscle of adult male 
offspring following MFAS is encoded on a sex chromosome (Table 4.2). Two of 
the differentially expressed genes, Sfrs12ip1 and Emb, are encoded on 
chromosome 2, with these residing on arm q13 and arm q15 respectively (Table 
4.2). In terms of methylation regulatory regions, three of the differentially 
expressed genes, Emb, Ubxn2a and Tob2, are known to be encoded within 20kb 
from a distal CpG island. 
 
Two of the differentially expressed genes, Mterf and Usp18, in the skeletal muscle 
of adult female offspring are encoded on chromosome 4 (Table 4.3). Furthermore, 
none of the differentially expressed genes in the skeletal muscle of adult female 
offspring is known to be encoded within 20kb from a distal CpG island. 
 
4.3.3. INGENUITY PATHWAY ANALYSIS FOR THE DIFFERENTIALLY 
EXPRESSED GENES IN ALL ADULT OFFSPRING 
Lipid metabolism (B-H P = 0.002) was identified as one of the over-represented 
biological functions affected by MFAS in skeletal muscle of adult offspring. This 
over-represented biological function was closely associated with the down-
regulated gene of Alox5ap, which encodes a 5-lipoxygenase required in 
leukotriene synthesis (Table 6.28). Correspondingly, abnormal quantity of 
leukotriene was identified as the specific aspect of function altered within lipid 
metabolism. Developmental disorder of adult polyglucosan body disease (B-H P = 




associated with increased expression of Gbe1, which encodes a glycogen 
branching enzyme that promotes solubility of glycogen molecules as a means of 
reducing osmotic pressure within the cell.385 Missense mutation in the gene of 
Gbe1 has been observed previously in patients with adult polyglucosan body 
disease.456 
 
In the skeletal muscle of all adult offspring, two molecular networks of significance 
were identified (Table 6.29), with the top network (IPA score = 11) being involved 
in lipid metabolism and molecular transport (Figure 4.4A), while the second 
network (IPA score = 3) was found to regulate RNA post-transcriptional 
modification (Figure 4.4B). No canonical pathway was affected by MFAS in the 
skeletal muscle of all adult offspring. Among the differentially expressed genes in 
the skeletal muscle of all adult offspring, IPA revealed 46 upstream regulators (P < 

















Figure 4.4 Molecular Networks Affected by Maternal Folic Acid Supplementation in the Skeletal Muscle of Adult Offspring. (A) Functions associated 
with this network include lipid metabolism, molecular transport and small molecule biochemistry; IPA score = 11. (B) Functions associated with this network 
include neurological disease, RNA post-transcriptional modification and cancer; IPA score = 3. Up-regulated genes are represented as nodes in red. Down-
regulated genes are represented as nodes in green. Biological relationship between two nodes is represented as a line, with solid lines representing direct 
interactions, while dashed lines indicate indirect interactions. All biological relationships are substantiated by findings in at least one academic journal 





4.3.4. INGENUITY PATHWAY ANALYSIS FOR THE DIFFERENTIALLY 
EXPRESSED GENES IN ADULT MALE OFFSPRING 
Lipid metabolism (B-H P = 0.003) was identified as a major biological function 
affected in skeletal muscle of adult male offspring following MFAS, with it being 
associated with the down-regulated gene of Alox5ap (Table 6.28). The 
differentially expressed genes in the skeletal muscle of adult male offspring 
following MFAS were not enriched in any canonical pathways; however, two 
molecular networks of significance (IPA score ≥ 3) were identified (Table 6.29). 
The first and top molecular network (IPA score = 16) was associated with the 
function of cellular growth and proliferation (Figure 4.5A), while the second 
network (IPA score = 3) was functionally related to RNA post-transcriptional 
modification (Figure 4.5B). Despite IPA having identified 40 upstream regulators 
for the differentially expressed genes (P < 0.05) in the skeletal muscle of adult 


















Figure 4.5 Molecular Networks Affected by Maternal Folic Acid Supplementation in the Skeletal Muscle of Adult Male Offspring. (A) Functions 
associated with this network include cancer, cellular development and cellular growth and proliferation; IPA score = 16. (B) Functions associated with this 
network include neurological disease, RNA post-transcriptional modification and cancer; IPA score = 3. Up-regulated genes are represented as nodes in red. 
Down-regulated genes are represented as nodes in green. Biological relationship between two nodes is represented as a line, with solid lines representing 
direct interactions, while dashed lines indicate indirect interactions. All biological relationships are substantiated by findings in at least one academic journal 




4.3.5. INGENUITY PATHWAY ANALYSIS FOR THE DIFFERENTIALLY 
EXPRESSED GENES IN ADULT FEMALE OFFSPRING 
Ingenuity Pathway Analysis revealed Gene Expression (B-H P = 0.004) as one of 
the major biological functions affected in the skeletal muscle of adult female 
offspring following MFAS (Table 6.28). Transcription termination of RNA was 
indicated as the specific aspect of function altered within Gene Expression and 
was closely associated with the down-regulated gene of Mterf. Ingenuity Pathway 
Analysis also identified two molecular networks (IPA score ≥ 3) affected by MFAS 
in the skeletal muscle of adult female offspring (Table 6.29), with the top affected 
molecular network being functionally related to metabolic disease (Figure 4.6A), 
while the second network was related to cellular assembly and organisation 
(Figure 4.6B). 
 
Oxidative phosphorylation (-log (B-H) P = 1.39), mitochondrial dysfunction (-log (B-
H) P = 1.39) and protein ubiquitination (-log (B-H) P = 1.38) were indicated as 
canonical pathways affected by MFAS in the skeletal muscle of adult female 
offspring (Table 6.31). The top two pathways were enriched for the up-regulated 
gene of Ndufs5, which encodes a NADH dehydrogenase within the mitochondrial 
electron transport chain that regulates ATP metabolism and energy production.256 
Moreover, 32 upstream regulators (P < 0.05) were identified for the differentially 
expressed genes in the skeletal muscle of adult female offspring; however, none 

















Figure 4.6 Molecular Networks Affected by Maternal Folic Acid Supplementation in the Skeletal Muscle of Adult Female Offspring. (A) Functions 
associated with this network include developmental disorder, hereditary disorder and metabolic disease; IPA score = 5. (B) Functions associated with this 
network include neurological disease, psychological disorders and cellular assembly and organisation; IPA score = 3. Up-regulated genes are represented as 
nodes in red. Down-regulated genes are represented as nodes in green. Biological relationship between two nodes is represented as a line, with solid lines 
representing direct interactions, while dashed lines indicate indirect interactions. All biological relationships are substantiated by findings in at least one 




4.3.6. INDEPENDENT QUANTIFICATION OF MRNA EXPRESSION IN 
SKELETAL MUSCLE OF ADULT OFFSPRING 
Consistent with microarray results, expression of Actc1 (4.37 fold, P = 0.004) was 
confirmed to be up-regulated in the skeletal muscle of adult offspring of folic acid 
supplemented dams relative to controls (Table 4.4; Figure 4.7A). Maternal folic 
acid supplementation also up-regulated the expression of Kcnj13 (3.11 fold, P = 
0.003) in the skeletal muscle of adult offspring, irrespective of sex (Table 4.4; 
Figure 4.7B).  
 
In the skeletal muscle of adult male offspring, MFAS up-regulated Actc1 
expression (5.90 fold, P = 0.048; Figure 4.7A). Maternal folic acid supplementation 
also up-regulated Actc1 expression (2.32 fold, P = 0.001) in the skeletal muscle of 
adult female offspring (Figure 4.7A). In contrast to microarray based findings, 
expression of Mterf (P = 0.114) was not altered in the skeletal muscle of adult 







Figure 4.7 Maternal Folic Acid Supplementation Alters Gene Expression in the Skeletal 
Muscle of Adult Offspring. Relative skeletal muscle expression of: (A) Actc1; (B) Kcnj13; and (C) 
Mterf in adult offspring of folic acid supplemented and control dams. Offspring from the two 
maternal dietary groups were analysed (C: 16, male = 8, female = 8; MFAS: 14, male = 8, female = 
8). Normally distributed data was analysed by independent samples t-test. Non-normally distributed 
data was analysed by Kruskal-Wallis H test. Expression values are normalised to skeletal muscle 
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0.271 ± 0.053 1.105 ± 0.238 0.004 0.23 ± 0.07 0.91 ± 0.27 0.048 0.325 ± 0.086 1.186 ± 0.145 0.001 
Gbe1 
 
0.20 ± 0.02 0.19 ± 0.02 0.563 0.17 ± 0.03 0.23 ± 0.04 0.263 0.21 ± 0.03 0.33 ± 0.08 0.228 
Kcnj13 
 
1.946 ± 0.381 3.561 ± 0.309 0.003 2.11 ± 0.69 3.66 ± 0.38 0.080 4.60 ± 1.28 5.34 ± 1.29 0.694 
Mterf   19 ± 1 17 ± 1 0.173 20 ± 2 18 ± 1 0.640 19 ± 2 14 ± 1 0.114 
Sixteen offspring per maternal dietary group (C: 16, male = 8, female = 6; FA: 16, male = 8, female = 6). Data was analysed with independent samples t-test. 
Expression values of the genes of interest are normalised to skeletal muscle expression of Ppia and are presented as mean ± SEM. CA, all offspring of 
control dams; CM, male offspring of control dams; CF, female offspring of control dams; FAA, all offspring of folic acid supplemented dams; FAM, male 





In the present study, we have shown that MFAS alters expression of the skeletal 
muscle transcriptome of adult offspring. The genes differentially expressed in the 
skeletal muscle of adult offspring following MFAS were found to engage in 
cytoskeletal actin remodelling, lipid metabolism and potassium ion homeostasis, 
which are closely related to insulin-stimulated glucose uptake. Cumulatively, these 
transcriptomic changes may contribute towards differences in metabolic 
functionality in the skeletal muscle of adult offspring following MFAS and, in effect, 
altering their susceptibility to metabolic disorders. 
 
In skeletal muscle, insulin mediated glucose uptake is elicited in part through 
cytoskeleton actin remodelling, which assists the recruitment of GLUT4 to the 
cellular surface.192, 387, 388 Upon stimulation by insulin, phosphoinositide 3-kinase 
(PI3K), a key constituent in a critical node of the insulin-signalling network, 
becomes activated.205 As a result of PI3K activation, downstream effectors are 
stimulated to promote downstream actin rearrangement, in turn, facilitating the 
translocation of GLUT4 vesicles into the plasma membrane.205 To potentiate 
cytoskeletal actin remodelling required for glucose uptake, insulin stimulates actin 
fibre formation via the transcriptional induction of α-actin and β-actin expression. 
282 With actin fibres being pivotal components of cytoskeletal remodelling, 
disruption to their expression or assembly has been demonstrated to impede the 
recruitment of glucose transporter to the plasma membrane in skeletal muscle.40, 
393 In support of this notion, insulin resistance in human skeletal muscle is 
characterised by a pronounced decrease in the expression of ACTN2, a critical 
regulator of cytoskeletal remodelling that binds and anchors α-actin.174 In the 
present study, MFAS increases expression of Actc1 consistently in the skeletal 
muscle of all adult offspring as well as in males and females separately. These 
observations suggest that increased expression of Actc1 may alter cytoskeletal 
remodelling dynamics in the skeletal muscle of the adult offspring following MFAS 
and may increase insulin-stimulated translocation of GLUT4. Concordantly, we 
have previously shown that MFAS increases insulin tolerance in the adult male 
offspring (Prof. Julie Owens, oral communication). Moreover, expression of actin 




nutrition during gestation. Nutrient restriction in the pregnant ewe during the first 
half of gestation has been found to increase Actc1 expression in the foetal heart 
and is broadly consistent with the observation that its expression is susceptible to 
nutritional modulation in early development.144 Intrauterine growth restricted 
newborn piglets also exhibited reduced Actb expression in the skeletal muscle, 
which is consistent with long-term impairments in insulin sensitivity as observed in 
numerous experimental models and species following intrauterine growth 
restriction.121, 414 Taken together, these observations reflect that cytoskeletal 
mechanics in the offspring are susceptible to the influence of maternal nutrition 
during gestation, including folic acid supplements; the extent to which altered 
cytoskeletal mechanics in skeletal muscle may contribute towards altered whole 
body insulin sensitivity in offspring remains to be directly determined.  
 
Potassium ion channels are well recognised to play a substantial role in the 
regulation of glucose homeostasis. In the pancreas, they are responsible for 
mediating glucose-stimulated insulin release, while in the skeletal muscle they 
facilitate glucose uptake.277 In line with this anabolic effect, expression of Kcnj13 
has been previously reported to be induced by insulin in FRTL-5, a rat follicular 
cell line.298 In the present study, MFAS markedly up-regulates expression of 
Kcnj13 in the skeletal muscle of adult offspring. As Kcnj13 expression is induced 
by insulin, its elevated expression may be a result of increased insulin-activated 
transcriptional actions in the skeletal muscle of the adult offspring following MFAS. 
This observation is broadly consistent with our previous finding that MFAS 
increases insulin tolerance in adult male offspring (Professor Julie Owens, oral 
communication). A member of the Kir (inwardly rectifying potassium channel) 
family, Kcnj13 is suggested to stabilise the resting membrane potential and to 
maintain potassium ion homeostasis.338 Increased expression of Kcnj13 may 
confer an enhanced capacity to regulate potassium ion homeostasis and resting 
membrane potential in the skeletal muscle of adult offspring of folic acid 
supplemented dams; this may contribute towards their improved glucose and 
insulin tolerance. However, current understanding on the ways by which increased 




metabolism in skeletal muscle is limited; its possible role in the regulation of insulin 
sensitivity of adult offspring following MFAS remains to be further determined.  
 
The differentially expressed genes affected by MFAS in the skeletal muscle of 
adult offspring, particularly those in the males, were found to be over-represented 
in the biological function of lipid metabolism. We have previously identified lipid 
metabolism as a major biological function affected by the differentially expressed 
genes in the liver of the adult offspring following MFAS (See Chapter 2). In line 
with this, hepatic expression of key regulators in lipid metabolism, including Ppara, 
Pparγ and LXRα, were reduced in adult offspring following MFAS.67 These 
observations support the notion that MFAS induces widespread changes in the 
expression of genes involved in lipid metabolism in key metabolic tissues of adult 
offspring. It is increasingly recognised that dysregulation of lipid metabolism is 
closely associated with the pathogenesis of metabolic disorders.99 The 
modification in expression of genes related to lipid metabolism in the adult 
offspring by MFAS suggests possible consequences for their metabolic regulation 
and susceptibility to chronic diseases; given the widespread antenatal use of folic 
acid supplements, this aspect warrants further investigation.  
 
In conclusion, the present study has shown that MFAS enhances the expression 
of genes involved in cytoskeletal actin remodelling and potassium ion homeostasis 
in the skeletal muscle of the adult offspring. Altered skeletal muscle expression of 
these various genes, which are closely related to insulin-stimulated glucose uptake, 
may contribute towards improvements in insulin tolerance and other metabolic 













5.1. THESIS DISCUSSION AND CONCLUSION 
As a pivotal cofactor in one-carbon metabolism, folate facilitates nucleotide 
synthesis, DNA repair and DNA methylation, all of which are essential biochemical 
processes to growth and development. To support foetal growth, folate 
metabolism adapts to maternal and foetal metabolic needs during pregnancy 
substantially.13 In particular, inadequate maternal folate intake during 
periconception has been established to increase the incidence of NTDs.290 Hence, 
to promote optimal neonatal outcomes, maternal supplementation of folic acid, the 
synthetic analogue of folate, is recommended and widely promoted to women of 
reproductive age. Intriguingly, epidemiological and experimental evidence in 
humans and rodents have shown that variations in maternal folate intake before 
and during pregnancy affect susceptibility of the offspring to chronic diseases after 
birth, particularly through perturbed DNA methylation patterns and expression of 
DNA methyltransferases in a time- and tissue-specific manner.67, 140, 158, 250, 309, 365, 
374 Besides DNA methylation, MFAS in late gestation has also been shown to 
increase miR expression in the foetal brain, leading to down-regulation of 
constituents in the Notch signalling pathway.23, 124 Given the interrelations between 
folate status, DNA methylation and gene and microRNA expression, MFAS before 
and during pregnancy may elicit its effects on metabolic pathways, including 
lipogenesis, cholesterogenesis and glucoregulation, and susceptibility of the 
offspring to chronic diseases through these aforementioned molecular 
mechanisms at critical prenatal and postnatal timepoints.23  
 
In this thesis, the effects of MFAS on expression of key metabolic and epigenetic 
regulatory genes in the liver of the offspring at prenatal and postnatal stages of 
development have been examined. We also examined the transcriptomic changes 
elicited in the skeletal muscle of the adult offspring following MFAS. Studies 
described herein provide compelling evidence for MFAS, from preconception to 
term, to be capable of inducing marked transcriptional changes to genes involved 
in lipid and cholesterol metabolic pathways in key glucoregulatory tissues, liver 
and skeletal muscle, in offspring prenatally and postnatally. Furthermore, 




non-coding miRs, are implicated as potential mediators of the developmental 
programming effects observed.  
 
In Chapter 2, MFAS is shown to decrease hepatic expression of two major types 
of DNMTs, Dnmt1 and Dnmt3b, in the female foetus, while the male foetus is 
unaffected. With these two DNMTs being primarily responsible for the 
establishment and maintenance of DNA methylation, this suggests that MFAS may 
alter epigenetic inheritance of offspring in a sex-specific manner through reduced 
hepatic expression of DNMTs. At present, the consequences of attenuated foetal 
expression of DNMTs on DNA methylation, at the global and specific gene levels, 
during foetal development require further examination. Characterising genome-
wide changes in DNA methylation using bisulphite genomic sequencing would 
provide key mechanistic insights into the ways by which MFAS may determine 
foetal epigenotype in late gestation and in postnatal life. Determining the changes 
in DNA methylation at specific gene loci would delineate the functional 
consequences as well as identify genes, which are responsive to MFAS in utero. 
Moreover, our observations are broadly consistent with the sexually dimorphic 
effects observed in a previous study, in which MFAS specifically alters the level of 
methylation in the promoter region of Pepck in the liver of adult female offspring, 
while this in male offspring is unaffected.158 Taken together, these observations 
indicate the potential for MFAS to establish sexually dimorphic differences in the 
regulation of DNA methylation in the liver of offspring and, in turn, alter their 
capacity to regulate the epigenome at prenatal and postnatal stages of 
development.  
 
Exiqon miR microarray and qRT-PCR analysis reported in Chapter 2 revealed that 
hepatic expression of miR-122 and miR-191 are increased by MFAS in the female 
foetus during late gestation. Increasingly, it is recognised that miR-122 plays a key 
and major regulatory role in hepatic lipid metabolism, with miR-122 KO mice 
exhibiting increased de novo lipogenesis.168 Quantification of hepatic triglyceride 
levels in the foetus in response to MFAS would directly determine if this does 




manner through a miR-122-related mechanism. Moreover, miR-122 has been 
demonstrated to promote the maturation and differentiation of mESCs.81 The 
observed increase in hepatic miR-122 expression in the female foetuses of folic 
acid supplemented dams may also promote the maturation and differentiation of 
hepatic progenitor cells; however, these aspects await direct assessment.  
 
In addition, hepatic expression of miR-122 and Sc4mol are found to be 
concomitantly increased by MFAS in the female foetus in Chapter 2. A previous 
study also reported that hepatic expression of miR-122 and Sc4mol are 
simultaneously decreased in miR-122 KO mice.168 To date, limited studies have 
examined the interaction between the expression of miR-122 and Sc4mol; hence, 
it would be of great interest to determine the mechanisms responsible for their 
simultaneous unidirectional transcriptional regulation.  
 
In Chapter 2, we reported that hepatic expression of miR-191 is accentuated by 
MFAS in the female foetus. In a previous study, expression of miR-191 in MCF7 
human breast cancer cells has been shown to be regulated by estrogen receptor 
alpha, which is stimulated by estrogen.83 At present, it is unknown whether MFAS 
can affect or increase estrogen abundance in the female foetus and through which 
increase hepatic expression of miR-191; thus, quantification of foetal serum 
estrogen levels would help with this clarification.  
 
Emerging findings from experimental studies support the existence of an 
interrelationship between folate and the modulation of miR expression.23 Given 
folate to be a key source of methyl group donor in DNA methylation, it remains 
possible for miRNA expression to be altered by DNA methylation directly, or 
indirectly through upstream signal transduction pathways.23,148 Therefore, 
bisulphite sequencing PCR would need to be conducted in order to determine 
whether perturbed DNA methylation in the promoter of miR-122 and miR-191 
contribute towards their increased expression in the liver of female foetuses 




In Chapter 2 and 3, MFAS is shown to induce opposing regulatory changes to 
hepatic expression of Ppara in offspring at different stages of development, with 
hepatic expression of Ppara being up-regulated in late gestation but down-
regulated by adulthood. As a transcriptional regulator, PPARA activation can 
increase hepatic expression of key genes involve in fatty acid uptake and 
oxidation.113 The latter observations are consistent with those of previous studies, 
in which offspring of folic acid supplemented dams are found to display reduced 
hepatic expression of Ppara postnatally.67, 249 Methylation in the promoter region of 
hepatic Ppara of offspring in the postnatal period has been previously shown to be 
susceptible to alterations by MFAS.249 Therefore, it is possible for MFAS to elicit 
this reduction in hepatic Ppara expression through altering DNA methylation levels 
in the hepatic promoter region of Ppara. The mechanisms whereby these changes 
elicited by MFAS vary with life stage are currently unknown. These mechanisms 
present a potential window of opportunity to intervene between foetal and adult life, 
wherein these deleterious effects may become prevented. 
 
Recent studies have revealed that prenatal and postnatal nutrition can interact to 
modify metabolic phenotype in postnatal life.44, 70, 204, 215, 357 In particular, adult 
offspring of folic acid supplemented dams that have been challenged with a post-
weaning high fat diet displayed increased plasma glucose and β-hydroxybutyrate 
as compared to corresponding offspring that have been fed a post-weaning diet of 
standard fat content.43 These observations indicate that in a postnatal dietary 
environment of high fat exposure, adult offspring of folic acid supplemented dams 
have a reduced capacity to maintain metabolic homeostasis, which may increase 
their predisposition to chronic diseases. At present, it is unknown whether adult 
offspring of folic acid supplemented dams may display an even more 
compromised capacity to maintain metabolic homeostasis in the adversity of a 
post-weaning diet of high fat and high sugar content. Direct studies to examine this 
are needed in order to reveal further insights into the susceptibility to chronic 
diseases of adult offspring of folic acid supplemented dams, particularly when 




Observations reported in Chapter 2 and 3 show that expression of key lipogenic 
genes in the liver of offspring are differentially regulated by MFAS between the 
prenatal and postnatal stages of development. In male offspring, hepatic 
expression of Acaca is suppressed by MFAS in late gestation; however, it is 
increased by adulthood. In the female offspring, hepatic expression of another 
lipogenic gene, Scd1, is reduced by MFAS in late gestation, but it is increased by 
adulthood. Both of these genes are known to encode key enzymes involved in de 
novo lipogenesis, their increase in expression after birth suggest that MFAS may 
potentiate the capacity for de novo lipogenesis in the liver of the offspring as 
development progresses from prenatal to postnatal stages. To determine if altered 
hepatic expression of lipogenic genes in the foetuses and adult offspring of folic 
acid supplemented dams does result in altered lipogenesis and hepatic lipid 
abundance, this could be assessed using incorporation of 3H1-glycerol into 
triglyceride and by histological assessment using oil red O staining. Moreover, 
earlier studies in animals have shown that hepatic expression of ACACA and SCD 
are both regulated by DNA methylation levels in their respective promoter 
regions.48, 253 An experimental study has shown hepatic expression of ACACA is 
inversely correlated with the methylation levels in its promoter region in chickens 
with fatty liver syndrome that have been fed with a methyl group donor deficient 
diet for 10 weeks.253 For SCD, hepatic expression of this lipogenic gene in 
neonatal piglets of betaine supplemented sows is lower than that of controls.48 
This decrease in SCD expression is accompanied by hypermethylation in the 
hepatic promoter of SCD.48 Hence, determining the methylation levels in the 
promoter region of these differentially expressed lipogenic genes would provide 
further mechanistic details on the means by which MFAS may affect the 
expression of these two genes in the liver of the offspring throughout different 
stages of development.  
 
It is currently unclear if sexually dimorphic differences in the hepatic expression of 
Acaca and Scd1 in the offspring of folic acid supplemented dams involve sex-
specific changes in their methylation state. In a previous study, MFAS during 
gestation has altered the levels of methylation in the promoter region of Pepck in 




been unaffected.158 Sex-specific differences in DNA methylation have also been 
reported in humans, wherein periconceptional folic acid supplementation is shown 
to reduce the levels of methylation in H19, the promoter region of IGF2, in the cord 
blood of male infants as compared to control male infants.166 In contrast, H19 
methylation levels in cord blood of female infants have been found to be 
unaffected by MFAS before or during pregnancy.166 Together with those of 
previous studies, our observations in Chapter 2 and 3 provide further evidence 
that MFAS establishes transcriptomic and epigenetic changes in the offspring that 
are highly sex- and age-specific. Characterising the methylation levels in the 
promoter regions of Acaca and Scd1 in the male and female offspring at prenatal 
and postnatal stages of development would help to determine if differences in 
DNA methylation could account for sex-specific changes in hepatic lipogenic gene 
expression following MFAS, from preconception to term.  
 
As suggested in Chapter 2, MFAS may accentuate the capacity for hepatic de 
novo lipogenesis but suppress that for fatty acid oxidation in the offspring through 
hepatic transcriptomic changes. These observations are broadly in line with other 
findings in animal studies, suggesting that maternal intake of folate during 
gestation impacts upon lipid homeostasis of offspring in postnatal life.67, 250 
Maternal folic acid supplementation throughout gestation in the rat also decreases 
the expression of several key regulators in lipid homeostasis, including Ppara, 
Pparγ and LXRα, in the liver of adult offspring.67 Maternal folic acid 
supplementation throughout gestation in the rat increases the high-density 
lipoprotein-cholesterol to total cholesterol ratio in the blood of adult offspring.67 
Maternal folic acid supplementation, from conception to term, also up-regulates 
genes, which have been identified as closely associated with fatty acid metabolic 
pathways, in the adult rat offspring.250 Besides MFAS, maternal folate deficiency in 
the rat also markedly perturbs lipid homeostasis in offspring, with maternal folate 
deficiency up-regulating hepatic expression of Cpt1a, a gene involved in fatty acid 
oxidation, but downregulating that of Cd36, a fatty acid translocase, in the foetus in 
late gestation.275 Maternal folate deficiency in the rat increases the percentage of 
body fat by three to four fold in the adult offspring.221 Plasma triglycerides, 




dams.221 In addition, maternal folate deficiency also enhances the activity of fatty 
acid synthase and acetyl-CoA carboxylase in the liver of adult male offspring.221 
These observations along with those presented in this thesis suggest that 
excessive or inadequate maternal intake of folate during gestation can perturb 
hepatic lipid homeostasis of offspring after birth, which may have unforeseen 
effects on their susceptibility to chronic diseases.  
 
In Chapter 4, it has been reported that Actc1 expression in skeletal muscle of adult 
offspring is markedly up-regulated by MFAS. Despite actin fibres being known to 
be involved in cytoskeletal remodelling and are required in insulin-stimulated 
GLUT4 translocation, it is incompletely understood as to whether this increased 
expression of Actc1 may alter GLUT4 translocation and insulin-stimulated glucose 
uptake in the skeletal muscle of adult offspring of folic acid supplemented dams; 
this aspect awaits further direct examination.  
 
One of the limitations in extrapolating from observations presented herein is 
interspecies differences in folate metabolism between rats and humans.14, 36, 416 In 
rats, hepatic activity of dihydrofolate reductase is higher than that in humans.14 
This renders an enhanced capacity to convert folic acid to 7, 8-dihydrofolate and 
increases bioavailability of folate in rats subsequent to folic acid 
supplementation.14 Consistently, folate content in erythrocytes and serum are 
higher in rats than in humans, and the rate of uptake of 5-methyltetrahydrofolic 
acid in erythrocytes in rats is also higher than that of humans.36 In our study 
design, we have taken into account the daily requirements and turnover rates of 
folate in the rats and the relationship between folic acid supplementation and 
folate turnover in humans; the final dosage of folic acid supplements used in our 
studies was determined to mimic these factors quantitatively.382 We have also 
considered that folate conjugase, an enzyme which facilitates intestinal absorption 
of polyglutamyl folate and polyglutamyl folic acid, has lower activities in rats than in 
humans and may, in effect, reduce folate bioavailability in the rats subsequent to 




account, interspecies differences in enzymatic activities inevitably exist; hence, 
these differences need to be acknowledged and noted with caution. 
 
Due to limited availability of high quality biological samples and experimental 
resources, we have been unable to conduct Affymetrix GeneChip®  Rat Gene 1.0 
ST Array analyses on the liver or skeletal muscle of gestational day 20 foetuses. 
Performing these Affymetrix Gene array analyses on the foetuses would otherwise 
generate data that is compatible with the existing Affymetrix array data on the 
adult offspring presented in Chapter 2. In turn, we would be afforded the 
opportunity to conduct robust comparisons using these datasets, with a rigorous 
biostatistical methodology in place. These comparative analyses would enable us 
to advance our understanding on the effects of MFAS on global mRNA 
transcriptome of offspring more comprehensively and would also enable us to 
delve our investigations more deeply into the interactive effects between MFAS 
and developmental stage, sex and organ of offspring. At present, we are greatly 
restricted by this limitation, as deriving casual, overly simplistic relationships from 
qRT-PCR datasets and Affymetrix array datasets in the absence of a rigorous 
biostatistical methodology is not regarded as robust by current practice; hence, we 
refrained from over-interpreting the existing data presented herein.  
 
In conclusion, the observations of the studies presented herein indicate that MFAS 
alters hepatic expression of key metabolic regulatory genes, DNMTs and non-
coding miRs of foetuses at late gestation in a sex-specific manner, with females 
being most affected. These differences in hepatic expression of epigenetic 
regulators, including DNMTs and non-coding miRs, in MFAS may in part 
contribute towards an altered capacity for the offspring to regulate DNA 
methylation and to regulate transcriptional networks needed for maintaining 
metabolic homeostasis in postnatal life. In adulthood, MFAS alters expression of 
the hepatic and skeletal muscle transcriptome in offspring, with genes related to 
lipid metabolism and cholesterogenesis being markedly perturbed. These 
transcriptomic changes are suggested to enhance the capacity for hepatic de novo 




oxidation and cholesterogenesis. In light of these observations, future studies are 
required to elucidate the consequences of MFAS, from periconception to term, on 
lipid and cholesterol homeostasis, epigenetic inheritance and susceptibility of 














Table 6.1 Developmental Programming Effects of Maternal Folic Acid Supplementation on Rodent Prenatal Offspring. 
Folic Acid Dosage 
 




Exposure Time Observed Effects in Offspring Animal Model 
   
Embryonic and foetal development 




MFAS was associated with increased embryonic loss, delay and 
reduced embryonic weight and length.313 
BALB/c Mthfr +/+ or 
Mthfr +/− mice 




MFAS was associated with increased embryonic loss, delay and 
increased incidence of embryonic ventricular septal defects.283 
BALB/c Mthfr +/+ or 
Mthfr +/− mice 




MFAS in normal, hyperglycaemic or diabetic dams increased 
proliferation of neuroepithelial cells in the forebrain of embryos at 
gestational day 11.5.446 Hyperglycaemic and 
diabetic Swiss albino 
mice 
 
MFAS in hyperglycaemic or diabetic dams reduced apoptosis of 






MFAS in hyperglycaemic and diabetic dams increased premature 
neuronal differentiation in embryonic telencephalon, which was 
accompanied by increased expression of Tuj1 and bHLH 






GD 5 - 18 
MFAS altered CpG methylation of 253 genes in the liver of 








MFAS was associated with reduced hepatic DNA methylation in the 
Folbp1 + /− and Folbp1 +/− foetuses.106 
Folbp1 −/− mice 




MFAS effectively rescued Folbp1 -/- foetuses, with these being 
phenotypically normal and survived beyond gestational day 10.314 







MFAS prolonged survival of RFC1 −/− foetuses until gestational day 
9.5 - 10.5.314 




These foetuses were developmentally delayed, smaller in size and 
had craniofacial abnormalities, with reduced numbers of 










MFAS prolonged survival of RFC1 −/− foetuses, with these being 
viable at gestational day 18.5 but had varying degrees of cardiac 
and lung malformations.123 
RFC1 +/− C57Bl/6J 
and SWV 
heterozygous mice 
2 mg/kg 20 mg/kg 
 
GD 11 - 17 
MFAS did not alter the number of progenitor cells in mitotic phase in 
the ventricular zones of foetal brain septum, caudate putamen or 
neocortex at gestational day 17.72 C57BI/6J mice 
 
MFAS did not alter the number of apoptotic cells in the dorsal 
regions of foetal brain septum. 




MFAS rescued embryonic lethality induced by nullizygosity of 
RFC1, with foetuses being viable at gestational day 18.5.72 
RFC1 +/− C57Bl/6J 
mice 
 
MFAS protected against the adverse effects of nullizygosity of 
RFC1 in foetuses; erythropoiesis was activated in foetal liver, bone 
























Observed Effects in Offspring 







MFAS increased the level of methylation at the DMR of IGF2 in the blood of children 







MFAS increased the level of methylation at the DMR of IGF2 in the cord blood of 
newborn at birth.140 
MFAS reduced the level of methylation at the DMR of PEG3 and LINE-1 in the cord 







MFAS decreased the level of methylation at the DMR of H19 in the umbilical cord 




















MFAS increased mean birth weight of newborn infants.225 
MFAS also reduced the incidence of maternal megaloblastic anaemia.225 
MFAS did not affect preterm births, stillbirths and neonatal deaths.225 
MFAS did not affect mean pre-delivery serum and red blood cell folate 
levels.225 
700 women 0.5 mg/day 
From mid-2nd 
trimester to term 
Increased maternal erythrocyte folate levels at 28 weeks were associated 






trimester to term 
Increased maternal plasma folate levels at 18 or 28 weeks of gestation 
were not associated with increased insulin resistance of 6 to 8 years old 
Nepali children.376 
654 women Unspecified Unspecified 
Increased maternal plasma folate concentrations at 30 weeks of gestation 






0.646 - 5.815 
mg/day 
At 18 and 32 
weeks of 
gestation 
Maternal intake of folic acid at 18 weeks and 32 weeks of gestation were 




0.4 - 0.5 mg/day Preconception 
Maternal intake of folic acid during pregnancy was not associated with 









Table 6.4 Developmental Programming Effects of Maternal Folic Acid Supplementation on Rodent Postnatal Offspring. 
Folic Acid 
Dosage  
Animal Experimental Studies 
Control MFAS 
 
Exposure Time Observed Effects in Offspring Animal Model 
   
Postnatal development 
2 mg/kg 5 mg/kg 
 
Throughout gestation 
MFAS decreased plasma levels of cholesterol and glucose in the 10 
weeks old offspring.67 
Wistar rats 
 
MFAS increased plasma levels of TAG and NEFA but decreased 
those of cholesterol in the 16 weeks old offspring.67 
 
MFAS decreased hepatic expression of Pparα, Pparγ and LXRα in the 
16 weeks old offspring.67 
1 mg/kg 5 mg/kg 
 
Throughout gestation 




MFAS increased plasma levels of glucose in adult offspring that were 
exposed to a post-weaning high fat diet.43 
1 mg/kg 5 mg/kg 
 
Throughout gestation 
MFAS decreased plasma level of glucose in adult female offspring but 
not in adult male offspring.158 
Wistar rats 
 
MFAS altered CpG methylation and increased binding of CEBPB to 
the promoter of Pepck in the liver of female offspring.158 
2 mg/kg 5 mg/kg 
 
Preconception to end 
of weaning 





MFAS reduced global DNA methylation in the liver of offspring at 
postnatal day 21 but not at postnatal day 98.365 
 
MFAS also reduced CpG methylation in the promoter region of Pparγ, 
ERα, p53 and Apc in the liver of offspring at postnatal day 21.365 
 
MFAS increased methylation at selected CpG sites of Pparγ, p16 and 








Table 6.5 MicroRNAs and Their Functions in Metabolic Homeostasis. 
MicroRNA Expression Observed Function 
miR-7, miR-9, miR-375 
and miR-376 
miR-7, miR-9, miR-375 and miR-376 were detected as highly expressed during human foetal 
pancreatic islet development.71, 186, 344 
miR-7 
miR-7 expression was detectable in human foetal pancreas at nine weeks of gestation and reached 
its maximal expression levels between 14 and 18 weeks of gestation.71 
↑ miR-7 expression was coincidental with increased insulin mRNA expression in mouse foetal 
pancreas.303 
↓ miR-7 pancreatic expression at embryonic day 10.5 reduced insulin production, pancreatic β-cell 
number and glucose tolerance in the postnatal mouse offspring at two weeks of age.303 
miR-24 
↓ miR-24 expression was detected in the skeletal muscle of diabetic Goto-Kakizaki rats. miR-24 
targets p38 MAPK, which facilitates the induction of Glut4 expression.170 
miR-33 
↑ miR-33 expression reduced cholesterol efflux in human HEK293 cells but did not alter total cellular 
cholesterol content or cholesterol uptake. miR-33 targets ABCA1 and ABCG1 expression.270 
↑ miR-33 expression reduced total plasma cholesterol levels and hepatic mRNA and protein 
expression of ABCA1 in mice.270 









↓ miR-33 expression increased ABCA1 expression in mouse macrophage J774 cell line.297 
Genetic deletion of miR-33 in mice increased serum HDL cholesterol levels and increased hepatic 
ABCA1 expression.164 
↑ miR-33 expression reduced ABCA1 expression and cellular export of cholesterol in human HepG2 
cells.125 
↑ miR-33 expression reduced expression of CPT1A and the rate of fatty acid oxidation in human 
HepG2 cells.125 
miR-103/107 
↓ miR-103/107 improved glucose infusion rate and clamp glucose turnover in obese mice, indicating 
an overall improvement in glucose tolerance and insulin sensitivity.390 
↓ miR-103/107 expression in mouse adipocytes increases expression of Cav1, which regulates the 
insulin receptor.390 
miR-122 
↓miR-122 expression decreased plasma levels of cholesterol and the rate of fatty synthesis and 
cholesterol synthesis in normal wild type mice.98 
↓ miR-122 expression reduced expression of HMG-CoA reductase and farnesyl diphosphate 
synthetase in normal wild type mice.220 
Genetic deletion of miR-122 increased hepatic lipid synthesis but decreased lipid export in mice. 
Homozygous miR-122 KO mice displayed increased hepatic concentrations of cholesterol and 
triglycerides.168, 392 
Genetic deletion of miR-122 reduced serum levels of HDL and VLDL in mice.168, 392 
Genetic deletion of miR-122 increased hepatic expression of enzymes involved in lipid biosynthesis 
and storage, including Agpat1, Cidec and Mogat1, in mice.168 
Genetic deletion of miR-122 suppressed functions in steroid biosynthesis and bile acid biosynthesis in 
two months old mice.391 
↑miR-122 expression promoted hepatic differentiation and maturation of mESCs, with 323 genes 








miR-122 expression was detected in the liver of healthy aborted human foetuses aged between nine 
and 12 weeks.114 
miR-122 expression positively correlated with endodermal gene expression in human ESCs.398 
miR-122 expression was minimal in human ESCs; moderate in human definitive endodermal cells; 
and abundant in human primary hepatocytes.211 
↓ miR-122 expression was detected in human hepatocarcinoma tissue.396 
↑ miR-122 expression suppressed cell proliferation and induced apoptosis in human HepG2 and 
Hep3B cells. miR-122 targets Wnt1, β-catenin and TCF-4.438 
↓ miR-122 expression was detected in human hepatocellular carcinoma with intrahepatic metastasis. 
miR-122 suppressed angiogenesis by targeting a disintegrin and metalloprotease 17.391 
miR-122 targets AKT3, which plays a key regulatory role in tumorigenesis. Repletion of miR-122 in 
hepatocarcinoma cells restored activation of apoptosis and inhibited cell proliferation and migration.300 
miR-128a 
miR-128a expression was detected in human skeletal muscle tissue.227, 289 
miR-128a targets the expression of insulin-signalling genes, including Insr, Irs1 and Pik3r1, in mouse 
primary myoblasts.289 
↑ miR-128a expression impedes cellular proliferation of mouse primary myoblasts.289 
miR-144 
In mouse 3T3L1 cells, miR-144 targets Irs1, a key mediator in the insulin-signalling pathway.193 
↑ miR-144 expression was detected in skeletal muscle, pancreas, liver, adipose tissues and blood of 
Type 2 diabetic Wistar rats.193 
miR-223 
↑ miR-223 expression was detected in insulin resistant heart of Type 2 diabetic patients.259 
In the absence of insulin stimulation, ↑ miR-223 expression increased GLUT4 expression and 
glucose uptake in rat ventricular myocytes.259 
miR-375 









↑ miR-375 expression reduced glucose-induced insulin secretion in mouse MIN6 cells. miR-375 was 
validated to target the expression of myotrophin, a protein which facilitates the release of insulin.322 
↑ miR-375 expression reduced protein expression of 3'-phoshoinositide-dependent protein kinase-1 
(PDK1), glucose stimulated expression of insulin and DNA synthesis in rat pancreatic β-cells.93 
Genetic deletion of miR-375 resulted in normoinsulinaemia despite hyperglycaemia and glucose 









Table 6.6 TaqMan®  Gene Expression Assays Used for Quantification of mRNA Expression. 
Gene Symbol Gene Name TaqMan®  Assay ID 
Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 Rn00583723_m1 
Acaca acetyl-CoA carboxylase alpha Rn00573474_m1 
Acsm3 acyl-CoA synthetase medium-chain family member 3 Rn01506548_m1 
Actb actin, beta Rn00667869_m1 
Akr1b10 aldo-keto reductase family 1, member B10 (aldose reductase) Rn01500311_m1 
Akr1b7 aldo-keto reductase family 1, member B7 Rn00587254_m1 
Idi1 isopentenyl-diphosphate delta isomerase 1 Rn01408058_g1 
Pck1 phosphoenolpyruvate carboxykinase 1 Rn01529014_m1 
Ppara peroxisome proliferator-activated receptor alpha Rn00566193_m1 
Ppargc1a peroxisome proliferator-activated receptor gamma coactivator 1 alpha Rn00580241_m1 
Ppia peptidylprolyl isomerase A (cyclophilin A) Rn00690933_m1 
Sc4mol sterol-C4-methyl oxidase-like Rn00590057_m1 




Table 6.7 Over-represented Gene Clusters in the Liver of Adult Offspring of 
Folic Acid Supplemented Dams. 
Cluster Members 
Gene clusters of all offspring 
1 Ifit3, Usp18 
2 Tor3a, Klrg1 
  
Gene clusters of male offspring 
1 Slc1a2, Aph1b, Mid1 
2 Acsm3, Spink3 
3 Cpa2, Akr1b7 
4 Arhgef3, Rogdi, Dab1 
5 Tor3a, G0s2 
6 Rcor2, Rpl21 
  
Gene clusters of female offspring 
1 LOC288521, Coq10b 
2 Il33, Slc1a2 
3 Slc16a10, Pls1 
4 Lifr, Creld2 
5 Ddah1, Abcd2 
6 
Acot5, Prlr, Ntrk1, Klrg1, Prom1, F7, A1bg, Sc4mol, Sqle, 
Dnajc12, Idi1, Zfp189 
7 Mettl7a, Scd1, S100g 
Hierarchical clustering identified over-represented gene clusters in the liver of adult offspring of folic 
acid supplemented dams. Expression of the differentially expressed genes (P < 0.05) within each 









Table 6.8 Diseases and Biological Functions Affected by Maternal Folic Acid Supplementation in the Liver of Adult 
Offspring. 
Category B-H P-value Functions Annotation # Molecules 
Diseases and biological functions of all offspring 
Lipid Metabolism 0.011 accumulation of palmitoleic acid 1 
Molecular Transport 0.011 accumulation of palmitoleic acid 1 
Small Molecule Biochemistry 0.011 accumulation of palmitoleic acid 1 
Gene Expression 0.011 binding of G1 proglucagon element 1 
Cancer 0.011 deficiency of steroid 17-alpha-monooxygenase 1 
    
Diseases and biological functions of male offspring 
Nervous System Development and Function 0.019 abnormal morphology of tectum mesencephali 2 
Organ Morphology 0.019 abnormal morphology of tectum mesencephali 2 
Organismal Development 0.019 abnormal morphology of tectum mesencephali 2 
Embryonic Development 0.019 abnormal morphology of rostral migratory stream 2 
Tissue Morphology 0.019 abnormal morphology of rostral migratory stream 2 
    
Diseases and biological functions of female offspring 
Lipid Metabolism 0.024 steroid metabolism 5 
Small Molecule Biochemistry 0.024 steroid metabolism 5 
Vitamin and Mineral Metabolism 0.024 steroid metabolism 5 
Cell-To-Cell Signalling and Interaction 0.024 synthesis of acetylcholine 2 
Small Molecule Biochemistry 0.024 synthesis of acetylcholine 2 
Diseases or biological functions with Benjamini-Hochberg corrected (B-H) P < 0.05 are considered as significant. # Molecules denote the differentially 




Table 6.9 Canonical Pathways Affected by Maternal Folic Acid 
Supplementation in the Liver of Adult Offspring. 




Differentially expressed genes of all offspring 
Glucocorticoid Biosynthesis 1.56 0.08 
Oleate Biosynthesis II (Animals) 1.56 0.08 
Androgen Biosynthesis 1.56 0.07 
Interferon Signalling 1.30 0.03 
   
Differentially expressed genes of female offspring 
Superpathway of Cholesterol Biosynthesis 2.95 0.10 
Cholesterol Biosynthesis III (via Desmosterol) 2.44 0.15 
Cholesterol Biosynthesis II (via 24,25-dihydrolanosterol) 2.44 0.15 
Cholesterol Biosynthesis I 2.44 0.15 
LXR/RXR Activation 1.84 0.02 
Epoxysqualene Biosynthesis 1.41 0.50 
Ingenuity canonical pathways with –log (B-H) P ≥ 1.3 are considered as significant. Ratio 
represents the number of differentially expressed genes over the total number of genes that 















Top Diseases and Functions 
Differentially expressed genes of all offspring 
1 32 11 Lipid Metabolism, Molecular Transport, Nucleic Acid Metabolism 
    
Differentially expressed genes of male offspring 
1 27 11 Lymphoid Tissue Structure and Development, Organ Morphology, Tissue Morphology 
2 24 10 
Cellular Development, Nervous System Development and Function, Organismal Injury and 
Abnormalities 
    
Differentially expressed genes of female offspring 
1 42 17 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 
2 33 14 Energy Production, Lipid Metabolism, Small Molecule Biochemistry 
3 3 1 - 
Molecular networks with IPA score ≥ 3 are considered as significant. Focus molecules represent the number of differentially expressed genes highly enriched 








Table 6.11 Upstream Regulators of the Differentially Expressed Genes in the Liver of Adult Offspring Following Maternal 
Folic Acid Supplementation. 
Upstream Regulator Activation z-score P-value of overlap Downstream Genes 
Upstream regulators of the differentially expressed genes of all offspring 
TNF 0.625 7.00E-03 CYP17A1,G0S2,IFIT3,SCD 
    
Upstream regulators of the differentially expressed genes of male offspring 
TNF -0.508 5.00E-02 EFNA1,G0S2,IL17RB,SLC1A2 
    
Upstream regulators of the differentially expressed genes of female offspring 
SCAP -1.000 1.00E-06 IDI1,SC4MOL,SCD,SQLE 
PPARA 0.230 2.00E-06 ABCD2,ACOT5,IDI1,LIFR,SC4MOL,SCD,SQLE 
SREBF2 -1.067 4.00E-06 IDI1,SC4MOL,SCD,SQLE 
SREBF1 -0.709 5.00E-06 ABCD2,IDI1,SC4MOL,SCD,SQLE 
POR 1.131 1.39E-04 IDI1,SC4MOL,SCD,SQLE 
IGF1 0.000 2.45E-04 NTRK1,PRLR,SCD,SQLE,SRD5A1 
Ins1 0.013 1.13E-03 LIFR,PRLR,PTPRN,SCD 
TGFB1 -0.887 1.80E-03 IDI1,IL33,LIFR,SC4MOL,PROM1,PTPRN,SCD,SLC1A2 
IL1B -0.588 5.63E-03 IL33,LIFR,NTRK1,PTPRN,SLC1A2 
TNF -0.599 5.81E-03 ABCD2,IL33,LIFR,PTPRN,SCD,SLC1A2,SQLE 
IFNG -1.000 8.13E-03 IDI1,LIFR,NTRK1,PTPRN,SLC1A2,SQLE 
Upstream regulators with P < 0.05 are considered as significant. Activation z-score ≥ 2 indicates the activation of an upstream regulator. Activation z-score ≤ -








Table 6.12 TaqMan®  Gene Expression Assays Used for Quantification of mRNA Expression. 
Gene Symbol Gene Name TaqMan®  Assay ID 
Acaca acetyl-CoA carboxylase alpha Rn00573474_m1 
Actb actin, beta Rn00667869_m1 
Dnmt1 DNA methyltransferase 1 Rn00709664_m1 
Dnmt3a DNA methyltransferase 3a Rn01027162_g1 
Dnmt3b DNA methyltransferase 3b Rn01536418_g1 
Gapdh glyceraldehyde-3-phosphate dehydrogenase Rn01775763_g1 
Idi1 isopentenyl-diphosphate delta isomerase 1 Rn01408058_g1 
Pck1 phosphoenolpyruvate carboxykinase 1 Rn01529014_m1 
Ppara peroxisome proliferator-activated receptor alpha Rn00566193_m1 
Ppargc1a peroxisome proliferator-activated receptor gamma coactivator 1 alpha Rn00580241_m1 
Ppia peptidylprolyl isomerase A (cyclophilin A) Rn00690933_m1 
Sc4mol sterol-C4-methyl oxidase-like Rn00590057_m1 
Scd1 stearoyl CoA desaturase Rn00594894_g1 










Table 6.13 Effects of Folic Acid Supplementation on Foetal Body and Relative Organ Weight in Late Gestation.  
Foetal   Significance 
Weight (g)   CA FAA   CA vs FAA (P) Maternal Diet x Foetal Sex (P) 
Total Body   1.98 ± 0.10 2.07 ± 0.06   0.442 0.150  
Liver   0.15 ± 0.01 0.17 ± 0.01   0.196 0.926 
Lungs   0.06 ± 0.01 0.06 ± 0.01   0.409 0.458 
Kidneys   0.013 ± 0.001 0.014 ± 0.001   0.876 0.852 
Heart   0.012 ± 0.001 0.013 ± 0.001   0.241 0.855 
Pancreas   0.005 ± 0.001 0.005 ± 0.001   0.951 0.299 
Twelve foetuses per maternal dietary group were analysed (C: 12, male = 6, female = 6; FA: 12, male = 6, female = 6). Differences in foetal body weight and 
relative organ weight were compared using repeated measures ANOVA, with maternal dietary treatment as between subject factor, foetal sex as within 
subject factor and dam as covariate. Relative organ weight is expressed as a percentage of total body weight. Values are represented as mean ± SEM. CA, 









Table 6.14 Effects of Folic Acid Supplementation on Maternal Body and Relative Organ Weight in Late Gestation.  
Maternal   Significance 
Weight (g)   C FA   C vs FA (P) 
Total Body   404.83 ± 29.58 376.71 ± 37.67 
 
0.181 
Liver   3.92 ± 0.12 3.76 ± 0.32 
 
0.298 
Kidneys   0.49 ± 0.04 0.48 ± 0.03 
 
0.873 
Lungs   0.27 ± 0.03 0.30 ± 0.06 
 
0.222 
Heart   0.24 ± 0.02 0.25 ± 0.02 
 
0.675 
Pancreas   0.17 ± 0.04 0.18 ± 0.02   0.376 
Six dams per maternal dietary group (C: 6, FA: 6) were analysed. Differences in body weight and relative organ weight between dams of the two maternal 
dietary groups were compared using independent samples t-test. Relative organ weight is expressed as a percentage of total body weight. Values are 








Table 6.15 Effects of Folic Acid Supplementation on Foetal Hepatic MicroRNA Expression in Late Gestation. 






Up-regulated miRs of all foetuses 
rno-miR-350 miR-350 13 Intergenic No 1.23 0.008 No 
rno-miR-200c miR-8 4 Intergenic Yes 1.15 0.041 No 




Yes 1.14 0.049 Yes 
rno-miR-500 miR-500 X Intergenic Yes 1.14 0.046 No 
rno-miR-743b miR-743 X Intergenic Yes 1.13 0.042 No 
rno-miR-34c* miR-34 8 Intergenic Yes 1.13 0.044 Yes 
rno-let-7d* let-7 17 
Intronic (Dtnbp1-201; 
intron 4) 
Yes 1.13 0.025 Yes 
rno-miR-196a* miR-196 7 
Intronic (Aaas-201; intron 
8) 
No 1.11 0.041 Yes 
  
      
  
Down-regulated miRs of all foetuses 
rno-miR-144 miR-144 10 Intergenic Yes -0.59  0.044  Yes 
rno-miR-33 miR-33 7 Intronic (Srebf2; intron 16) No -0.55  0.008  Yes 
rno-miR-142-5p miR-142 10 Intergenic No -0.54  0.013  Yes 
rno-miR-376a miR-368 6 Intergenic Yes -0.52  0.008  No 
rno-miR-142-3p miR-142 10 Intergenic No -0.51  0.042  Yes 
rno-miR-136 miR-136 6 
Intronic (Ccdc88c-201; 
intron 6) 
No -0.47  0.010  No 








rno-miR-101b miR-101 1 
Intronic (Scgb2a2-201; 
intron 1) 
No -0.45  0.005  No 
rno-miR-32 miR-32 5 Intergenic No -0.40  0.008  No 
rno-miR-494 miR-154 6 Intergenic Yes -0.35  0.004  No 
rno-miR-101a miR-101 5 Intergenic No -0.34  0.005  No 
rno-miR-20a miR-17 15 Intergenic Yes -0.33  0.023  No 
rno-miR-341 miR-341 6 
Intronic (Ccdc88c-201; 
intron 3) 
Yes -0.33  0.011  No 
rno-miR-376b-3p miR-368 6 Intergenic Yes -0.31  0.007  No 
rno-miR-323 miR-154 6 Intergenic Yes -0.30  0.000  No 
rno-miR-19b miR-19 15 Intergenic Yes -0.27  0.008  No 
rno-miR-183 miR-183 4 Intergenic Yes -0.27  0.016  Yes 
rno-miR-347 miR-347 N/A N/A N/A -0.23  0.047  N/A 
rno-miR-16 miR-15 2 
Intronic (Slc7a11-201; 
intron 3) 
Yes -0.21  0.035  No 
rno-miR-411 miR-379 6 Intergenic Yes -0.21  0.002  No 
rno-miR-301a miR-130 10 
Intronic (Rad51c-201; 
intron 5) 
No -0.19  0.011  No 
rno-miR-652 miR-652 X Intergenic No -0.18  0.048  No 
rno-miR-30e miR-30 5 Intergenic Yes -0.18  0.008  No 
rno-miR-182 miR-182 4 Intergenic Yes -0.17  0.036  No 
rno-miR-30a miR-30 9 Intergenic No -0.15  0.049  No 
MicroRNA expression levels were measured by Exiqon miR microarray version 11 (Exiqon, Denmark), with fold changes and P-values presented. Genomic 



















Up-regulated miRs of female foetuses 
rno-let-7d* let-7 17 
Intronic (Dtnbp1-201; 
intron 4) 
Yes 1.22 0.011 Yes 
rno-miR-500 miR-500 X Intergenic Yes 1.22 0.037 No 
rno-miR-196a* miR-196 7 
Intronic (Aaas-201; intron 
8) 
No 1.20 0.021 Yes 
rno-miR-325-3p miR-325 X Intergenic No 1.18 0.049 No 
        Down-regulated miRs of female foetuses 
rno-miR-142-3p miR-142 10 Intergenic No -1.18 0.031 Yes 
rno-miR-33 miR-33 7 
Intronic (Srebf2; intron 
16) 
No -0.99 0.027 Yes 
rno-miR-142-5p miR-142 10 Intergenic No -0.98 0.006 Yes 
rno-miR-376a miR-368 6 Intergenic Yes -0.89 0.028 No 
rno-miR-101b miR-101 1 
Intronic (Scgb2a2-201; 
intron 1) 
No -0.75 0.005 No 
rno-miR-20a miR-17 15 Intergenic Yes -0.66 0.000 No 
rno-miR-122 miR-122 18 Intergenic Yes -0.60 0.011 No 
rno-miR-19a miR-19 15 Intergenic Yes -0.59 0.006 No 
rno-miR-341 miR-341 6 
Intronic (Ccdc88c-201; 
intron 3) 
Yes -0.58 0.028 No 
rno-miR-101a miR-101 5 Intergenic No -0.57 0.014 No 
rno-miR-32 miR-32 5 Intergenic No -0.57 0.007 No 
rno-miR-503 miR-503 X Intergenic Yes -0.57 0.001 Yes 








rno-miR-183 miR-183 4 Intergenic Yes -0.52 0.018 Yes 
rno-miR-347 miR-347 N/A N/A N/A -0.48 0.012 N/A 
rno-miR-103 miR-103 10 Intergenic No -0.45 0.005 Yes 
rno-miR-26a miR-26 8 Intergenic No -0.43 0.021 No 
rno-miR-323 miR-154 6 Intergenic Yes -0.41 0.006 No 
rno-miR-135b miR-135 13 Intergenic No -0.41 0.007 No 
rno-miR-19b miR-19 15 Intergenic Yes -0.41 0.021 No 
rno-miR-127 miR-127 6 
Intronic (Ccdc88c-201; 
intron 8) 
Yes -0.40 0.021 No 
rno-miR-107 miR-103 1 Intergenic No -0.38 0.023 No 
rno-miR-16 miR-15 2 
Intronic (Slc7a11-201; 
intron 3) 
Yes -0.37 0.041 No 
rno-miR-130a miR-130 3 
Intronic (Lnp-201; intron 
4) 
Yes -0.35 0.022 Yes 
rno-miR-9 miR-9 2 Intergenic Yes -0.31 0.046 No 
rno-miR-411 miR-379 6 Intergenic Yes -0.30 0.011 No 
rno-miR-301a miR-130 10 
Intronic (Rad51c-201; 
intron 5) 
No -0.28 0.029 No 
rno-miR-20b-3p miR-17 X 
Intronic (Gpc3-201; 
intron 4) 
Yes -0.28 0.028 No 
rno-miR-216a miR-216 14 Intergenic Yes -0.27 0.040 No 
rno-miR-30e miR-30 5 Intergenic Yes -0.24 0.023 No 
rno-miR-126 miR-126 3 Intergenic Yes -0.21 0.028 No 
rno-miR-29a miR-29 4 Intergenic Yes -0.21 0.020 No 
MicroRNA expression levels were measured by Exiqon miR microarray version 11 (Exiqon, Denmark), with fold changes and P-values presented. Genomic 









Table 6.17 Effects of Folic Acid Supplementation on Maternal Hepatic MicroRNA Expression in Late Gestation. 




Down-regulated miRs of dams 
rno-miR-33 miR-33 7 Intronic (Srebf2; intron 16) No -0.51 0.034 Yes 
MicroRNA expression levels were measured by Exiqon miR microarray version 11 (Exiqon, Denmark), with fold changes and P-values presented. Genomic 









Table 6.18 Predicted Targets of rno-miR-122 and rno-miR-191. 
Entrez ID Predicted Target Gene Name 
Gene 
Symbol 
Seed Match Function 




Aldoa 8mer fructose metabolic process 
NM_030816 ankyrin repeat domain 13C Ankrd13c 7mer-m8 
regulation of receptor biosynthesis 
process 
NM_001164773 
branched chain amino-acid 
transaminase 2, mitochondrial 
Bcat2 8mer 
amino acid biosynthetic process: leucine; 
isoleucine and valine 
NM_001003694 
bromodomain and PHD finger 
containing, 1 
Brpf1 8mer histone H3 acetylation 
NM_004060 cyclin G1109 Ccng1 8mer cell growth 
NM_001165895 CD320 molecule95 Cd320 7mer-m8 cobalamin metabolic process 
NM_001114086 chloride intracellular channel 5 Clic5 7mer-m8 
regulation of ion transmembrane 
transport 
NM_001202543 cut-like homeobox 1437 Cux1 8mer regulation of transcription 
NM_000799 erythropoietin Epo 8mer positive regulation of cell proliferation 
NM_004501 
heterogeneous nuclear 
ribonucleoprotein U (scaffold 
attachment factor A) 
Hnrnpu 8mer RNA splicing 
NM_014045 
low-density lipoprotein receptor-
related protein 10 
Lrp10 8mer lipid transport 
NM_001205254 occludin Ocln 8mer S-adenosylmethionine metabolic process 
NM_000917 
prolyl 4-hydroxylase, alpha 
polypeptide I98 
P4ha1 8mer oxidoreductase activity 
     NM_001130964 phospholipase C, delta 1 Plcd1 8mer phospholipid binding 
NM_001199260 torsin A interacting protein 2 Tor1aip2 8mer N/A 








(C/EBP), beta process 
NM_007218 ring finger protein 139 Rnf139 7mer-m8 





Bdnf 7mer-m8 chronic inflammatory response 
NM_012326 
microtubule-associated protein, 
RP/EB family, member 3 
Mapre3 7mer-m8 cell cycle 
Predicted mRNA targets enlisted are over-represented by TargetScan version 6.1 (Whitehead Institute for Biomedical Research, http://www.targetscan.org/), 
miRanda (Memorial Sloan-Kettering Cancer Center, http://www.microrna.org/microrna/home.do) and RNAhybrid (Bielefeld Bioinformatics Service, 
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/), with their Entrez ID, gene name, gene symbol, miR target sequence, seed match and cellular function 
shown. 7mer-1A indicates an exact match to positions 2-7 of the mature miR; 7mer-m8 indicates an exact match to positions 2-8 of the mature miR; 8mer 
indicates an exact match to positions 2-8 of the mature miR. Predicted mRNA targets, which have been validated by experimental means, are shown with 








Table 6.19 Predicted Targets of rno-miR-17. 
Entrez ID Predicted Target Gene Name Gene Symbol Seed Match Function 
Predicted targets of rno-miR-17 
NM_001160147 DDHD domain containing 1 Ddhd1 8mer lipid catabolic process 
NM_022898 
B-cell CLL/lymphoma 11B (zinc 
finger protein) 
Bcl11b 8mer 







St6galnac3 8mer protein glycosylation 
NM_020645 
nuclear receptor interacting 
protein 3 
Nrip3 8mer proteolysis 
NM_018646 
transient receptor potential cation 
channel, subfamily V, member 6 
Trpv6 8mer calcium ion import 
NM_031857 protocadherin alpha 9 Pcdha9 7mer-m8 cell adhesion 
NM_018899 
protocadherin alpha subfamily C, 
2 
Pcdhac2 7mer-m8 cell adhesion 
NM_018898 
protocadherin alpha subfamily C, 
1 
Pcdhac1 7mer-m8 cell adhesion 
NM_018904 protocadherin alpha 13 Pcdha13 7mer-m8 homophilic cell adhesion 
NM_018903 protocadherin alpha 12 Pcdha12 7mer-m8 homophilic cell adhesion 
NM_018902 protocadherin alpha 11 Pcdha11 7mer-m8 cell adhesion 
NM_018901 protocadherin alpha 10 Pcdha10 7mer-m8 cell adhesion 
NM_018911 protocadherin alpha 8 Pcdha8 7mer-m8 cell adhesion 
NM_018910 protocadherin alpha 7 Pcdha7 7mer-m8 cell adhesion 
NM_018909 protocadherin alpha 6 Pcdha6 7mer-m8 cell adhesion 
NM_018908 protocadherin alpha 5 Pcdha5 7mer-m8 cell adhesion 
NM_018907 protocadherin alpha 4 Pcdha4 7mer-m8 cell adhesion 








NM_018905 protocadherin alpha 2 Pcdha2 7mer-m8 cell adhesion 
NM_018900 protocadherin alpha 1 Pcdha1 7mer-m8 cell adhesion 
NM_005632 
small optic lobes homolog 
(Drosophila) 
Solh 8mer proteolysis 
NM_001242333 LIM homeobox 6199 Lhx6 7mer-m8 regulation of transcription 
NM_002266 
karyopherin alpha 2 (RAG cohort 
1, importin alpha 1) 
Kpna2 7mer-m8 
regulation of transcription by 
glucose 
NM_001177591 
protein phosphatase 2, regulatory 
subunit B, alpha 
Ppp2r2a 7mer-m8 
nuclear-transcribed mRNA catabolic 
process 
NM_014952 
bromo adjacent homology 
domain containing 1 
Bahd1 7mer-m8 heterochromatin assembly 
NM_152536 
FYVE, RhoGEF and PH domain 
containing 5 
Fgd5 8mer actin cytoskeleton organisation 
NM_001145373 OTU domain containing 1 Otud1 7mer-m8 proteolysis 
NM_001004426 
phospholipase A2, group VI 
(cytosolic, calcium-independent) 
Pla2g6 8mer 
maternal process involved in 
pregnancy 
NM_005342 high mobility group box 3 Hmgb3 7mer-m8 DNA recombination 
NM_001015048 BCL2-associated athanogene 5 Bag5 7mer-m8 
negative regulation of protein 
ubiquitination 
NM_007039 
protein tyrosine phosphatase, 
non-receptor type 21 
Ptpn21 7mer-m8 protein dephosphorylation 
NM_153612 






mitogen-activated protein kinase 
969 
Mapk9 7mer-m8 
positive regulation of apoptotic 
process 
NM_003566 early endosome antigen 1 Eea1 7mer-m8 endocytosis 
NM_002848 
protein tyrosine phosphatase, 
receptor type, O439 
Ptpro 7mer-m8 cell morphogenesis 








Predicted mRNA targets enlisted are over-represented by TargetScan version 6.1 (Whitehead Institute for Biomedical Research, http://www.targetscan.org/), 
miRanda (Memorial Sloan-Kettering Cancer Center, http://www.microrna.org/microrna/home.do) and RNAhybrid (Bielefeld Bioinformatics Service, 
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/), with their Entrez ID, gene name, gene symbol, miR target sequence, seed match and cellular function 
shown. 7mer-1A indicates an exact match to positions 2-7 of the mature miR; 7mer-m8 indicates an exact match to positions 2-8 of the mature miR; 8mer 
indicates an exact match to positions 2-8 of the mature miR. Predicted mRNA targets, which have been validated by experimental means, are shown with 








Table 6.20 Predicted Targets of rno-miR-370. 
Entrez ID Predicted Target Gene Name 
Gene 
Symbol 
Seed Match Function 
Validation 
Reference 
Predicted targets of rno-miR-370 
NM_001134375 cyclin J Ccnj 8mer N/A - 
NM_001001560 
golgi-associated, gamma 
adaptin ear containing, ARF 
binding protein 1 
Gga1 8mer 
positive regulation of protein 
catabolic process 
- 
NM_001717 basonuclin 1 Bnc1 8mer 




bromodomain adjacent to zinc 
finger domain, 2A 
Baz2a 8mer heterochromatin assembly - 
NM_003257 
tight junction protein 1 (zona 
occludens 1) 
Tjp1 8mer apoptotic process - 






(GABA) B receptor, 2 
Gabbr2 7mer-1A 
negative regulation of adenylate 
cyclase activity 
- 
NM_018982 Yip1 domain family, member 1 Yipf1 8mer N/A - 
NM_004625 
wingless-type MMTV 
integration site family, member 
7A 
Wnt7a 8mer 
positive regulation of cell 
proliferation 
- 
NM_001719 bone morphogenetic protein 7 Bmp7 8mer negative regulation of transcription - 
NM_003394 
wingless-type MMTV 
integration site family, member 
10B 
Wnt10b 8mer cellular response to cAMP - 
NM_001242318 phosphodiesterase 7A Pde7a 8mer cAMP-mediated signalling - 
NM_018403 
DCP1 decapping enzyme 
homolog A (S. cerevisiae) 









transforming growth factor, 
beta receptor II (70/80kDa) 
Tgfbr2 8mer response to cholesterol - 
NM_006329 fibulin 5 Fbln5 8mer regulation of cell growth - 
NM_007249 Kruppel-like factor 12 Klf12 7mer-m8 regulation of transcription - 
NM_017590 
zinc finger CCCH-type 
containing 7B 
Zc3h7b 8mer virus-host interaction - 
NM_004539 asparaginyl-tRNA synthetase Nars 7mer-m8 asparaginyl-tRNA aminoacylation - 
NM_001092 active BCR-related gene Abr 7mer-m8 





complex 3, mu 1 subunit 
Ap3m1 8mer intracellular protein transport - 
NM_002031 fyn-related kinase Frk 8mer 





channel, subfamily J, member 
11 
Kcnj11 8mer response to oestradiol stimulus - 
NM_001142281 archain 1 Arcn1 8mer intracellular protein transport - 
NM_033389 
slingshot homolog 2 
(Drosophila) 
Ssh2 7mer-1A protein dephosphorylation - 
NM_001038707 CDC42 small effector 1 Cdc42se1 8mer negative regulation of JNK cascade - 
NM_001010938 
tyrosine kinase, non-receptor, 
2 
Tnk2 8mer endocytosis - 
NM_025015 heat shock 70kDa protein 12A Hspa12a 7mer-m8 response to stress - 
NM_001160423 
insulin-like growth factor 2 
mRNA binding protein 1 
Igf2bp1 7mer-1A 
regulation of cytokine biosynthetic 
process 
- 
NM_012282 KCNE1-like Kcne1l 7mer-m8 




CDC42 effector protein (Rho 
GTPase binding) 4 
Cdc42ep4 8mer Rho protein signal transduction - 








NM_153347 transmembrane protein 86A Tmem86a 7mer-m8 N/A - 
NM_006941 
SRY (sex determining region 
Y)-box 10 
Sox10 7mer-m8 positive regulation of transcription - 
NM_013260 SAP30 binding protein Sap30bp 8mer positive regulation of cell death - 
NM_019071 
inhibitor of growth family, 
member 3 
Ing3 7mer-m8 
positive regulation of apoptotic 
process 
- 
NM_005507 cofilin 1 (non-muscle) Cfl1 7mer-m8 cytoskeleton organisation - 
NM_005879 TRAF interacting protein Traip 7mer-m8 apoptotic process - 
NM_152753 
signal peptide, CUB domain, 
EGF-like 3 
Scube3 7mer-m8 protein homooligomerisation - 
NM_006037 histone deacetylase 4 Hdac4 7mer-m8 histone deacetylation - 
NM_001126054 
calcium/calmodulin-dependent 
serine protein kinase (MAGUK 
family) 
Cask 7mer-m8 
negative regulation of cell-matrix 
adhesion 
- 




NM_003632 contactin associated protein 1 Cntnap1 7mer-m8 signal transduction - 
NM_001165927 Meckel syndrome, type 1 Mks1 7mer-m8 cilium morphogenesis - 
NM_014830 
zinc finger and BTB domain 
containing 39 
Zbtb39 7mer-m8 regulation of transcription - 
NM_199044 
NOP2/Sun domain family, 
member 4 
Nsun4 7mer-m8 methyltransferase activity - 
NM_001105079 fibrosin Fbrs 7mer-m8 
positive regulation of fibroblast 
proliferation 
- 
NM_001831 clusterin Clu 7mer-m8 







negative regulation of protein 
polymerisation 
- 
NM_032840 SPRY domain containing 3 Spryd3 7mer-m8 N/A - 












Bdnf 7mer-m8 mitochondrial electron transport - 
NM_001202464 
zinc finger, MYND-type 
containing 11 
Zmynd11 7mer-m8 cell proliferation - 
NM_052897 
methyl-CpG binding domain 
protein 6 
Mbd6 7mer-m8 N/A - 
NM_001207055 
DNA (cytosine-5-)-
methyltransferase 3 beta 




Raver2 7mer-m8 N/A - 
NM_207311 
coiled-coil domain containing 
64 
Ccdc64 7mer-m8 golgi to secretory granule transport - 
NM_022836 DNA cross-link repair 1B Dclre1b 7mer-m8 telomere maintenance - 
NM_145754 kinesin family member C2 Kifc2 7mer-m8 microtubule-based movement - 
NM_001143981 chordin-like 1 Chrdl1 7mer-1A cell differentiation - 




Hnrnpa1 7mer-1A RNA splicing - 
NM_001100426 
RAP1, GTP-GDP dissociation 
stimulator 1 
Rap1gds1 7mer-m8 




TNF receptor-associated factor 
4 
Traf4 7mer-m8 




protein tyrosine phosphatase, 
non-receptor type 14 
Ptpn14 7mer-m8 
regulation of protein export from 
nucleus 
- 
NM_052874 syntaxin 1B Stx1b 7mer-m8 intracellular protein transport - 
NM_016113 
transient receptor potential 
cation channel, subfamily V, 
member 2 
Trpv2 7mer-m8 
positive regulation of calcium ion 
import 
- 










reprimo, TP53 dependent G2 
arrest mediator candidate 
Rprm 7mer-m8 cell cycle arrest - 
NM_033116 
NIMA (never in mitosis gene 
a)- related kinase 9 
Nek9 7mer-m8 mitosis - 
NM_001080469 F-box protein 46 Fbxo46 7mer-m8 N/A - 
NM_004090 dual specificity phosphatase 3 Dusp3 7mer-m8 toll-like receptor signalling pathway - 
NM_002181 Indian hedgehog Ihh 7mer-m8 










NM_001012426 forkhead box P4 Foxp4 7mer-m8 regulation of transcription - 
NM_014935 
pleckstrin homology domain 
containing, family A member 6 
Plekha6 7mer-m8 N/A - 
NM_014876 Josephin domain containing 1 Josd1 7mer-1A proteolysis - 
NM_003045 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 1 
Slc7a1 7mer-m8 amino acid transport - 
NM_002198 interferon regulatory factor 1 Irf1 7mer-m8 




SRY (sex determining region 
Y)-box 12 
Sox12 8mer regulation of transcription - 
NM_018674 
amiloride-sensitive cation 
channel 4, pituitary 
Accn4 7mer-m8 sodium ion transport - 
NM_001650 aquaporin 4 Aqp4 7mer-m8 transporter activity - 
NM_014751 metastasis suppressor 1 Mtss1 7mer-m8 
negative regulation of epithelial cell 
proliferation 
- 
NM_001033551 target of myb1-like 2 (chicken) Tom1l2 7mer-m8 intracellular protein transport - 
NM_001204204 SEC14-like 2 (S. cerevisiae) Sec14l2 7mer-m8 













Senp5 7mer-m8 proteolysis - 
Predicted mRNA targets enlisted are over-represented by TargetScan version 6.1 (Whitehead Institute for Biomedical Research, http://www.targetscan.org/), 
miRanda (Memorial Sloan-Kettering Cancer Center, http://www.microrna.org/microrna/home.do) and RNAhybrid (Bielefeld Bioinformatics Service, 
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/), with their Entrez ID, gene name, gene symbol, miR target sequence, seed match and cellular function 
shown. 7mer-1A indicates an exact match to positions 2-7 of the mature miR; 7mer-m8 indicates an exact match to positions 2-8 of the mature miR; 8mer 
indicates an exact match to positions 2-8 of the mature miR. Predicted mRNA targets, which have been validated by experimental means, are shown with 















Top Diseases and Functions 
Predicted targets of the differentially expressed miRs of all foetuses 
1 40 31 Post-Translational Modification, Protein Degradation, Protein Synthesis 
2 40 31 
Dermatological Diseases and Conditions, Developmental Disorder, Organismal Injury and 
Abnormalities 
3 40 31 Cancer, Haematological Disease, Gene Expression 
4 34 28 Embryonic Development, Nervous System Development and Function, Organ Development 
5 32 27 Cell Morphology, Cellular Assembly and Organisation, Cellular Development 
6 32 27 Developmental Disorder, Immunological Disease, Organismal Development 
7 30 26 Cardiac Arrhythmia, Cardiovascular Disease, Molecular Transport 
8 30 26 Molecular Transport, Cellular Function and Maintenance, Amino Acid Metabolism 
9 30 26 Cellular Compromise, Cell Cycle, Cellular Assembly and Organisation 
10 30 26 Tissue Morphology, Behaviour, Nervous System Development and Function 
11 30 26 Respiratory System Development and Function, Tissue Morphology, Gene Expression 
12 28 25 Cardiovascular Disease, Organismal Injury and Abnormalities, Cellular Growth and Proliferation 
13 28 25 
Cellular Assembly and Organisation, Cellular Function and Maintenance, Post-Translational 
Modification 
14 26 24 Amino Acid Metabolism, Lipid Metabolism, Molecular Transport 
15 24 23 Post-Translational Modification, Cell Morphology, Cellular Assembly and Organisation 
16 23 22 Cellular Assembly and Organisation, Cellular Function and Maintenance, Cell Morphology 
17 23 22 Post-Translational Modification, Cardiovascular Disease, Congenital Heart Anomaly 
18 23 22 Gene Expression, RNA Post-Transcriptional Modification, Cellular Assembly and Organisation 
19 21 21 
Cell-To-Cell Signalling and Interaction, Nervous System Development and Function, Neurological 
Disease 
20 21 21 Infectious Disease, Cardiovascular Disease, Auditory Disease 
21 21 21 Connective Tissue Disorders, Dental Disease, Developmental Disorder 








23 15 17 Cellular Movement, Cell-To-Cell Signalling and Interaction, Cellular Assembly and Organisation 
24 15 17 Cell Morphology, Cellular Assembly and Organisation, Embryonic Development 
25 15 17 Carbohydrate Metabolism, Small Molecule Biochemistry, Cell Morphology 















Top Diseases and Functions 
Predicted targets of the differentially expressed miRs of female foetuses 
1 44 33 Molecular Transport, Cellular Function and Maintenance, Cell Morphology 
2 41 32 Post-Translational Modification, Cancer, Respiratory Disease 
3 39 31 Gene Expression, Endocrine System Development and Function, Molecular Transport 
4 35 29 Developmental Disorder, Hereditary Disorder, Neurological Disease 
5 35 29 Amino Acid Metabolism, Hereditary Disorder, Nervous System Development and Function 
6 33 28 
Post-Translational Modification, Cardiovascular Disease, Cardiovascular System Development 
and Function 
7 33 28 
Cellular Assembly and Organisation, Cellular Function and Maintenance, Carbohydrate 
Metabolism 
8 33 28 
Cellular Growth and Proliferation, Haematological System Development and Function, 
Haematopoiesis 
9 31 27 
Connective Tissue Development and Function, Embryonic Development, Nervous System 
Development and Function 
10 31 27 Neurological Disease, Skeletal and Muscular Disorders, Cellular Function and Maintenance 
11 27 25 Cellular Movement, Cancer, Cell-To-Cell Signalling and Interaction 
12 27 25 Cardiovascular Disease, Congenital Heart Anomaly, Developmental Disorder 
13 25 24 Cardiac Arrhythmia, Cardiovascular Disease, Connective Tissue Development and Function 
14 25 24 Inflammatory Disease, Neurological Disease, Dermatological Diseases and Conditions 
15 25 24 
Digestive System Development and Function, Embryonic Development, Endocrine System 
Development and Function 
16 24 23 Cell Signalling, Cell Death and Survival, Cellular Development 
17 24 23 Antimicrobial Response, Inflammatory Response, Reproductive System Disease 
18 24 23 Cell Cycle, Cellular Assembly and Organisation, DNA Replication, Recombination and Repair 
19 24 23 Cell Signalling, Vitamin and Mineral Metabolism, Cell Morphology 








21 20 21 Lipid Metabolism, Small Molecule Biochemistry, Cell Cycle 
22 20 21 Cell Morphology, Cellular Assembly and Organisation, Cellular Development 
23 20 21 Connective Tissue Development and Function, Embryonic Development, Organ Development 
24 17 19 Cell Morphology, Cellular Movement, Cell-To-Cell Signalling and Interaction 
25 17 19 Post-Translational Modification, Cell Cycle, Hair and Skin Development and Function 
















Top Diseases and Functions 
Predicted targets of the differentially expressed miRs of dams 
1 36 14 Developmental Disorder, Hereditary Disorder, Metabolic Disease 
2 15 7 Cardiovascular Disease, Organismal Injury and Abnormalities, Molecular Transport 
Molecular networks with IPA score ≥ 3 are considered as significant. Focus molecules represent the number of predicted targets highly enriched within the 








Table 6.24 Effects of Folic Acid Supplementation on Maternal Hepatic Gene Expression in Late Gestation.  
Maternal   Significance 
Relative mRNA Expression   C FA   C vs FA (P) 
Dnmt1   0.0125 ± 0.0002 0.0092 ± 0.0016   0.089 
Dnmt3a   0.0107 ± 0.0004 0.0105 ± 0.0004   0.639 
Dnmt3b   0.013 ± 0.001 0.015 ± 0.001   0.337 
            
Acaca   0.07 ± 0.01 0.05 ± 0.01   0.154 
Scd1   2.6 ± 0.3 3.2 ± 0.4   0.287 
            
Idi1   0.034 ± 0.004 0.028 ± 0.006   0.417 
Sc4mol   0.082 ± 0.004 0.086 ± 0.010   0.733 
Sqle   0.0302 ± 0.0032 0.0307 ± 0.0002   0.875 
            
Pck1   0.042 ± 0.013 0.013 ± 0.004   0.081 
Ppara   0.045 ± 0.006 0.044 ± 0.005   0.824 
Ppargc1a   0.0014 ± 0.0001 0.0015 ± 0.0001   0.540  
Gapdh   0.19 ± 0.03 0.24 ± 0.02   0.230  
Six dams per maternal dietary group were analysed (C: 6, FA: 6). Data was analysed with independent samples t-test. Expression values of the genes of 



























 rno-miR-17   0.136  0.008  -0.123  0.393  -0.160  0.332  -0.111  -0.069  -0.090  0.045  0.127  
 rno-miR-20a   0.085  -0.100  0.435  0.307  0.182  0.421  0.326  -0.233  -0.238  0.037  0.154  
 rno-miR-33   0.014  -0.373  -0.022  0.190  0.341  0.430  0.380  -0.399  -0.078  -0.153  0.550  
 rno-miR-103   0.074  0.075  0.252  0.280  -0.013  0.175  0.090  0.119  -0.320  -0.099  0.166  
 rno-miR-122a   -0.011  -0.430  -0.085  0.693** -0.051  0.597* 0.461  -0.593  -0.426  -0.328  0.276  
 rno-miR-127   0.096  0.068  0.558* -0.263  0.516  -0.043  0.024  0.065  0.162  0.230  -0.303  
 rno-miR-142-3p   0.139  -0.437  0.280  0.564* -0.131  0.480  0.491  -0.476  -0.493  -0.434  0.031  
 rno-miR-183   -0.315  -0.072  0.309  0.079  -0.612  -0.017  0.485  -0.194  -0.380  -0.389  -0.090  
 rno-miR-191   -0.221  -0.484  0.317  0.444  -0.305  0.630* 0.671* -0.724* -0.367  -0.368  0.212  
Pearson’s one-tailed bivariate correlation was performed to determine for the correlation coefficients between hepatic expression of miRs and genes in 









Table 6.26 Correlations between Hepatic Expression of MicroRNAs and Genes in Dams in Late Gestation. 
Maternal 
Pearson Correlation 
Coefficient (r)  









0.103 0.268 0.137 -0.174 -0.287 0.053 0.400 0.028 -0.329 -0.166 -0.388 -0.046 
 rno-miR-33 
 
-0.202 0.040 -0.593* 0.399 -0.197 -0.728** -0.441 -0.288 0.217 -0.499* -0.053 -0.262 
 rno-miR-122 
 
-0.080 0.311 0.295 -0.542* -0.552* 0.006 0.322 -0.045 -0.233 0.038 -0.493 -0.413 
 rno-miR-191 
 
-0.387 -0.872* -0.155 0.125 -0.053 -0.410 -0.333 -0.022 0.024 -0.375 0.360 -0.138 
Pearson’s one-tailed bivariate correlation was performed to determine for the correlation coefficients between hepatic expression of miRs and genes in dams. 








Table 6.27 TaqMan®  Gene Expression Assays Used for Quantification of mRNA Expression. 
Gene Symbol Gene Name TaqMan®  Assay ID 
Actc1 actin, alpha, cardiac muscle 1 Rn01513700_g1 
Gbe1 glucan (1,4α-), branching enzyme 1 Rn01402260_m1 
Kcnj13 potassium inwardly-rectifying channel, subfamily J, member 13 Rn00586020_m1 
Mterf mitochondrial transcription termination factor Rn01526547_m1 









Table 6.28 Disease and Biological Functions Affected by Maternal Folic Acid Supplementation in the Skeletal Muscle of 
Adult Offspring. 
Category B-H P-value Functions Annotation # Molecules 
Diseases and biological functions of all offspring 
Lipid Metabolism 0.002 abnormal quantity of leukotriene 1 
Molecular Transport 0.002 abnormal quantity of leukotriene 1 
Small Molecule Biochemistry 0.002 abnormal quantity of leukotriene 1 
Developmental Disorder 0.002 adult polyglucosan body disease 1 
Hereditary Disorder 0.002 adult polyglucosan body disease 1 
    
Diseases and biological functions of male offspring 
Lipid Metabolism 0.003 abnormal quantity of leukotriene 1 
Molecular Transport 0.003 abnormal quantity of leukotriene 1 
Small Molecule Biochemistry 0.003 abnormal quantity of leukotriene 1 
Cardiovascular Disease 0.003 atrial septal defect type 5 1 
Developmental Disorder 0.003 atrial septal defect type 5 1 
    
Diseases and biological functions of female offspring 
Gene Expression 0.004 transcription termination of RNA 1 
Cellular Growth and Proliferation 0.004 generation of bone marrow-derived dendritic cells 1 
Tissue Development 0.004 generation of bone marrow-derived dendritic cells 1 
Neurological Disease 0.006 vertigo 1 
Post-Translational Modification 0.006 conjugation of protein 1 
Diseases or biological functions with Benjamini-Hochberg corrected (B-H) P < 0.05 are considered as significant. # Molecules denote the differentially 








Table 6.29 Molecular Networks Affected by Maternal Folic Acid Supplementation in the Skeletal Muscle of Adult Offspring. 
Network IPA Score Focus Molecules Top Diseases and Functions 
Differentially expressed genes of all offspring 
1 11 4 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 
2 3 1 Neurological Disease, RNA Post-Transcriptional Modification, Cancer 
    
Differentially expressed genes of male offspring 
1 16 6 Cancer, Cellular Development, Cellular Growth and Proliferation 
2 3 1 Neurological Disease, RNA Post-Transcriptional Modification, Cancer 
    
Differentially expressed genes of female offspring 
1 5 2 Developmental Disorder, Hereditary Disorder, Metabolic Disease 
2 3 1 Neurological Disease, Psychological Disorders, Cellular Assembly and Organisation 
Molecular networks with IPA score ≥ 3 are considered as significant. Focus molecules represent the number of differentially expressed genes highly enriched 








Table 6.30 Upstream Regulators of the Differentially Expressed Genes in the Skeletal Muscle of Adult Offspring Following 
Maternal Folic Acid Supplementation. 
Upstream Regulator Molecule Type Predicted Activation State Activation z-score P-value Downstream Genes 
Upstream regulators of differentially expressed genes of all offspring 
Id group - - 0.0004 ACTC1 
SRFBP1 other - - 0.0007 ACTC1 
miR-135a-5p mature miR - - 0.0020 ALOX5AP 
miR-199a-5p mature miR - - 0.0020 ALOX5AP 
GATA5 transcription regulator - - 0.0022 ACTC1 
      Upstream regulators of differentially expressed genes of male offspring 
Id group - - 0.0006 ACTC1 
SRFBP1 other - - 0.0009 ACTC1 
miR-135a-5p mature miR - - 0.0028 ALOX5AP 
miR-199a-5p mature miR - - 0.0028 ALOX5AP 
ARID4B other - - 0.0031 EMB 
      Upstream regulators of differentially expressed genes of female offspring 
TBL1XR1 transcription regulator - - 0.0008 USP18 
TBL1X transcription regulator - - 0.0011 USP18 
RNASEL enzyme - - 0.0020 USP18 
SKP2 other - - 0.0024 USP18 
IFNAR2 transmembrane receptor - - 0.0029 USP18 
Upstream regulators with P < 0.05 are considered as significant. Activation z-score ≥ 2 indicates the activation of an upstream regulator. Activation z-score ≤ -








Table 6.31 Canonical Pathways Affected by Maternal Folic Acid Supplementation in the Skeletal Muscle of Adult Offspring. 
Ingenuity Canonical Pathways -log (B-H) P-value Ratio Molecules 
Differentially expressed genes of female offspring 
Mitochondrial Dysfunction 1.39 0.006 NDUFS5 
Oxidative Phosphorylation 1.39 0.009 NDUFS5 
Protein Ubiquitination 1.38 0.004 USP18 
Ingenuity canonical pathways with –log (B-H) P ≥ 1.3 are considered as significant. Ratio represents the number of differentially expressed genes over the 
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